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Abstract 
 
 In 2017, only 70.4% of U.S. children ages 19-35 months were up-to-date (UTD) for their 
routine series of vaccines, a rate that consistently misses the national target of 80%. Recent 
evidence has demonstrated that those rates are declining. As a result of an under-vaccinated 
population, vaccine preventable disease outbreaks are becoming more frequent and places 
vulnerable populations at risk for disease, disability, or death. Contributors to sub-optimal 
immunization rates include challenges in identifying vaccination needs, incomplete or inaccurate 
vaccination records, missed opportunities, and vaccine hesitancy among parents and providers. 
One strategy to improve immunizations in the U.S. is through the utilization of immunization 
information systems (IISs). Although large investments into their infrastructure, implementation, 
and operation have led to widespread adoption of IISs by state immunization programs, research 
evaluating the impacts of these systems on immunizations is still in early stages and has resulted 
in mixed findings. The purpose of this dissertation is to explore the relationship of IISs on 
immunizations.  
 Using data from the National Immunization Survey, The IIS Legislative Survey, and the 
IIS Annual Reports (IISARs), I analyze the association of IIS policies and participation on 
immunization status in children 19-35 months of age. Following a three-essay format, I utilize a 
series of multiple logistic and linear regression models to examine the relationship between IIS 
participation on UTD status and invalid doses, and IIS policies and provider participation on 
state-level immunization rates. Consistent with the previous literature, my overall findings on IIS 
participation resulted in mixed findings. While there was little to no association between IIS 
participation and the odds of a child completing their full vaccines series, I did find a statistically 
significant relationship between IIS participation and the odds of invalid doses. Further, previous 
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studies found no association between mandate or consent policies on state-level UTD 
immunization rates. While supporting previous work, I also find a statistically significant 
interaction between mandate and consent policies as it relates to UTD rates. This work 
contributes to the literature by expanding what is known about how IIS policies and participation 
relate to immunization rates. These studies further highlight the dynamic but important 
relationships between policy, and participation by providers and parents that can inform future 
immunization improvement strategies.  
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Background 
In the United States (U.S.), vaccines prevented an estimated 322 million illnesses, 21 
million hospitalizations and 732,000 deaths from 1994-2013 (Centers for Disease Control and 
Prevention, 2014; Whitney, Zhou, Singleton, & Schuchat, 2014). Since the uptake of widespread 
vaccination, along with improvements in hygiene, sanitation, clean water, and antibiotics 
discovery, morbidity and mortality of vaccine preventable diseases (VPDs) has been reduced by 
more than 99% for most diseases (Centers for Disease Control and Prevention, 1999; Roush & 
Murphy, 2007). They are widely cited as one of the greatest public health achievements and cost-
effective preventive health measures of the 20th century saving the U.S. an estimated $295B in 
direct and $1.38T in society costs over the same twenty-year period (Control & Prevention, 
2011; Whitney et al., 2014). In order to maintain the current disease reduction and gain ground 
on further reducing the incidence and burden of disease, high levels of vaccination need to be 
sustained (Andre et al., 2008b).  
U.S. immunization policies focus primarily on childhood vaccines. Younger children are 
more at risk for contracting and spreading infections and for complications that can cause 
significant disability or death (Andre et al., 2008a). For most vaccines, rates of childhood 
vaccination have been relatively high (Hill, Elam-Evans, Yankey, Singleton, & Kolasa, 2015), 
but recent evidence over the last three years suggests that those rates are declining (Hill, Elam-
Evans, Yankey, Singleton, & Kang, 2017) and consistently miss national immunization targets 
(Healthy People 2020 [Internet], Office of Disease Prevention and Health Promotion). Sub-
optimal rates leave un-vaccinated or under-vaccinated individuals susceptible to vaccine-
preventable diseases and have spurred increases in the frequency and sizes of outbreaks in 
communities (Constable, Blank, & Caplan, 2014; Malone & Hinman, 2003). 
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The contributors to lower immunization rates are well-established in the public health 
literature. Increases in the number of vaccines needed and the changes to the immunization 
schedule create difficulties in tracking immunization status by parents and providers (Butte, 
Shaw, & Bernstein, 2001). Tracking is further complicated by record fragmentation and 
scattering (Stokley, Rodewald, & Maes, 2001; Yusuf et al., 2002) which can result when a child 
has multiple providers or moves out of state since the U.S. lacks a universal electronic health 
record (Feikema, Klevens, Washington, & Barker, 2000; Orenstein, Douglas, Rodewald, & 
Hinman, 2005). Oftentimes, providers do not have access to a child’s full vaccination history 
which prevents determining vaccination needs while at the point of care (Gostin & Lazzarini, 
1995). Aside from electronic data factors, other reasons for low vaccination rates include 
increasing vaccine hesitancy by providers and parents which has increased the utilization of 
alternative, and unvalidated, vaccine schedules (Feemster & Offit, 2013; Offit & Moser, 2009). 
The failure of the U.S. to increase immunization coverage motivated large investments 
into Immunization Information Systems as a strategy to improve rates (Hinman, Urquhart, & 
Strikas, 2007). IISs are confidential, centralized, electronic repositories that house vaccination 
data and offer many features designed to improve the overall quality and delivery of vaccines. 
IISs were designed to assist providers, hospitals, public health officials, and other stakeholders 
such as Medicaid plans (Freeman & DeFriese, 2003). They offer clinical decision support tools 
to assist providers in providing the age-appropriate vaccines using embedded algorithms based 
on the Advisory Committee on Immunization Practices (ACIP) recommended schedule and the 
patient’s IIS vaccination history (Rajamani, Bieringer, & Muscoplat, 2015). IISs also help 
providers improve immunizations and quality through its Assessment, Feedback, Incentives, and 
eXchange (AFIX) program (American Immunization Registry Association, 2015). IISs can 
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provide immunization histories directly to patients or parents that can be useful for care 
coordination or for proof of vaccines for school entry (Galemore, 2011). Several states even have 
policies allowing for data exchange agreements that allow IISs to share immunization data across 
other stakeholders (Hinman et al., 2007) and these agreements can consolidate multiple sources 
of vaccine information to improve rates (Kempe et al., 2001).  
The capabilities of IISs are designed to promote and encourage improvements in 
immunizations but the effectiveness of IISs in the literature is less clear. This is likely because 
individual states have a large influence over the effectiveness of their IISs. In the U.S., the 
Federal government makes immunization recommendations and conducts immunization 
surveillance nationally, but immunization policies are enacted by State governments. Today, 
most of the operating IISs are operated by State immunization programs though some larger 
cities and regions also operate an IIS separately from their state IIS (Centers for Disease Control 
and Prevention, 2018b). Policies that govern the operation of IISs are complex in design and 
interpretation, have been described in detail elsewhere (Horlick, Beeler, & Linkins, 2001; 
Martin, Lowery, Brand, Gold, & Horlick, 2015). These policies include the type of governing 
authority under which states operate their IIS. States may have an explicit law to operate an IIS 
or may operate under a more general public health statute by which they extrapolate their 
authority as a public health interest (Horlick et al., 2001). Additionally, these policies dictate the 
immunization entities that are mandated to report immunizations to the IIS (if any), the type of 
patient consent required to include information in the IIS (opt-in, opt-out, or mandatory), and 
who will have access to this data (authorized access and interoperability laws). While the laws 
have been described in detail in the IIS literature, there remains a gap in the research examining 
these laws effects on immunization rates.  
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Early research examining whether the probability that a child was up-to-date (UTD) on 
all of their vaccines demonstrated no effect between provider IIS participation and UTD status 
(Kim, Frimpong, Rivers, & Kronenfeld, 2007; Mennito & Darden, 2010). However it is possible 
that IISs were not well-established at the time of the studies. Research in Australia demonstrated 
a 30% increase in overall immunization rates ten years after the implementation of an IIS 
(Groom et al., 2015). Rates for individual immunizations, such as the seasonal influenza vaccine, 
showed that IIS utilization to conduct proactive outreach and send vaccine reminders increased 
immunization rates (Bluml, Brock, Hamstra, & Tonrey, 2017; Dombkowski, Harrington, Dong, 
& Clark, 2012).  
It is possible that progress in improving rates with IISs is slow and that is why previous 
research did not demonstrate an effect on UTD status and more time is needed. Research so far 
has not looked at individual vaccine improvements for incremental progress or assessed whether 
IISs improve the quality of vaccines by reducing the number of invalid doses- doses that are 
delivered too young or too close together. Several studies have examined invalid doses, though 
these studies are also quite dated. The rate of invalid doses in U.S. children is around 10%. IISs 
have the capacity to forecast vaccine needs, using immunization histories housed within the IIS 
and ACIP recommended guidelines, to support providers at the point of care. Thus far, research 
has not examined whether IISs are effective at reducing the number of invalid doses.  
To support state immunization programs’ goals for increasing immunization rates and 
improving quality using IISs, a series of Functional Standards were developed through a 
collaboration between the Centers for Disease Control and Prevention (CDC), National Center 
for Immunizations and Respiratory Diseases (NCIRD), the Immunizations Information Systems 
Support Branch, IIS managers and other technical experts (Immunization Information Systems 
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Support Branch within CDC/NCIRD, 2013). These standards promote the utilization of IISs to 
improve immunization delivery at the point of care, maintain accurate and complete 
immunization records while maintaining confidentiality, and working with all authorized 
stakeholders within the purview of state laws and statutes (Immunization Information Systems 
Support Branch within CDC/NCIRD, 2013). These functional standards offer a framework for 
IISs to measure their progress and effectiveness, but to date, literature has not measured these 
functional standards to evaluate IISs. 
Research Aims 
Vaccines are highly effective at preventing disease which can cause complications such 
as disability and death (Andre et al., 2008a). Although child immunization rates are relatively 
high, the U.S. consistently misses its targets and rates show evidence of declines (Hill et al., 
2017). These declining rates leave communities vulnerable, with vaccine-preventable disease 
outbreaks increasing in frequency and size. Since the mid-1990s, numerous investments have 
been put into the development of IISs to improve immunization rates and help reduce the burden 
of VPDs (Freeman & DeFriese, 2003; Hinman et al., 2007). Although widespread adoption of 
IISs by states has occurred, research on their effectiveness at improving the quality and rates of 
vaccination are unclear. 
Proponents of IISs have claimed that IISs have the capacity to improve immunization 
rates, but only when providers participate and when patient data is sent to the IIS (Clark, Cowan, 
& Bartlett, 2006; Freeman & DeFriese, 2003). However, early research suggests IIS participation 
is not associated with improvements in completion rates for the full combined childhood vaccine 
series (Kim et al., 2007; Mennito & Darden, 2010). Work from Australia suggest this change 
may occur over a longer period of time, and it is possible (Groom et al., 2015). Few studies have 
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explored deeper the participation by providers and patients’ influences over this participation and 
utilization of IISs (Kim et al., 2007; Luman, McCauley, Stokley, Chu, & Pickering, 2002). Both 
provider beliefs and parental characteristics have been associated with improved immunization 
rates (Kempe et al., 2017; Luman, McCauley, Shefer, & Chu, 2003). And while details about 
IISs policies are available in the literature (Horlick et al., 2001; Martin et al., 2015), a gap exists 
in how IIS policies affect immunization rates. Further, studies on IIS utilization and effectiveness 
are often limited to targeted populations, localized areas, or specific immunization needs, all of 
which prevents generalizability to the broader population (Groom et al., 2015).  
The purpose of this dissertation is to examine relationships between IIS policy and 
participation on immunizations in pre-school aged children. Throughout this dissertation, I 
incorporate data from the national, state, provider, and aggregate individual levels to examine the 
association of IISs with immunizations using three sources of publicly available data from the 
CDC: The National Immunization Survey (NIS), the Survey of State Immunization Information 
System Legislation (IIS Leg), and the Immunization Information Systems Annual Reports 
(IISARs). To address this overarching aim, I conducted three separate studies using the 
following research aims: 
Research Aim 1: Evaluate the relationship between provider participation in an IIS and up-to-
date vaccination status for the full combined series of routine vaccines in children aged 19-35 
months in the United States.  
Hypothesis 1: Children whose providers participate in an IIS have a higher probability 
of receiving the full combined series of age-recommended vaccines than children whose 
providers do not participate in an IIS. 
8 
 
Research Aim 2: Examine the relationship between IIS utilization and invalid vaccinations in 
children 19-35 months of age. 
Hypothesis 2: Children whose providers participate in an IIS will have fewer invalid 
vaccines administered outside of the required age and interval between doses. 
Research Aim 3: Analyze the relationship between mandate, consent, and vaccine forecasting as 
proxies for measuring the IIS functional standards and state up-to-date immunization rates. 
Hypothesis 3a: States with full reporting mandates and mandatory consent policies will 
be associated with higher state UTD rates. 
Hypothesis 3b: States that forecasted vaccines to an electronic health record will be 
associated with higher state UTD rates than states that did not forecast vaccines. 
Dissertation Contributions 
This dissertation research adds to the growing literature on IIS evaluation by examining 
the relationships of IISs on vaccination status. This work contributes to the literature in three 
ways. First, it supports the previous literature in finding no effect of IIS participation on child 
UTD status but adds new data on the association between IIS participation on invalid doses. 
Second, this research aligns with previous studies on the effect of mandate and consent types on 
state immunization rates and adds new findings about the effect of an interaction between 
mandate type and consent. The finding that states with no provider mandate are associated with 
higher immunization rates highlights the importance of provider beliefs on immunizations. This 
dissertation also contributes meaningful data as to the role of states influence on immunizations. 
States with higher odds of child UTD and lower odds of invalid doses may have policies, 
programs, and resources that prioritize quality of immunizations over quantity compared with 
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states that are associated with higher odds of child UTD and higher odds of invalid doses. Finally 
these studies further highlight the dynamic but important relationships between policy, and 
participation by providers and parents that can inform future immunization improvement 
strategies. 
Dissertation Organization  
This dissertation is organized into six chapters following a hybrid three-essay format. In 
Chapter 2, I present a review of the literature that provides background information and 
conceptualizes the impacts IISs have on immunizations, critiques the current research, and 
identifies the gaps that I will address in the remaining chapters. This literature chapter adds 
context and background that is not present in the literature sections of the three essays to help the 
reader understand the structure and function of IISs. In Chapters 3-5, I present my three research 
essays examining the association of IIS participation on the up-to-date vaccination status in 
children 19-35 months old (Chapter 3), the relationship between IISs and invalid doses (Chapter 
4), and lastly I evaluate the association of IIS policies and provider participation on state-level 
immunization rates (Chapter 5.). I will then provide concluding remarks and future directions for 
IIS research in Chapter 6.  
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Chapter 2 Literature Review 
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Background 
Immunization information systems (IISs) have been widely adopted to increase 
immunization rates, reduce record fragmentation, and improve the overall quality of vaccines. 
Research is needed to understand how large investments in immunization information system 
technologies are generating improvements in vaccine coverage and reducing vaccine preventable 
diseases that are predicted by theory. Existing studies offer mixed evidence regarding the 
relationship between IISs, and vaccinations. Several studies find that IISs help improve 
immunization delivery by improving immunization record keeping and increasing immunization 
rates through features such as clinical decision support (Bluml et al., 2017; Dayton, 2014; Groom 
et al., 2015; Zimmerman, Bartlett, Enger, Gosney, & Williams, 2007). Others fail to reject the 
null of no effect of IIS participation on immunization rates (Kim et al., 2007; Mennito & Darden, 
2010).  
Several gaps exist in current IIS evaluative research. There is a dearth of literature on the 
effects between state IIS policies on immunization rates. Functional standards have been 
designed to promote the utilization of IISs to improve immunization rates and help programs 
measure the effectiveness of IISs, yet research on how well IISs achieve these functional 
standards is remarkably absent. In the following paragraphs, I provide the background on 
immunization information systems and their relationship to vaccine-preventable diseases to 
better understand how they can function to improve immunization rates and quality of vaccines 
administered, as well as identify gaps in the current research. 
Links Between Vaccinations and Vaccine-preventable Diseases 
 Vaccinations are one of the greatest public health achievements (Control & Prevention, 
2011). Widespread adoption of vaccines has led to dramatic decreases in morbidity and mortality 
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worldwide. Although there has been more than a 99% decrease in disease and deaths attributable 
to these diseases (Roush & Murphy, 2007). However, recent evidence suggests that 
immunization rates are declining (Hill et al., 2017), and vaccine-preventable disease outbreaks 
are increasing in frequency and size (Gahr et al., 2014). Contributors to these low rates include 
record fragmentation and incomplete vaccination histories, the inability to determine vaccination 
needs, and rising prevalence of vaccine hesitancy (Larson, Jarrett, Eckersberger, Smith, & 
Paterson, 2014; Stokley et al., 2001). 
Currently, the ACIP recommends vaccines to protect children against 16 vaccine-
preventable diseases (Centers for Disease Control & Prevention, 2015a). The age and timing of 
immunization is important to maximize the protective benefits of vaccination. The complex 
childhood vaccination schedule increases the difficulty in tracking immunization status by 
providers and parents and increases the likelihood of missed opportunities or receiving 
inappropriate doses (Feikema et al., 2000; Luman et al., 2002). Additionally, children frequently 
have multiple providers or receive immunization outside of their primary care provider’s office 
which leads to fragmented records (Freeman & DeFriese, 2003; Yusuf et al., 2002). To increase 
immunization rates, it is important to have a system that can track immunizations across 
providers and provide real-time immunization histories (Gostin & Lazzarini, 1995). The use of 
immunization information systems is one strategy that has the potential to achieve these benefits 
and to improve immunization rates. 
Operation of IISs 
In the U.S., IISs are operationalized primarily at the state level and are governed by a 
variety of state laws and statutes (Martin et al., 2015). As a result, state IISs are at various stages 
of maturation which affects how they perform and function. Although states have varying 
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priorities, a series of functional standards guide state immunization programs on how to 
maximize the benefits of the IIS and provide a framework for evaluation (Immunization 
Information Systems Support Branch within CDC/NCIRD, 2013). Generally, there are six 
functional standards that IISs strive to achieve: 
1. Support the delivery of clinical immunization services at the point of immunization. 
2. Support the activities and requirements for publicly-purchased vaccine, including the 
Vaccines For Children (VFC) and state purchase programs. 
3. Maintain data quality (accurate, completely, timely data) on all immunization and 
demographic information in the IIS. 
4. Preserve the integrity, security, availability and privacy of all personally-identifiable 
health and demographic data in the IIS. 
5. Provide immunization information to all authorized stakeholders. 
6. Promote vaccine safety in public and private provider settings. 
Operationally, IISs contain a list of core data elements that are suggested for collection 
(Centers for Disease Control and Prevention, 2013). Examples of the types of data include 
patient-specific information (e.g. name, address, birth date, birth facility, demographics and other 
identifiers, historical vaccine/disease data), vaccine-specific information (e.g. manufacturer, lot 
number, expiration date), and vaccine-administration information (e.g. site of delivery, date of 
administration, vaccine information statement version number) and provider-specific information 
(e.g. provider facility, ordering providers, administering provider)(Immunization Information 
Systems Support Branch within CDC/NCIRD, 2013). The core data elements are critical for 
information data exchange, for example, when multiple records from different systems are being 
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merged or transferred to a new system. The core data elements are also vital for ensuring 
complete and accurate records in the IIS. 
IISs consolidate immunization records to improve immunization rates 
Historically, there has never been a standardized way to document, track, and access 
vaccination information in the U.S. leading to fragmented or scattered records (Yusuf et al., 
2002). Fragmentation of immunization records across multiple providers led to the 
administration of vaccines at inappropriate ages or intervals between doses, extra immunizations, 
or allowed for completely missed opportunities for vaccination (Feikema et al., 2000; Stokley et 
al., 2001; Yusuf et al., 2002) and is considered a barrier to completion of the immunization series 
(Klevens & Luman, 2001).  
While electronic medical records have standardized documentation practices for 
vaccinations, they did not fix the problem of record scattering or fragmentation. Many children 
have multiple immunization providers (Yusuf et al., 2002). In a rapidly changing vaccine 
delivery system, the likelihood of multiple providers is increasing with the ability to now receive 
vaccines from school settings, pharmacies, or other wellness clinics (Orenstein et al., 2005). 
Additionally, Americans today are increasingly mobile thereby creating fragmentation of 
medical records if records are not migrated to the new location (Stokley et al., 2001). In one 
study, 30% of children who were not up-to-date on their vaccines had changed providers since 
birth (Freeman & DeFriese, 2003) highlighting the impact of record fragmentation on 
immunization rates. 
Today’s immunization information systems (IISs) are confidential, centralized, electronic 
hubs that house immunization data and offer additional functionality to serve immunization 
programs (Centers for Disease Control & Prevention, 2013). IISs consolidate demographic 
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information and immunization records, from all sources (e.g. pharmacies, vital statistics, etc.) 
while maintaining patient privacy and confidentiality (Hendrickson, Panchanathan, & Petitti, 
2015; Wood, Saarlas, Inkelas, & Matyas, 1999) addressing the problem of record scattering and 
fragmentation. Multiple sources of vaccine information have been linked with higher accuracy of 
immunization histories and are more likely to result in complete records (Davidson et al., 2003; 
Hendrickson et al., 2015). However, systems may not be linked to other data sources (Dayton, 
2014). Concerns over data accuracy have arisen over record duplications because of data 
mismatches (Davidson et al., 2003; Hendrickson et al., 2015). 
IISs rely on data submitted by participating providers electronically, or in some cases, by 
hard copy (e.g. paper records, faxed documents, etc.) (Hinman & Ross, 2010; "Progress in 
development of immunization registries--United States, 1999," 2000). When a provider enters a 
dose on a patient into the EHR, that information is sent either in real-time or batched at specific 
times to the IIS (Martin et al., 2015). For many IISs, this electronic linkage was unidirectional 
meaning data went from EHR to IIS, but providers were not always able to retrieve the vaccine 
information from the IIS (Murthy, Rodgers, Pabst, Fiebelkorn, & Ng, 2017).  
State-wide IISs will not completely solve the problem of fragmented records since they 
are limited to the state where they operate. Currently, there are no plans for a nationally linked 
IIS due to differences in policies and laws surrounding privacy, consent, and data collection.  
IISs improve rates by supporting providers at the point of care 
IISs can also improve rates by supporting providers at the point of care using clinical 
decision support tools. As IISs were further developed, a bi-directional communication pathway 
was created that allowed other providers, health officials, or school nurses to query the system to 
obtain a vaccination record or retrieve a vaccine forecast that recommended vaccines that were 
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“due” for a specific patient (Immunization Information Systems Support Branch within 
CDC/NCIRD, 2013). This enables providers to provide appropriate vaccinations and reduces 
errors in vaccine administration or prevents a missed opportunity to vaccinate (Freeman & 
DeFriese, 2003). Due to the complexity and expanding ACIP schedule of routine vaccines, the 
clinical decision support feature helps physicians choose the appropriate vaccine at the right time 
for a specific patient.  
It has been difficult to evaluate how well these features work due to the inability to 
conduct evaluations at the clinical sites on how providers utilize IIS features (Groom et al., 
2015). Additionally, not every IIS has forecasting capabilities which further limits evaluation. 
Few studies have examined clinical decision support tools in proactive influenza campaigns and 
demonstrated improvements in immunization rates (Bluml et al., 2017; Zimmerman et al., 2007). 
These studies, however, did not look at complex vaccine series and were conducted in adult 
populations. In theory, by offering a centralized hub for immunization data, public health 
officials, providers, and other stakeholders can actively monitor immunizations, deliver better 
patient care, and use the information in the IIS to improve the overall immunization program. 
IIS policies can influence participation and overall immunization rates 
Every state that operates an IIS has policies that dictate the capabilities, participation, and 
utilization of the vaccine information. The type of authority that states use to operate an IIS vary 
among the states from being explicit about operating an IIS to the operation of one under an 
assumption of a public health statute (Horlick et al., 2001). In addition to the authority are 
policies that dictate participation in the IIS. Mandates for reporting immunizations to the IIS 
affect providers, pharmacies, and other facilities that administer immunizations (Centers for 
Disease Control & Prevention, 2015b; Madewell et al., 2017). They may be full mandates that 
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apply to all facilities and all age groups, or they may specify restrictions that only apply to some 
facilities or providers, such as those who participate in the VFC program, or to specific age 
groups (e.g. children under 6 years, or all ages) (Centers for Disease Control & Prevention, 
2015b).  
Participation also extends to those patients who have their data in an IIS which is 
determined often by the IIS consent policy. Some states have an explicit consent process which 
requires patients to actively opt-in to having their vaccines submitted to the IIS. This requires 
recruitment of patients, often by the participating providers, who would have to educate and 
provide informed consent to patients prior to submitting data (Berry et al., 2013; Boom, Sahni, 
Nelson, Dragsbaek, & Franzini, 2010). Other states use an implicit consent process which is an 
implied consent that automatically opts patients into the IIS. They are still educated and notified 
of the IIS, and in some cases, are given information on how to opt-out should they wish to have 
their data excluded from the IIS (Berry et al., 2013; Hedden, Jessop, & Field, 2012). However, 
there are states that mandate patient participation in an IIS with no ability to opt out with the 
rationale that vaccinations are a public health issue and included in statutes that govern other 
public health data in the state.  
Finally, data sharing policies and interoperability are a critical component in the 
operation and success of an IIS. The presence of data in an IIS is not useful if there is no access 
or policy for using or sharing the data with other immunization stakeholders (e.g. other providers 
who may need records) (Hendrickson et al., 2015; Hinman et al., 2007). States determine which 
users can have access to the data, and what type of access they will have (read-only or capable of 
making changes to the information) (Centers for Disease Control and Prevention, 2018b). 
Additionally, states will sometimes have agreements with other IISs for data-sharing, but these 
18 
 
agreements are complicated by differences in confidential data-sharing laws and privacy of 
health data through Health Information Portability and Accountability Act (HIPAA) (Freeman & 
DeFriese, 2003; Hendrickson et al., 2015).  
The policies mentioned above have been well-documented in the literature and updated 
over time to reflect policy changes (Hedden et al., 2012; Horlick et al., 2001; Martin et al., 
2015), however, there has been little research about how these policies that govern the operation 
of an IIS affect immunization rates. Madewell et. al., (2017) states that provider participation 
will be lower in the presence of a reporting mandate, yet another group says that mandates are 
required for increasing provider participation (Groom et al., 2015). Consent policies are a little 
clearer in the literature. Participation will be higher with implicit or mandate policies and lower 
with explicit opt-in policies that require extra steps by the patients to opt-in (Berry et al., 2013; 
Boom et al., 2010). Studies have not examined the effects of these policies on actual 
participation, highlighting an important gap in the literature and for policymakers considering 
other policy types for their state IISs. 
 The gaps identified throughout this review serve as the impetus for the research aims 
outlined in Chapter 1. This dissertation will address the IIS literature by examining the 
relationship between IIS participation on child UTD status, IIS participation on invalid doses, 
and IIS policies and provider participation on state UTD rates in the next three chapters. 
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Chapter 3 Immunization Information Systems’ and the Association with Up-to-
Date Status in U.S. Children 19-35 Months of Age 
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Introduction 
Vaccines are widely accepted as safe and cost-effective strategies for preventing the 
contraction and spread of vaccine-preventable diseases (VPDs). In many cases, morbidity and 
mortality have been reduced by as much as 99%  (Andre et al., 2008b; Roush & Murphy, 2007), 
and rates for individual vaccines have remained “high and stable” (Hill et al., 2015) over the last 
decade. However, as successful as vaccines have been, in order to maintain the protection against 
VPDs, high rates of vaccination must be sustained (Brunson, 2013). Evidence that protection 
may not be at optimal levels remains present throughout the United States (Diekema, 2012).  
Several recent examples of outbreaks in the U.S. have demonstrated the vulnerability of 
under-protected populations. Between 2001 and 2015, more than 1,789 confirmed measles were 
recorded and at least 70% of those occurred in unvaccinated individuals (Clemmons, Wallace, 
Patel, & Gastañaduy, 2017). The multi-state outbreak of measles originating in a crowded theme 
park in 2016 demonstrated the speed and mobility of a highly contagious infection to spread 
throughout an under-protected population (Chemerinsky & Goodwin, 2016). In 88% of those 
confirmed cases (110/125), patients were either unvaccinated or had an unknown vaccination 
status (Porteous et al., 2016) and the close contact within a crowd further increased the risk of 
spreading the disease. In 2017, Minnesota experienced an outbreak of measles with 75 confirmed 
cases including at least 20 hospitalizations (Hall et al., 2017; Minnesota Department of Health 
[MDH], 2018). Ninety-five percent of those cases were in unvaccinated people (Hall et al., 
2017). That outbreak also demonstrated the capacity for these diseases to cause serious illness in 
modern day society. Outbreaks have not been strictly due to measles; the number of pertussis 
cases is also increasing even after accounting for the natural cyclical incidence of the pertussis 
organism (Carrico & O'keefe, 2013; Cherry, 2012). In 2014, California documented 10,831 cases 
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of pertussis including two infant deaths and hundreds of hospitalizations (Minnesota Department 
of Health [MDH], 2018).  
In these examples, most infected patients were unvaccinated, though it remains unclear 
how many were simply under-vaccinated, or were not able to be vaccinated, and how many 
infections could have been prevented. While the U.S. has been successful in achieving relatively 
high rates of vaccination (Hill et al., 2015) these outbreaks have been associated in the literature 
with decreases in vaccination (Aloe, Kulldorff, & Bloom, 2017) and provides the impetus for 
further investigation into the vaccination status of the U.S. population. 
The U.S. national vaccine program has different recommendations for vaccination 
dependent upon age, health status, and other risk factors. Children are frequently the focus of 
vaccination efforts to increase vaccine uptake for several reasons. First, they represent a 
vulnerable population as their immune systems are not fully mature (McDade, 2003) placing 
them at increased risk of infection and complications. Often, people with immune system defects 
are identified in early childhood and represent a smaller population who should not be vaccinated 
with certain types of vaccines (Cooper, Pommering, & Koranyi, 2003; Rubin et al., 2013). These 
children rely on herd immunity for protection against those diseases where vaccines are 
contraindicated. Second, the majority of routine childhood immunizations are given in the first 
three years of life and it can be challenging for parents to adhere to an increasingly complex 
vaccination schedule thus reducing the likelihood that a child receives all of the necessary doses 
for full protection (Zell, Ezzati-Rice, Battaglia, & Wright, 2000). Third, when un-vaccinated 
children reach school-aged they may become carriers for these infections which places 
classmates, younger children in day cares, grandparents, and other potentially vulnerable people 
at risk for contracting serious infections (Salmon et al., 2005).  
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The progress of the U.S. national immunization program is measured in part by 
estimating rates of vaccine completion (Murray & Frenk, 2000). The Advisory Committee on 
Immunization Practices (ACIP) is a group of leading experts on immunizations who evaluate the 
scientific evidence pertaining to the safety and effectiveness of vaccines (Centers for Disease 
Control & Prevention [CDC], 2016). They release updated schedules which recommend the type, 
number, spacing, and ages for each dose of a vaccine that would be required for a child to be 
optimally protected (Ahmed, Temte, Campos-Outcalt, Schünemann, & ACIP Evidence Based 
Recommendations, 2011). These recommendations are available publicly, along with 
information about the vaccines themselves so that parents and providers can make informed 
choices. The immunization schedule represents the standard by which vaccination progress is 
measured.  
In the U.S., immunization information is collected using the National Immunization 
Survey (NIS), the current gold-standard since 1994 for estimating vaccination rates (Zell et al., 
2000). This two-part survey culminates with the collection of immunization data on age-eligible 
children whose households were selected for participation. The information is submitted by a 
child’s vaccination providers and, following a complex survey design, is weighted to be 
representative of the population of children in target age ranges (e.g., 19-35 months, 4-6 years, 
etc.). Rates derived from the NIS are used to measure progress toward achieving the Healthy 
People 2020 immunization objectives (US Department of Health and Human Services, 2011a). 
When comparing the NIS vaccination rates published in an annual Morbidity and Mortality 
Weekly Report (MMWR), the U.S. consistently fails to reach the immunization targets of 90% 
for individual vaccines and 80% for the routine full combined series by the age of three years 
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(US Department of Health and Human Services, 2011c). This has motivated the public health 
community to improve the national rates.  
Multiple strategies have been utilized to improve vaccination rates in children since the 
Healthy People initiative began publishing immunization goals in 1979 (United States 
Department of Health Education Welfare, 1979). Aggressive campaigns were created for 
increasing vaccine awareness, acceptance, and uptake. Programs to improve access to vaccines at 
lower out of pocket costs, such as the Vaccines For Children (VFC) program and a preventive 
health mandate in the Affordable Care Act which included vaccines at no out of pocket costs, 
have helped families throughout the U.S. (Koh & Sebelius, 2010; Lee et al., 2007). Additionally, 
stricter requirements for school entry motivated many parents to get their children up-to-date on 
their vaccines (Orenstein & Hinman, 1999). To help parents with the complicated vaccine 
schedule, provider-based reminder/recall systems were able to inform parents when their 
children were due for a vaccination (Freeman & DeFriese, 2003).  
Even though efforts to improve vaccination rates have been somewhat successful, 
progress has been attenuated by several threats to vaccine uptake which have simultaneously 
gained momentum in recent years. Currently, there is no real-time and precise method to 
determine vaccination rates, or gaps of unvaccinated within a community which would allow 
public health officials and clinicians to target immunization interventions (Freeman & DeFriese, 
2003). Estimated rates are only reliable at a national level and may not represent the true 
coverage within a community and potentially increases the risk for outbreaks of VPDs in 
communities that are not fully protected (Luman et al., 2002). 
It is important to mention these challenges that public health officials face because it 
helps to explain why achieving target vaccination rates remains elusive. First, parental and 
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provider vaccine hesitancy is increasing in the U.S. with many parents perceiving the risks of 
vaccination greater than the risk of the disease it prevents (Chatterjee & O’Keefe, 2010; Smith et 
al., 2011). Though risks of contracting a VPD may be low within a person’s community, the 
increasing mobility of society has led to an increase in outbreaks due to importation of an 
infection. Importation of an infection into an under-protected community has the potential to be 
catastrophic (Boggild et al., 2010; Gushulak & MacPherson, 2004). Second, the reduced 
incidence rate of VPDs has led to a generation of providers’ who lack experience in identifying 
and treating vaccine-preventable infections (Brookes, 2017; Chatterjee & O’Keefe, 2010). Third, 
safety-conscious parents concerned with the number of vaccines recommended at a single visit 
have sought providers willing to provide an alternative vaccination schedule, which arbitrarily 
spaces vaccines out over more time and additional visits (Offit & Moser, 2009; Pediatrics, 2012). 
However, these alternative schedules only serve to delay vaccinations and the safety and efficacy 
has not been supported by the literature at this time (American Academy of Pediatrics, 2008). 
Finally, children are more likely to have multiple providers (National Center for Immunization 
and Respiratory Diseases, 2017; Stokley et al., 2001), which in the absence of a universal 
electronic health record, creates the potential for fragmented vaccine records and raises questions 
about the true vaccination status for the child.  
One strategy to improve rates that is gaining national traction are the use of Immunization 
Information Systems (IISs) or immunization registries. An Immunization Information System is 
an electronic repository that has the capability of housing all the specifics of a given vaccine 
dose in a population-based database (Groom et al., 2015). IISs rely on participating providers to 
supply vaccination data electronically. When a vaccine is given to a patient, the information is 
sent either in real-time, or batched at specific times, as an upload to the IIS (Martin et al., 2015). 
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IISs also contain a feature which can recommend or forecast vaccines for a specific patient, 
provided they are in the IIS database, according to the ACIP schedule for that child’s age and 
history of vaccination (Groom et al., 2015). Depending on the data sharing and query capabilities 
of the IIS and facility, other providers, health officials, or school nurses, with consent, can query 
the system providing a bi-directional unified flow of vaccine information which would ideally 
lead to improved adherence, documentation, tracking and rates of vaccination.  
The real-time capability could also allow public health officials to use geographical 
coding to look at localized immunization rates in specified areas for targeted interventions or 
outbreak investigations if data quality and assurance could be optimized. Additionally, it could 
potentially solve the problem of record scattering (Martin et al., 2015) since the IIS houses all 
vaccine information on a specific patient which was uploaded by participating providers. This 
means for example, that if a child has four immunization providers and all are participating in an 
IIS, they would be able to receive the vaccine information from each other using a single query 
and without the need for their EMRs to be directly linked. A potential drawback remains if a 
child were to leave the catchment area of the IIS, which frequently happens when children move 
out of state. 
Though IISs have been stated as a proven strategy for improving immunization rates, and 
large investments have been made by states’ and the federal government (Freeman & DeFriese, 
2003; Rask, Wells, Kohler, Rust, & Cangialose, 2000), there is a paucity of research regarding 
the effect IISs have had on immunization rates. There is currently no national IIS since 
immunization programs are implemented at the state level, but there are 55 IISs operating at 
state, local, and regional scopes (Murthy et al., 2017). These independent IISs can capture and 
coordinate records within a state or region but sharing information between these IISs is 
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complicated by the various state laws and statutes that govern their operation (Groom et al., 
2015; Martin et al., 2015), and thus leaves the U.S. without a linked system for vaccine tracking. 
The interoperability of IISs is outside the scope of this paper and is covered elsewhere in this 
dissertation. 
There has been little research specifically on the role that provider’s participation in an 
IIS has on the impact on childhood vaccinations. The goal of this chapter is to evaluate the 
relationship between provider participation in an IIS and up-to-date vaccination status for the full 
combined series of routine vaccines in children aged 19-35 months in the United States. 
Conceptual Framework 
Vaccination policies occur at the national and state-levels in the U.S., while vaccine 
uptake results from a series of complex and dynamic relationships between public health entities, 
providers, and parents. To guide my research, I developed a conceptual framework (Figure 3.1) 
that depicts the most important relationships relevant to childhood vaccination status. In this 
paper, child’s vaccination status will be measured by whether a child is fully up-to-date on the 
full combined series of routine vaccinations recommended by the ACIP which is determined at a 
national level in the U.S. Specifically, I am interested in the relationship between provider 
participation in an IIS and the likelihood that a child has received the full series of recommended 
vaccines, also known as being up-to-date (UTD). In my model, I include child characteristics as 
controls, as well as maternal characteristics since a child’s mother is often the most influential 
person in vaccine decision-making, I include characteristics that are potential influencers of the 
mother’s knowledge and behavior since this cannot be directly measured by this dataset. Finally, 
as my predictor of interest, I include a variable that proxies for provider participation in an IIS.  
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Figure 3.1 Conceptual Framework for Child Vaccination Status 
 
Methods 
Data source. The National Immunization Survey data is collected through a two-phase 
process described in detail in the literature (Smith et al., 2001; Zell et al., 2000) and throughout 
this dissertation. The first phase is intended to identify households with children in the targeted 
age range of 19-35 months during the 2016 calendar year. The NIS uses random-digit dialing 
survey (RDD) and a dual-frame design that encompasses sampling techniques for both telephone 
landlines and mobile numbers due to the decrease utilization of household landlines. During the 
first phase, demographic information and some vaccine information is collected from the person 
in the household most knowledgeable about vaccines for the child- typically a parent or 
guardian; most frequently the mother is the respondent (National Center for Immunization and 
Respiratory Diseases, 2017). During this phase, the parent/guardian is asked to identify all the 
child’s immunization providers and consent is obtained to contact those providers and request 
the immunization records. 
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The second phase of the NIS, the provider record check study, a survey is mailed to all of 
the identified providers for the eligible child(ren) identified in phase I. Providers are asked to list 
all vaccines in a child’s record, type, and date given so that an age for each dose can be 
calculated.  
Study sample. Children ages 19 to 35 months of age in the 2016 National Immunization 
Survey data set in the fifty states and Washington, D.C. with adequate provider data are included 
in this study (N = 14,988). Adequate provider data is defined as one or more vaccine providers 
who report immunization data on a child during the provider-record check portion of the NIS. 
Children who are unvaccinated are also considered to have adequate provider data if a provider 
is identified by the parents and the provider responded with “child has received no vaccines”. I 
exclude Puerto Rico and other territories since I am interested in understanding the effect of 
participation in IIS within the states and information about how IIS operate in Puerto Rico, if 
any, is not within the scope of this research. I also exclude children who are missing values for 
the registry variable (N = 237) for a final sample size of N = 14,751.  
Design. In this study, I analyze the relationship between the up-to-date vaccination status 
and whether the provider reported a participant child’s vaccination data to an IIS. I conduct a 
secondary analysis using the 2016 NIS. Survey weights (Dual-Frame RDD weights) are utilized 
for the summary statistics and Chi-squared analyses to examine bi-variate relationships. Provider 
weights are suggested in the NIS Data User Guide for conducting immunization assessments on 
children with adequate provider data and are utilized in the regression analyses (National Center 
for Immunization and Respiratory Diseases, 2017). The complex survey design makes the 
dataset representative of the U.S. population of 19-35 months old children. Lastly, to examine 
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the effect of registry participation on UTD status, I use a logistic regression model that is guided 
by the conceptual framework.  
Dependent variable. For this analysis, the dependent variable is a dichotomous up-to-
date (UTD) indicator for whether a child received the full combined series of ACIP routinely 
recommended vaccines. This series includes 4 DTaP, 3 Polio, 1 MMR, 3 Hib, 3 HepB, 1 Var, 
and 4 PCV doses by 35 months of age (Hill et al., 2015), also known as the 4:3:1:3:3:1:4 series, 
hereafter referred to as the full combined series. I examine the full series of routinely 
recommended vaccines since it is the most representative of a child’s overall protection against 
vaccine preventable diseases and is the series recommended for school entry.  
Independent variables. The independent variable of interest is whether a child’s data 
was submitted to a registry or IIS by their providers. This data is collected in response to a 
question on the provider record check survey in phase II of the NIS and is proxying for provider 
participation in an IIS or registry. This categorical variable is re-coded as No Participation if the 
child is recorded as “None” of the child’s providers submitted the immunization information to 
an IIS, Any Participation if the child is recorded as having “Some but possibly or definitely not 
all”, or “All of the providers” submitted to an IIS, and Unknown Participation for children whose 
providers marked “Unknown” when asked if child’s records were submitted to an IIS.  
Provider characteristics. This dataset does not capture much information about the 
provider, however, the type of provider(s) a child has (e.g. All public, All private, All hospital) is 
included and is used to proxy for provider’s beliefs since providers choose their type of practice 
which is potentially influenced by their beliefs. For example, public providers are more likely to 
participate in federal vaccine funding programs and may be more likely to administer 
immunizations than private providers (Mennito & Darden, 2010). In the provider-record check 
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portion of the survey, providers self-identify the type of facility they practice in (Centers for 
Disease Control and Prevention, 2016). Providers may select multiple choices from the facility 
type including private (solo, group, or health maintenance organization), hospital-based clinic, 
public health clinic, military hospital, various health centers (migrant, rural, community), and 
other facilities such as pharmacies, Women, Infants, and Children, and school-based clinics. I 
make the assumption that all public-health clinics, including rural and community health centers, 
are categorized as public facilities, hospital-based clinics as hospital facilities. Those that do not 
fit into the criteria of public, private, or hospital, (e.g. pharmacies) are assumed to be categorized 
in the Military/Other category. The provider type variable is re-coded and  aggregated at the 
child level in the public-use data file and prevents analyses of individual providers.   
State-level influence. Current state of residence is included to help control for state-level 
immunization policies. There are currently no national laws, however, the ACIP makes national 
recommendations which are then carried out by state immunization programs. These 
immunization policies also affect state-run IIS and may influence provider behavior. 
Additionally, I include a variable that assesses mobility measured by whether a child currently 
lives in a different state from where they were born to adjust for state selection effects of 
vaccination history 
Maternal characteristics. Previous literature on vaccination behaviors suggests that 
mothers are the most influential person in childhood vaccination decisions (Luman et al., 2003); 
their attitudes toward vaccination were significantly predictive of infant vaccination status (Fadel 
et al., 2017). There is no direct way to measure maternal beliefs and behavior, so I proxied for it 
in several ways. I select variables that have been identified in the literature as influential on a 
mother’s vaccine knowledge and decision-making (Luman et al., 2003) including: maternal age, 
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maternal education, a household income and poverty variable, and whether a child received a 
birth dose of Hep B vaccine.  
Younger maternal age has been associated with lower child vaccination rates (Luman et 
al., 2003), so controlling for maternal age (≤ 29 yrs or > 29 yrs) is important when evaluating the 
effect of IIS on rates. The effect of maternal education is less clear on child vaccination status. 
For example, older studies have shown that advanced maternal education is associated with 
higher rates of childhood vaccinations (Luman et al., 2003), however, more recent studies have 
shown there are clusters of individuals with college education who are less accepting of vaccines 
(Healy & Pickering, 2011). Therefore, I include maternal education (< 12yrs, 12 yrs, > 12 yrs- 
non-college grad, College Grad) as a control to help improve the fit of the model.  
Disparities in vaccination rates have also been identified based on socio-economic status 
(Reich, 2014), therefore, I include a poverty status variable, available for all children, that is 
based on the 2011 through 2015 Census data for poverty thresholds (Centers for Disease Control 
& Prevention, 2017). This variable is coded as “below poverty”, “above poverty but less than 
$75k” and “above poverty and more than $75k” and an “unknown/refused to answer” group. 
Poverty thresholds are determined annually using the using data from the Census Bureau 
(National Center for Immunization and Respiratory Diseases, 2017). I control for year fixed 
effects in my models to adjust for the annual change. Finally, the birth dose of Hep B may proxy 
for maternal beliefs and behaviors towards vaccination and has been used elsewhere in the 
literature as a covariate or control (Mennito & Darden, 2010; Yusuf, Daniels, Smith, Coronado, 
& Rodewald, 2000). Accepting the birth dose of Hep B might provide insight to the maternal 
beliefs about vaccination at a critical time in parent and child-development. 
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Child characteristics. Child characteristics are included in the model as controls. The 
ACIP recommendations for the full series of routine vaccination, excluding the annual vaccines 
for Flu prevention and the Rotavirus series, to be completed by 18 months of age, therefore, this 
sample of 19-35 months of age old children should all have completed the series at the time of 
data collection (Zell et al., 2000). I use child age group in months (19-23, 24-29, 30-35), gender 
(Male/Female) and race/ethnicity (Black, Hispanic, White, Multiple/Other) as controls. I include 
the child’s race/ethnicity as a control in the model since there are known disparities in the 
immunization rates for vulnerable populations which are typically racially diverse (Hill et al., 
2015). Lastly, I include an indicator for first-born status (Yes/No) because children at lower birth 
orders are more likely to be UTD (Brenner, Simons-Morton, Bhaskar, Das, & Clemens, 2001). 
Analysis. Bivariate Statistics. First, to look for potential sources of selection bias, I 
conduct a series of corrected, weighted Pearson chi-square statistics or design-based F statistics 
to determine statistical significance (α = .05). In Table 3.1, I use the survey tabulate function in 
Stata to obtain design-based F statistics for the variables in my regression model while 
accommodating for the complex survey design (Kreuter & Valliant, 2007) to compare those 
children whose providers answered the provider-check portion of the NIS (those with adequate 
provider data) using provider survey weights, to those who did not have adequate provider data 
and therefore, no vaccine information. This allows for evaluation of differences in those who are 
included in the dataset and those who are excluded. Provider information is not available since 
one of the comparison groups did not complete the provider record check portion of the survey. 
Table 3.2 presents bivariate statistics comparing children’s provider IIS participation so 
that any differences can be attributed to IIS participation and not because of differences in 
participation levels. Finally, I use bivariate statistics to test for relationships between 1) the 
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dependent variable (UTD status) and independent variables, and 2) multicollinearity between 
that may bias regression coefficients.  
Regression Analysis. To address the main research question, I analyze the 2016 NIS data 
using a logistic regression model and cluster the error terms at the state-level, as described 
previously (Cameron & Miller, 2015), and report the adjusted Odds Ratios (aOR) in Table 3.3. 
These states’ fixed-effects treat all data within a state the same with respect to unobserved 
variables such as state immunization policies. The full model for the regression analysis, based 
upon my conceptual framework, is shown below. All variables in the model are categorical with 
variables in bold representing categorical variables with more than two levels.  
Full Model: utdstati= β0 + β1*IISParticipationi1+ β2*Statei2 + β3*ProviderTypei3 + 
β4*Mobilityi4 + β5*MaternalAgei5 + β6*MaternalEducationi6 + β7*IncPovi7 + 
β8*ChildAgei8 + β9*Genderi9 + β10*ChildRace/Ethnicityi10 + β11*First-borni11 + εi 
where utdstat is the dependent dichotomous variable for UTD status and β0 is the probability that 
a child is UTD holding all other variables constant at zero. Provider-level variables include IIS 
Participation as the indicator for provider participation in an IIS and ProviderType as the facility 
type(s) that the child’s provider(s) are employed within. Maternal factors include the 
MaternalAge, MaternalEducation, and IncPov, a measure of income and poverty threshold. Child 
factors included as controls are ChildAge group, ChildRace/Ethnicity, child Gender, first-born 
status, and a Mobility variable to indicate if a child has moved from their birth state. State is also 
included as a geographic control since immunization programs are implemented at the state level 
and this chapter examines state-level IISs. 
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Results 
Summary statistics. Table 3.1 includes the weighted proportions, using the dual-frame 
sampling weights, for the full sample, those with adequate provider data, and those without 
adequate provider data. State-level data can be found in Appendix A. 
Children with adequate provider data did not have statistically significant differences 
from those without adequate provider data by child age group (p = .85), child gender (p = .11), or 
first-born status (p = .67). There are statistically significant differences by child race/ethnicity (p 
= .004) and whether the children were living in a state different from where they were born (p = 
.026). Children who are White or Multiple/Other race/ethnicities have higher rates of 
representation in children with adequate provider data (47.9% and 14.1% respectively) than 
those without adequate data (44.6% and 13.5%); however, the reverse pattern is seen for Black 
and Hispanic children. Black children represent 14.6% and Hispanic children 27.3% of children 
without adequate data compared to the 12.1% and 25.9% respectively for children with adequate 
data.  
Maternal age group does not differ significantly (p = .71) but maternal education (p = 
.009) and poverty status (p < .001) are associated with statistically significant differences 
between children with and without adequate provider data. There is a higher proportion of  
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Table 3.1 Summary Statistics of Sample by Adequate Provider Data Status 
Dual-frame RDD sample weights were used to calculate summary statistics. 
i. Only available for those who have adequate provider data since this is collected during the Phase 2: Provider 
Record Check Survey; aggregated at child-level 
 
 Full Sample  
With Adequate 
Provider Data 
Without Adequate 
Provider Data 
 
p 
Child Age Group (Months)      .85 
   19-23    30.3%    30.3%    30.2%  
   24-29 33.9 34.2 33.7  
   30-35 35.8 35.5 36.1  
Child Gender      .11 
   Male 51.2 50.3 52.1  
   Female 48.8 49.7 47.9  
Child Race/Ethnicity       .004 
   Black 13.3 12.1 14.6  
   Hispanic 26.6 25.9 27.3  
   Other/ Multiple 13.8 14.1 13.5  
   White 46.3 47.9 44.6  
Child First-born Status      .67 
   No 59.9 60.1 59.7  
   Yes 40.1 39.9 40.3  
Moved from birth state        .026 
   No 88.6 89.3 87.8  
   Yes 11.4 10.7 12.2  
Maternal Age (Years)      .71 
   ≤ 29 years 38.3 38.5 38.1  
   > 29 years 61.7 61.5 61.9  
Maternal Education         .009 
   < 12 years (no HS degree) 14.8 16.0 13.3  
      12 years (HS degree) 25.8 25.3 26.4  
   > 12 years, no college degree 23.0 22.1 24.0  
   > College Graduate 36.4 36.6 36.3  
Income/Poverty Status     < .001 
   Above Poverty, > $75k 30.7 31.3 30.0  
   Above Poverty, ≤ $75k 33.3 32.5 34.4  
   Below Poverty 29.0 31.2 26.4  
   Unknown 7.0   5.0 9.2  
Provider Typei    N/A 
   All Public  12.8   
   All Hospitals  13.6   
   All Private  55.8   
   All Military/Other    2.4   
   Mixed  13.9   
   Did not answer (Left Blank)    1.5   
Providers submit to IISi    N/A 
   None    9.4   
   Some, but not all    7.3   
   All  67.7   
   Unknown/Unsure  14.1   
   Did not answer (Left Blank)    1.5   
 N = 27,455 N = 14,988 N = 12,467  
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mothers with less than a high school education in the adequate provider data sample (16.0 vs 
13.3%) and a higher proportion of high school graduates with some college but no degree in the 
sample without adequate provider data group compared to the adequate provider data group 
(24.0 vs 22.1%). Poverty levels are different among the two groups as well. Households who did 
not report their income were present in higher proportions of the sample without adequate 
provider data (9.2% of the sample compared to 5.0% of those with adequate data) and those 
reporting incomes below the poverty level represented a higher proportion of those in the sample 
with adequate provider data (31.2% vs 26.4%). 
For children with adequate provider data, I compare the child, maternal, geographic, and 
provider variables by IIS participation in Table 3.2 to evaluate whether IIS participation varies 
for the independent variables. No variation in IIS participation is noted based on child age group 
(p = .05), first-born status (p = .10), or whether children live in a different state from where they 
were born (p = .26). However, differences are demonstrated for child gender (p = .04), and child 
race/ethnicity (p < .001), maternal age and education (p = .03 and p < .001 respectively), poverty 
status (p < .001), provider facility type (p < .001) and for state of residence (p < .001) (state data 
not shown but available in Appendix B).  
When testing the relationship between variables, I find a statistically significant 
relationship between UTD status and IIS participation (p < .001). As a check for robustness, I 
also test IIS participation as a dichotomous categorical variable (recoding the “Unknown” 
categorized as missing data) to show that the statistical significance remains regardless of how 
the registry participation is categorized (not shown). Tests for multi-collinearity between the 
independent variables in the 
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Table 3.2 Chi-squared Statistics of IIS Participation by Child, Maternal, and Provider Characteristics 
 IIS Participation   
 None Some/ All Unknown p 
Child Age Group (months)     .05 
   19-23    3.3%    22.1%    4.9%  
   24-29 3.0 26.7 4.2  
   30-35 3.3 27.0 5.5  
Child Gender    0.04 
   Male 5.6 38.2 7.4  
   Female 4.0 37.6 7.2  
Child Race/Ethnicity    < .001 
   Black 0.7 10.6 1.8  
   Hispanic 1.4 20.4 4.9  
   Other/ Multiple 1.7  9.8 2.5  
   White  5.8 35.0 5.4  
Child First-Born Status     .10 
   No 5.7 46.0 8.1  
   Yes 3.9 29.7 6.5  
Moved from birth state*     .26 
   No 8.4 67.5 12.8  
   Yes 1.2 8.3  1.9  
Maternal Age (Years)     .03 
   ≤ 29 years 3.0 29.5 5.4  
   > 29 years 6.6 46.2 9.3  
Maternal Education    < .001 
   < 12 years (no HS degree) 0.8 12.1 2.2  
      12 years (HS degree) 1.0 21.0 3.3  
   > 12 years, no college degree 2.2 17.1 3.8  
    College Graduate 5.6 25.6 5.4  
Income/Poverty Status    < .001 
   Above Poverty, > $75k 4.5 21.5 5.2  
   Above Poverty, ≤ $75k 3.1 25.6 4.4  
   Below Poverty 1.3 23.9 4.0  
   Unknown 0.7 4.7 1.2  
Provider Typei    < .001 
   All Public 0.6 10.4 1.9  
   All Hospitals 0.7 10.3 2.9  
   All Private 6.8 42.5 6.9  
   All Military/Other 1.0   1.0 0.8  
   Mixed 0.5 11.6 2.2  
N= 14,751 
*The only statistically significant difference when using a binary registry variable (p=0.06) versus a multi-level 
categorical variable (p < .001). 
i- aggregated at child-level 
 
model (results not shown) demonstrate minimal impact on the aORs with no changes in 
statistical significance when variables are added or subtracted in a stepwise manner.  
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Results from logistic regression. Results from regressing IIS participation on child up-
to-date status controlling for child, maternal, and provider characteristics are shown in Table 3.3, 
except for individual state data that is excluded from the table due to the number of categories 
(See Appendix C). 
There is no association between children whose providers submitted data to an IIS and 
child UTD vaccination status, however, children whose providers were unsure whether data was 
sent to an IIS are associated with lower odds of being UTD for the full combined series of 
vaccines (aOR 0.73, 95% CI 0.64, 0.83) when compared to children who had no providers 
reporting to an IIS. Provider type is associated with UTD status for some provider types. When 
compared with all public Providers, children who had all private, all military, or mixed provider 
types were associated with significantly higher odds of being UTD than those with all public 
providers (aORs= 1.29, 1.38, 1.27 respectively, 95% CIs 1.12-1.48, 1.02-1.85, 1.04-1.53) though 
the association is strongest for all private providers (p < .001). 
Where children live and whether that differs from where they were born are both 
associated with children’s up-to-date status (Figure 3.3). Variation among state of residence 
ranges (See Appendix) from states associated with significantly lower odds (Oregon, aOR= 0.65, 
95% CI 0.62, 0.69) of up-to-date children to those that are associated with significantly higher 
odds of being up-to-date (Massachusetts, aOR= 2.12, 95% CI 2.04, 2.20) when compared to 
California. Forty-five states and D.C. are associated with UTD status when compared to the 
reference state, with 4 states (LA, NM, OR, and WY) associated with lower odds and the 
remaining 41 states and D.C. associated with higher odds of being UTD. Regional differences 
were only notable for states in the Western region; compared to states in the  
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Table 3.3 Adjusted Odds Ratios of IIS Participation on Up-to-Date status on Children 19-35 months in the 
NIS 
Outcome: UTD Status aOR 95% CI 
IIS Participation   
   None Ref  
   Some/ All   1.14 [1.00, 1.29] 
   Unknown/ Don’t Know      0.73*** [0.64, 0.83] 
Prov Fac Type   
   All Public Ref  
   All Hospital  1.12 [0.95, 1.33] 
   All Private      1.29*** [1.12, 1.48] 
   All Military   1.38* [1.02, 1.85] 
   Mixed   1.27* [1.04, 1.53] 
Moved from Birth State   
   No Ref  
   Yes      0.53*** [0.46, 0.62] 
Maternal Age   
≤ 29 years      0.85*** [0.78, 0.93] 
> 29 years Ref  
Maternal Education   
< 12 years (non-HS grad)      0.69*** [0.58, 0.83] 
   12 years (HS grad)      0.72*** [0.62, 0.83] 
> 12 years, Non-Coll Grad      0.79*** [0.71, 0.88] 
   College Grad Ref  
Income/Poverty Status   
   Above Poverty, > $75k Ref  
   Above Poverty, < $75k      0.74*** [0.66, 0.83] 
   Below Poverty      0.75*** [0.66, 0.84] 
   Unknown  0.80 [0.62, 1.02] 
Child Age Group   
   19-24 months Ref  
   25-29 months      1.48*** [1.35, 1.63] 
   30-35 months      1.48*** [1.34, 1.64] 
Child Race/Ethnicity   
   Black  0.86 [0.74, 1.00] 
   Hispanic      1.34*** [1.15, 1.56] 
   Other/Multiple  1.05 [0.93, 1.18] 
   White Ref.  
Child Gender   
   Male Ref  
   Female  1.00 [0.93, 1.08] 
Child First-born Status   
   No Ref  
   Yes      1.49*** [1.37, 1.63] 
_constant      1.80*** [1.47, 2.21] 
N= 14,751  0.045 
* p < 0.05, ** p < 0.01, *** p < 0.001     
  Note: State is also in the model as a control (Ref: CA), results not shown due to space.  
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Legend: Black (Reference), White bars (no statistical significance), Gray bars (statistically significant, OR < 1.0), 
Shaded bars (statistically significant, OR > 1.0) 
Figure 3.2 Adjusted Odds Ratios from Logistic Regression of States on UTD Status 
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Northeast region, states in the Western region have lower odds of being UTD (aOR = 0.76, 95% 
CI 0.61, 0.95- data not shown). Further, children who reside in a state different from where they 
are born have significantly lower odds of being UTD compared to those who remain in their 
birth state (aOR=0.53, 95% CI 0.46, 0.62).  
Maternal factors (age, education, and income) are all highly correlated with children’s 
UTD status. Younger maternal age (≤ 29 years) is associated with lower odds of having a child 
who is UTD compared to mothers > 29 years (aOR 0.85, 95% CI 0.78, 0.93). Similar trends are 
seen for maternal education. Mothers with less than high school, high school degrees but no 
college, and some college but no degree were all associated with lower odds of UTD status when 
compared to mothers with college degrees, however, odds do increase with levels of education 
(aOR 0.69, 95% CI 0.58, 0.83; aOR 0.72, 95% CI 0.62, 0.83; aOR 0.79, 95% CI 0.71, 0.88 
respectively). Mothers whose household income is above $75k have higher odds of having UTD 
children than those below poverty (aOR 0.74, 95% CI 0.66, 0.84), as well as those above poverty 
but below $75k (aOR 0.75, 95% CI 0.66, 0.83). 
Some child-level characteristics are also associated with UTD status. Odds of being UTD 
increases in older children. Compared to children 19-24 months, children 25-29 months and 30-
35 months were associated higher odds of being UTD (aOR 1.48, 95% CI 1.35, 1.64 and 1.48, 
95% CI 1.34, 1.63 respectively). Child race/ethnicity is only associated with UTD status for one 
group. Hispanic children have significantly higher odds of being UTD (aOR= 1.34, 95% CI 1.15, 
1.56) than White children. Lastly, birth order demonstrates a statistically significant relationship 
with UTD status. Children who are first-born children have higher odds of being UTD than those 
of higher birth order (aOR= 1.49, 95% CI 1.37, 1.63). 
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Discussion 
Freeman and Defriese stated that one of the intentions of registries was to increase 
immunization rates in the U.S. (Freeman & DeFriese, 2003). Measuring the effects of the 
investments in IIS, using data directly from the IIS, is still in early stages as many of the state 
and local IISs are still validating their data and experiencing complications with data quality 
(Khare, Piccinino, Barker, & Linkins, 2006; Robison, 2015). The NIS is the largest, most 
established, data source that publicly provides information on vaccines and IIS participation. 
This study contributes to the literature in several ways. First, it provides an updated analysis on 
the relationship between providers who have submitted data to an IIS and the odds of a child 
being up-to-date on routine vaccines. Two studies examined IIS participation on UTD in various 
ways, but the studies are more than a decade old (Kim et al., 2007; Mennito & Darden, 2010). 
Logically, states with IISs in those studies (exact number not available) are more mature and in 
theory would be expected to show larger impacts on vaccination rates over time. Similar to 
previous studies that reported on this relationship with NIS data from 2004-2006, I find no 
association between IIS participation and increased rates of UTD vaccination (Kim et al., 2007; 
Mennito & Darden, 2010). Consistent with the study by Kim et. al., children’s providers who are 
unsure whether vaccines were submitted to an IIS have lower odds of completing the full 
combined series of vaccines compared with children whose do not have providers that participate 
in IISs. This finding suggests a persistent knowledge gap (Kim et al., 2007) or that providers’ 
awareness of IISs, or other immunization policies and programs, may be associated with child 
vaccination status.  
Second, I find that state of residence and geographic mobility is significantly correlated 
with UTD status for this sample. Although state immunization rates can be found in the 
43 
 
literature, few studies have included it as a significant contributor to the discussion on 
immunization rates (Hill et al., 2015; Luman, Barker, McCauley, & Drews-Botsch, 2005) as 
most discussions focus on national-level estimates or in small targeted locations. I find that UTD 
status for children ages 19-35 months varies significantly across the states after accounting for 
potential effects of State policies by clustering the error terms. The range of results (aOR: 0.65 
(Oregon) to 2.12 (Massachusetts)) suggest that states may have a significant influence on child 
vaccination status and is further explored in Chapter 5 of this dissertation.  
Additionally, mobility appears to be an important indicator of childhood vaccination 
status. Children who resided in a state different from their birth state are significantly less likely 
to be up-to-date which may increase the risk for medical record fragmentation by increasing the 
overall number of vaccine providers (Hamlin, Wood, Pereyra, & Grabowsky, 1996). Children 
who moved out of state were also less likely to have all their providers respond to the survey 
according to the findings in this study. Transferring care to another provider can create 
challenges in care continuity and it is possible that not every immunization provider was 
identified during the household interview phase of the NIS and thus were left out of the provider 
record check phase of the survey or that providers may be uncertain about their role in the NIS if 
their patient is new or perhaps no longer under their care. The magnitude of this finding was 
surprising and supports the need for IIS linkage or a national IIS that providers can access in 
real-time.  
Third, this study also adds to the overall discussion of childhood vaccination rates. Child, 
maternal, and provider factors are all known contributing factors in whether children receive 
their recommended vaccines (Luman et al., 2003; Sturm, Mays, & Zimet, 2005). In studies 
reporting findings using NIS data, child age group is not frequently discussed as a significant 
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predictor of immunization rates (Hill et al., 2015; Stokley, Maurice, Smith, & Klevens, 2004). In 
this study, children in the older two age groups are associated with higher odds of receiving the 
full combined series of vaccines when compared with those less than 24 months old. This may 
be explained by vaccination policy variations by child-care providers. According to the U.S. 
Census Bureau, younger children are more likely to have child-care arrangements with relatives 
or non-center-based environments, and as they age, may be more likely to be enrolled in center-
based day cares and pre-schools like Head Start (Laughlin, 2013). Center-based organizations 
typically have vaccination policies similar to those of schools which have been associated with 
increases in vaccination rates (Diekema, 2014; Freeman & DeFriese, 2003).  
My findings are also inconsistent with the literature on immunization disparities by child 
race/ethnicity. Hill et. al. reports on this racial disparity in the NIS frequently through the 
MMWRs published by the CDC. The authors find that black children have lower rates of 
vaccination compared with white children (Hill et al., 2017; Hill et al., 2015). I find no 
difference in the UTD status for black children or children with multiple/other race ethnicities 
compared to white children in this study. However, I do find that when adjusting for maternal 
factors, location, and IIS participation, Hispanic children are associated with significantly higher 
odds of UTD vaccination, a finding that differs from other studies (Hill et al., 2015; Kim et al., 
2007). These differences may be methodological as I control for states of residence, mobility, 
birth order, and record of a Hep B birth dose; when state is removed from my model, I find a 
shift in the effect to be more in alignment with previous studies- statistically lower odds in black 
children and no effect for children of Hispanic ethnicity.  
First-born status’ positive correlation with UTD status is a significant finding in this 
study. Birth order, while occasionally mentioned in the vaccine literature, is not frequently 
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discussed. I find that children who were first-born have significantly higher odds of being fully 
vaccinated than those who were not first-born. In one case, it is plausible that mothers with 
multiple children would have increased awareness, knowledge, and exposure to vaccinations 
leading to more informed decision-making. However, it has been demonstrated that lower birth 
order is correlated with higher vaccination rates (Dombkowski, Lantz, & Freed, 2004; Schaffer 
& Szilagyi, 1995). This may be due to the challenges with coordinating preventive care services 
for multiple children, who may have different vaccination requirements, since the schedules 
change by age, and the perceived barriers by larger families trying to stay compliant (Sabnis & 
Conway, 2015). This finding suggests that additional support may be needed for larger families 
to ensure timely vaccines for all children.  
Results in this study also show that the odds of a child being up to date on their 
vaccinations varies by maternal characteristics. These data are largely consistent with the 
literature and suggest that higher incomes and increased education are associated with higher 
likelihood of vaccine uptake (Hill et al., 2015). Additionally, the literature suggests mothers will 
choose vaccination providers that align with their own beliefs on vaccination which may be 
correlated with age, education, exposure, and access to vaccines (Dombkowski et al., 2004; 
Luman et al., 2003; Mergler et al., 2013). In this study, I find that children with all private 
providers are correlated with higher odds of complete vaccination compared to children with all 
public providers, a finding consistent with a study by Luman et al. (2002), but inconsistent with a 
previous report of no effect by provider type (Kim et al., 2007). The parent-provider relationship 
regarding vaccination behaviors is particularly interesting and these findings could indicate a 
potential interaction between maternal behavior and provider characteristics. 
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Finally, my study contributes to the literature by providing a fuller model to examine the 
relationship between IIS participation and UTD status for the full combined vaccine series. 
According to the study by Freeman and colleagues, 30% of children in an under-vaccinated 
group had changed providers since birth which can increase the possibility of record 
fragmentation, poor continuity of care, and missed opportunities (Freeman & DeFriese, 2003). In 
this study, 10.7% of children with adequate provider data were no longer living in their birth 
state with a statistically higher proportion of mobile children lacking adequate provider data (p = 
.026). Mobility may also be associated with different socioeconomic status and parental 
behaviors since a long-distance move requires resources may not be available to vulnerable 
families. Geography can also play a key role in childhood immunizations; immunization 
programs are implemented and governed by the individual states in the U.S. I include state as a 
control but also use states’ fixed-effects improve the specification of the model.  
Limitations  
There are several limitations in this study. First, the cross-sectional design of the NIS 
limits the ability to conclude a causal effect. Initially, I explored an instrumental variable 
approach because of anticipated endogeneity, but when tested, none of the variables were 
deemed endogenous nor was a good instrument discovered. Second, there were some differences 
in children whose providers returned the provider-check survey compared with those who did 
not, as well as differences in providers who submitted data to an IIS compared with those who 
did not. Questions in the provider record check such as whether data was sent to an IIS, are self-
reported by providers and are not verified as to the existence of an IIS or directly validated with 
an IIS and are subject to reporting errors. Survey and provider weights were used at different 
points of analysis to try to account for differences among the groups in this study. Third, the 
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regression model did not explain a large portion of the variance in UTD status in this study and 
wide confidence intervals and a decrease in coefficient precision from clustering the error terms 
may have affected the statistical significance as it reduced the sample size to the number of 
clusters (N = 51). I decided on a conservative approach to not over-inflate the importance of the 
findings. I also anticipate that some of this explanation is lost in the recoding of the raw data for 
public-use or is not able to be captured through the NIS. Accessing the raw data through a 
Federal Research Data Center may improve the fit of the model, however, it is more likely that 
the NIS may not be sufficient as a stand-alone data source to answer this research question.  
Finally, I made several assumptions to the data, based on my conceptual framework, by 
proxying for maternal beliefs and provider beliefs by including maternal characteristics and type 
of provider facility in the regression model. Prior to 2012, parental knowledge of childhood 
vaccines was collected in phase I of the NIS, however, those questions were removed to reduce 
the survey length. Adding questions in Phase I of the survey on parental beliefs toward vaccines 
may help improve the model. The NIS is not sufficient to explicitly study “providers” according 
to the NIS Data User Guide. Finally, while the NIS is the gold-standard for analyzing 
immunization data in the U.S., there are children outside of the sampling frame, such as those 
without landline or cell phone service, who would not be screened for inclusion in the NIS. The 
NIS uses a complex stratified survey design and complex survey weights to account for those 
children and to make the survey representative, but information on those children outside the 
sampling frame is not available and affects the generalizability of these results. 
Conclusion 
Expanding the utilization of Immunization Information Systems is one strategy 
recognized by public health officials and policymakers to improve vaccination rates by providing 
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vaccine recommendations in real-time while the child is in a provider’s office and improving 
vaccine inventory tracking and ordering. Over the last twenty years, substantial investments have 
been dedicated to improving the infrastructure and utilization of Immunization Information 
Systems but there is scant literature regarding the impact of IISs on progress toward meeting the 
nation’s immunization goals. Findings in this study suggest no relationship between child up-to-
date status for the full combined series of vaccines and whether their providers submitted data to 
an IIS, though children whose providers were unsure of their IIS participation status were 
associated with lower odds of vaccine series completion. Several factors were identified as 
significant contributors to up-to-date status including state of residence, mobility, and first-born 
status suggesting a complicated dynamic between child, maternal, provider, and state 
immunization programs. A deeper examination into how these factors are associated with 
immunization rates would help public health officials understand these relationships and lead to 
potential new interventions to improve immunization rates. 
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Chapter 4 The Association Between Immunization Information Systems and 
Invalid Doses in Children 19-35 months of Age in the National Immunization 
Survey 
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Introduction 
Relatively high and sustained rates of vaccination have resulted in reductions as much as 
a 99.9% in vaccine-preventable diseases in the U.S. (Chen, 1999; Roush & Murphy, 2007). 
However, waning immunity and decreases in vaccination rates threaten the progress of 
vaccination efforts. For example, recent studies have shown that immunity to the current child 
formulation of the Diphtheria Tetanus and aceullar Pertussis (DTaP) vaccine begins to wane as 
early as five years after administration of the fifth dose (Klein, Bartlett, Rowhani-Rahbar, 
Fireman, & Baxter, 2012; McGirr & Fisman, 2015), yet current vaccines schedules approved by 
the Advisory Committee on Immunization Practices (ACIP) do not include recommendations for 
additional boosters for most people; an additional dose is recommended once during teenage 
years, during each pregnancy, in adults with no or uncertain history of pertussis vaccination and 
in people over 65 who are expected to have close contacts with infants and children (Centers for 
Disease Control and Prevention, 2011). Additionally, the protective effect of the vaccine, 
measured as a titer, or the level of antibodies in circulation, following the Measles, Mumps, and 
Rubella (MMR) vaccine has also demonstrably decreased over time resulting in vulnerability to 
the highly contagious infections (Davidkin, Jokinen, Kontio, Paunio, & Peltola, 2012; LeBaron 
et al., 2007).  
In addition to waning immunity, rates of vaccination have declined for several vaccines 
when compared to previous years and is correlated with increases in vaccine hesitancy and 
decreasing confidence in vaccines (Hill et al., 2017; Salmon, Dudley, Glanz, & Omer, 2015). In 
2016, 70.7% of children 19-35 months of age were up-to-date (UTD) for the full series of 
recommended vaccines including ≥ 4 DTaP doses, ≥ 3 Polio doses, ≥ 1 Measles Mumps and 
Rubella dose, ≥ 3 Haemophilus influenzae b doses, ≥ 3 Hepatitis B doses, ≥ 1 Varicella dose, and 
51 
 
≥ 4 Pneumococcal doses. That UTD rate is down 1.5% points compared to 2015 and is the 
lowest since 2013 (Hill et al., 2017). These rates also demonstrate a failure of the U.S. to meet 
one of the Healthy People 2020 immunization objectives of 80% vaccination for the full series 
by the age of three years (US Department of Health and Human Services, 2011b). As a result, the 
population’s protection toward vaccine-preventable diseases is reduced and outbreaks in vaccine-
preventable illness are on the rise (Cherry, 2012; Phadke, Bednarczyk, Salmon, & Omer, 2016; 
Salmon et al., 2015). Along with increases in morbidity and mortality, these outbreaks are 
associated with increased costs and utilization of health care system resources (e.g. physician 
visits, hospitalizations) (Ortega-Sanchez, Vijayaraghavan, Barskey, & Wallace, 2014).  
The ACIP approves the child and adult recommended vaccine schedules, including both 
the recommended ages and intervals between doses for each vaccine, which are based on “age-
specific risks for disease, age-specific risks for complications, age-specific responses to 
vaccination, and potential interference with the immune response by passively transferred 
maternal antibodies” (Centers for Disease Control & Prevention, 2019). The ACIP also publishes 
the minimum ages and intervals required between doses in a series based on vaccine safety data 
which vary from the ACIP recommended schedules (Ahmed et al., 2011; Hamborsky, Kroger, 
Wolfe, Control, & Prevention, 2015). Children who receive a dose before the dose-required age 
have a higher likelihood of having a reduced or absent immunological response to the vaccine 
and leaves them susceptible to disease (Hamlin et al., 1996); they may also have higher risks of 
adverse reactions as the vaccines have not been tested for safety and efficacy at those ages 
(Luman et al., 2002). Further, doses that are administered too close to each other may not 
stimulate robust immune responses (Butte et al., 2001; Jilg, Schmidt, & Deinhardt, 1989) and 
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may limit the overall protective effect of those doses even though they will appear to be 
vaccinated against disease.  
Vaccinating children outside of the validated ages and intervals, and failure to receive a 
full series, may give the impression of a vaccinated and protected population, when, the 
protective benefits of individual and herd immunity are not optimal and may leave the population 
vulnerable to infection. For example, receiving vaccines too early in age can interfere with the 
immune response. When administered before one year of age, the presence of maternal 
antibodies transferred during childbirth in a child’s circulation may prevent them from 
developing their own antibodies to the measles, mumps, and rubella (MMR) vaccine (Ceyhan, 
Kanra, Erdem, & Kanra, 2001). While the child would have an MMR recorded and appear 
vaccinated in their health record, their lack of response to the vaccine would not offer full 
protection against measles.  
This effect is also demonstrated in larger populations such as in the 1990 Pennsylvania 
measles outbreak. Of the more than 27,600 cases of measles reported during the outbreak, only 
5,100 (18.4%) were appropriately vaccinated, and 22,500 (81.4%) were unvaccinated, which 
includes children who may have received untimely or inappropriate vaccinations (Centers for 
Disease Control, 1991). Of those children who were categorized as unvaccinated, 12,268 
(44.3%) were inappropriately vaccinated and received their measles vaccine before the age of 
one year and demonstrates the importance of the timing of vaccines in addition to receiving the 
correct number of doses. These children did not have the benefit of optimal individual protection 
and because there were so many, likely lowered the protective herd immunity benefits. 
Doses that have been administered too young or too close together are deemed “invalid” 
and require re-vaccination at the appropriate age and/or interval for optimal protection against 
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VPDs (Centers for Disease Control & Prevention, 2019). Re-vaccination adds to the number of 
clinic visits, increased costs and utilization of vaccine resources, and represents unnecessary 
exposure to biological substances (Stokley et al., 2004). These additional vaccinations may also 
increase the risk potential for adverse reactions. The full impact of invalid doses is unclear in the 
current immunization estimates since all doses given to a child are included in vaccine estimates 
regardless of whether they meet the required or recommended age and intervals for 
administration (Luman et al., 2005). One study from 2000 examined the number of invalid doses, 
and the cost of re-vaccinating children who had received them, and determined that at least 11% 
of children ages 19-35 months had one or more invalid vaccine doses when using the most 
stringent ACIP criteria (Stokley et al., 2004). The authors’ cost analysis estimated a vaccine 
purchase cost of $10M to $18M for re-vaccinating these children which demonstrates added cost 
and burden of inappropriately timed vaccines.  
Reducing invalid vaccines, and therefore increasing the overall quality of vaccine 
delivery, is a complex problem. The delivery of vaccines is complicated by increasing numbers 
of vaccine providers which causes fragmentation of immunization records (e.g. when a child sees 
a new provider or moves out of state and fails to migrate their records) (Hamlin et al., 1996; 
Stokley et al., 2001; Yusuf et al., 2002). Increasingly complex immunization schedules (Butte et 
al., 2001) may add additional complications for providers and parents trying to track 
immunizations. Parental and provider vaccine hesitancy regarding the safety and efficacy of 
vaccines also contributes to non-compliance to the recommended vaccine schedule and missed 
vaccination targets. As a result of vaccine hesitancy, parental and clinician mistrust of vaccines, 
vaccine manufacturers, and other vaccine advocates, (Larson et al., 2014; Mills, Jadad, Ross, & 
Wilson, 2005), many parents are opting to use alternative vaccination schedules (Feemster & 
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Offit, 2013; Offit & Moser, 2009) which further increases the opportunity for missed and under-
vaccinated children. 
One suggested strategy to improve the quality of vaccinations administered, and reduce 
the number of invalid vaccines, is through the utilization of immunization information systems 
(Freeman & DeFriese, 2003; Stokley et al., 2004). These population-based electronic repositories 
offer a centralized hub for not only storing immunization data, but sharing data with other 
providers and/or states and forecasting future immunization needs in real-time (Groom et al., 
2015) so providers can administer the right vaccine to the right patient at the right time- a central 
tenet to patient-centeredness. These coordinated efforts are anticipated to reduce scattering and 
fragmentation of records, missed opportunities, and inappropriately delivered vaccines (National 
Vaccine Advisory Committee, 1999; Stokley et al., 2001; Yusuf et al., 2002). 
Currently, there is no national immunization data tracking system (Gostin & Lazzarini, 
1995). In the U.S., the first IIS was established in 1974 (Ortega et al., 1997). After several 
philanthropic efforts to expand their utilization stalled, the Clinton administration’s 
immunization initiative allowed for federal dollars to be invested for the expansion and 
utilization of IIS at the state and local levels (Freeman & DeFriese, 2003). Although there have 
been substantial changes in IISs over the last ten years, and every state now operates at least one 
IIS either at a state, regional, or local level, there has been little research on the effects these IIS 
are having on vaccination rates and/or the quality of vaccine delivery (Kempe et al., 2001). 
Using the National Immunization Survey (NIS), the current gold-standard for immunization data 
in the U.S., I examine the relationship between IIS utilization and invalid vaccinations in 
children 19-35 months of age. In this paper, I address the following questions: First, how have 
invalid doses for the full recommended series changed from 2012 to 2016; and second, are 
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children whose providers submitted immunization data to an IIS less likely to have an invalid 
dose?  
Conceptual Framework 
 Vaccination policies occur at the national and state-levels in the U.S. In order to achieve 
immunization goals, vaccine uptake strategies are enacted through a series of complex and 
dynamic relationships between public health entities, providers, and parents. Using the 
Conceptual Framework from Chapter 3 (Figure 4.1), I analyze the effect of IIS participation on 
invalid doses. Using my conceptual framework and the ACIP’s criteria for minimum required 
age and interval between doses, I determine the validity of each dose in the most recent five 
years of National Immunization Survey Data. In my models, I include child characteristics as 
controls, as well as maternal characteristics since a child’s mother is often the most influential 
person in vaccine decision-making (Luman et al., 2003). I include characteristics that are 
potential influencers of the mother’s knowledge and behavior since this cannot be directly 
measured by this dataset, such as whether a child received a birth dose of the Hepatitis B 
vaccine. Finally, provider characteristics are included in the model as covariates to determine if 
certain provider types are associated with the quality of vaccines (e.g. invalid doses) and as my 
predictor of interest, I include a variable that proxies for provider participation in an IIS.  
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Figure 4.1 Conceptual Framework for Child Vaccination Status as presented in Ch. 3 (Fig 3.1) 
 
Methods 
 This study is a retrospective secondary analysis of an annually conducted, nationally 
representative, cross- survey of households with children ages 19-35 months of age and their 
immunization providers from 2012 to 2016.  
Data source. Five years of data from the 2012-2016 National Immunization Surveys 
(NIS) are included in this study. The NIS is conducted via a two-phase process summarized here 
but described in detail elsewhere (Smith et al., 2001; Zell et al., 2000). The first phase screens for 
households with children in the targeted age range of 19-35 months. Household screening is 
conducted using random-digit dialing (RDD) and a dual frame design that encompasses sampling 
techniques for both telephone landlines and mobile numbers. During this first phase, 
demographic, household, and vaccine provider information is collected from the person in the 
household with the most knowledge about the eligible child’s vaccines- typically a parent or 
guardian (National Center for Immunization and Respiratory Diseases, 2017). Additionally, the 
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parent/guardian is asked for consent to contact the child’s vaccination providers to obtain their 
immunization records. 
The Provider Record Check is the second phase of the NIS where a survey is mailed to 
all providers for the eligible child(ren) who were identified in phase I. Providers are asked to list 
all vaccines in a child’s record (including historical vaccines), vaccine type/manufacturer, dates 
administered, and if the provider reporting the vaccine is the one who administered the doses. 
Additionally, a question pertaining to whether the child’s vaccines were reported to a registry is 
included in the survey.  
Study sample. Children aged 19 to 35 months during the survey periods in the 2012 to 
2016 NIS, with adequate provider data, and residing in the fifty states and Washington, D.C. are 
included in this analysis. Children living in Puerto Rico and other territories were excluded from 
this analysis since information about how IISs operate was inconsistent and/or incomplete at the 
time of this study.  
The pooled 2012-2016 NIS data set includes 75,346 with adequate provider 
immunization data. Children who have received zero doses are also considered to have adequate 
provider data if a provider was identified by the parents and the provider responded with “child 
has received no vaccines”. However, since this study examines the validity of vaccines, I exclude 
children with zero vaccines in the data set (N = 980) for a final sample size of 74,366.  
Determination of vaccine dose validity. All doses in the recommended full series for 
children aged 19-35 months are evaluated for validity. The full series includes 4 DTaP, 3 Polio, 1 
MMR, 3 Hib, 3 HepB, 1 Var, and 4 PCV doses (Hill et al., 2015). No changes were noted in the 
vaccine schedules and recommendations over the five-year study period.  
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Doses (e.g. DTaP 1, DTaP2, etc.) are evaluated using strict interpretations of the 
recommendations and flagged as “invalid” if they failed to meet the minimum required ACIP 
criteria for age and/or interval between doses. Doses that were administered before the minimum 
age criteria are “invalid due to age” whereas doses that were delivered too soon are considered 
“invalid due to interval”.  
In many cases, children had received more than the recommended number of doses for a 
given series, for example, five polio doses when three are recommended. In these cases, the 
criteria for the “last” dose in the series is used to evaluate these doses for validity (e.g. a fifth 
DTaP dose was evaluated using the criteria for dose 4, or interval 4). There is no upper limit to 
the age and/or interval for classifying a dose as valid. The flags are created based on the 
specified ages and intervals as depicted in Figure 4.2 below. 
Flags are created as binary variables for each possible dose and interval and indicated that 
the dose is valid (flag=0) or invalid (flag=1). Validity of the birth dose of Hep B is not 
determined since there is no minimum age, however, the interval between the birth dose and 
second dose of Hep B is evaluated.   
Additionally, for retrospective analyses of immunization records, the Centers for Disease 
Control & Prevention recommends a 4-day grace period in most vaccine situations, 
  
59 
 
 
Figure 4.2 Minimum Required Ages and Intervals for Doses in the Full Combined Series According to ACIP 
Guidelines 
 
except where noted (Centers for Disease Control & Prevention, 2015a). The ACIP recommends 
applying this grace period when determining vaccine dose validity to account for errors in entry 
or when providers miss a “vaccination window” due to weekends and/or holidays. This 
allowance also helps to provide conservative estimates in those children who might be receiving 
doses “close” to the required timing.  
One challenge of retrospective analyses of NIS data is that the ACIP provides 
recommendations in weeks (up to 4 months) and in months thereafter, while the NIS captures 
ages of doses in days and months. I convert the ACIP recommendations into days by multiplying 
the number of weeks by 7 days or months by 30 days. The purpose of using days for the ages is 
to make it easier to apply the four-day grace period for retrospective analysis. This may 
introduce potential error into the dataset due to the different numbers of days per month. This 
method of determining age and validity has been used previously by Stokley et. al. (2004), but 
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was modified slightly to reflect the four day grace period and include the full recommended 
series. 
Dependent variables. Three dependent variables are created for invalid doses: 1) any 
invalid, 2) invalid due to age, and 3) invalid due to interval. Each variable is first created as a 
dichotomous variable based on a series of flags created from the ACIP age and interval table 
described previously in Figure 2. First, a dose-level flag was created, followed by a vaccine-level 
flag, and then a full-series flag for each of the three dependent categories with “any invalid” 
combining both age and interval flags. However, since it is possible that one vaccine dose could 
be invalid for both age and interval, invalid doses were not additive. Figure 3 below 
demonstrates this multi-level flagging. 
 
Figure 4.3 Diagram of Multi-level Flag Creation for Invalid Doses 
 
Independent variables. The independent variable of interest is whether a child’s data 
was submitted to a registry, hereafter called IISs. This data is collected in response to a question 
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on the provider record check survey in phase II of the NIS and is proxying for provider 
participation in an IIS. This categorical variable was initially provided in the data set as “no 
providers” submitted data to a registry, “some but probably or definitely not all” providers, “all 
providers”, and those who marked “Unknown/Don’t know”. Because of the uncertainty around 
“some but probably or definitely not all”, I recode the registry variable to reflect no participation, 
any participation, and unknown participation. I assume that those providers who are unsure of 
their registry participation may be different from those who opted to leave the survey question 
blank, and thus left them as a separate category.  
The following independent variables are also included in the previous chapter of this 
dissertation.  
Provider characteristics. This dataset does not capture much information about the 
provider, however, the type of provider(s) a child has (e.g. All public, All private, All hospital) is 
included and is used to proxy for provider’s beliefs since providers choose their type of practice 
which is potentially influenced by their beliefs. For example, public providers are more likely to 
participate in federal vaccine funding programs and may be more likely to administer 
immunizations than private providers (Mennito & Darden, 2010). In the provider-record check 
portion of the survey, providers self-identify the type of facility they practice in (Centers for 
Disease Control and Prevention, 2016). Providers may select multiple choices from the facility 
type including private (solo, group, or health maintenance organization), hospital-based clinic, 
public health clinic, military hospital, various health centers (migrant, rural, community), and 
other facilities such as pharmacies, Women, Infants, and Children, and school-based clinics. I 
make the assumption that all public-health clinics, including rural and community health centers, 
are categorized as public facilities, hospital-based clinics as hospital facilities. Those that do not 
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fit into the criteria of public, private, or hospital, (e.g. pharmacies) are assumed to be categorized 
in the Military/Other category. The provider type variable is re-coded and  aggregated at the 
child level in the public-use data file and prevents analyses of individual providers.   
 State-level influence. Current state of residence is included to help control for state-level 
immunization policies. There are currently no national laws, however, the ACIP makes national 
recommendations which are then carried out by state immunization programs. These 
immunization policies also affect state-run IISs and may influence provider behavior. Policies 
and behavior at within a state may change over time, so I also control for year fixed effects and 
an interaction between year and state. Additionally, I include a variable that assesses mobility 
(Yes/No) measured by whether a child lives in a different state from where they were born to 
adjust for state selection effects of vaccination history. 
Maternal characteristics. Previous literature on vaccination behaviors suggests that 
mothers are the most influential person in childhood vaccination decisions (Luman et al., 2003); 
their attitudes toward vaccination were significantly predictive of infant vaccination status (Fadel 
et al., 2017). There is no direct way to measure maternal beliefs and behavior, so I proxied for it 
in several ways. I select variables that have been identified in the literature as influential on a 
mother’s vaccine knowledge and decision-making (Luman et al., 2003) including: maternal age, 
maternal education, a household income and poverty variable, and whether a child received a 
birth dose of Hep B vaccine.  
Younger maternal age has been associated with lower child vaccination rates (Luman et 
al., 2003), so controlling for maternal age (≤ 29 yrs or > 29 yrs) is important when evaluating the 
effect of IIS on rates. The effect of maternal education is less clear on child vaccination status. 
For example, older studies have shown that advanced maternal education is associated with 
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higher rates of childhood vaccinations (Luman et al., 2003), however, more recent studies have 
shown there are clusters of individuals with graduate or professional school education who are 
less accepting of vaccines (Healy & Pickering, 2011). Therefore, I include maternal education (< 
12yrs, 12 yrs, > 12 yrs- non-college grad, College Grad) as a control to help improve the fit of 
the model.  
Disparities in vaccination rates have also been identified based on socio-economic status 
(Reich, 2014), therefore, I include a poverty status variable, available for all children, that is 
based on the 2011 through 2015 Census data for poverty thresholds (Centers for Disease Control 
& Prevention, 2017). This variable is coded as “below poverty”, “above poverty but less than 
$75k” and “above poverty and more than $75k” and an “unknown/refused to answer” group. 
Poverty thresholds are determined annually using the using data from the Census Bureau 
(National Center for Immunization and Respiratory Diseases, 2017). I control for year fixed 
effects in my models to adjust for the annual change. Finally, the birth dose of Hep B may proxy 
for maternal beliefs and behaviors towards vaccination and has been used elsewhere in the 
literature as a covariate or control (Mennito & Darden, 2010; Yusuf et al., 2000). Accepting the 
birth dose of Hep B might provide insight to the maternal beliefs about vaccination at a critical 
time in parent and child-development. 
Child characteristics. Child characteristics are included in the model as controls. The 
ACIP recommendations for the full series of routine vaccination, excluding the annual vaccines 
for Flu prevention and the Rotavirus series, to be completed by 18 months of age, therefore, this 
sample of 19-35 months of age old children should all have completed the series at the time of 
data collection (Zell et al., 2000). I use child age group in months (19-23, 24-29, 30-35), gender 
(Male/Female) and race/ethnicity (Black, Hispanic, White, Multiple/Other) as controls. I include 
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the child’s race/ethnicity as a control in the model since there are known disparities in the 
immunization rates for vulnerable populations which are typically racially diverse (Hill et al., 
2015). Lastly, I include an indicator for first-born status (Yes/No) because children at lower birth 
orders are more likely to be UTD (Brenner et al., 2001). 
Analysis. The analysis plan for this research question consists of a series of bivariate 
statistical tests and a set of regression models which are developed with guidance from the 
conceptual framework.  
Bivariate statistics. First, to look for potential sources of selection bias, I conducted a 
series of corrected, weighted Pearson chi-square statistics or design-based F statistics to 
determine significance (α= .05). I present the summary statistics using column percentages to 
compare the distribution of characteristics over the five-year study period using the provider 
survey weights in the public-use file as recommended by the data user guide (National Center for 
Immunization and Respiratory Diseases, 2017).  
Next, in order to attribute any meaningful change to the predictor (IIS Participation), I 
test for statistically significant differences on the sample, aggregated across years, by provider 
IIS participation.   
Invalid dose assessment. Invalid doses are analyzed at the child-level and presented as 
counts (number of children) and percent of children with at least one invalid dose due to age, 
interval, or combined age or interval. Children with zero recorded vaccines are excluded for this 
analysis. Each vaccine (e.g. DTaP, Hib, etc.) for each year had a different denominator because 
of excluding children with “zero DTaPs in 2012” resulted in a different number than those 
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children with “zero Hib in 2014”, as an example. The numbers of children are counted and then 
divided by the new denominator to get the proportion of children with invalid doses. 
Regression analysis. To address my research questions, I utilize a series of three logistic 
regression models and cluster the error terms at the state-level to account for policies and 
programs enacted at the state level. This approach allows the error terms to be correlated within 
each cluster (Cameron & Miller, 2015). The states’ fixed-effects capture state-level factors, such 
as preferences or cost difference, that are stable over time. Including state effects means that the 
IIS effects are estimated within state and then averaged across states. Three separate models 
were used to examine the effect of IIS participation on valid doses. The full model for the 
regression analysis is shown below, with descriptions of the three models by dependent 
variables. All variables in the models are categorical with variables in bold represent categorical 
variables with more than two levels. 
Full Model: InvalidVarsi= β0 + β1*IISParticipationi1 + β2*Yeari2 + β3*Statei3 + 
β4*(Yeari4 X Statei4)+ β5*ProviderTypei5 + β6*HepBBirthDosei6 + β7*MaternalAgei7 + 
β8*MaternalEducationi8 + β9*IncPovi9 + β10*ChildAgei10 + 
β11*ChildRace/Ethnicityi11+ β12*Genderi12 + β13*FirstBorni13 + β14*Mobilityi14 εi 
where InvalidVars represents three different dependent variables for invalid doses including a 
variable for “any invalid dose” (Model 1), “any invalid dose due to age” (Model 2), and “any 
invalid dose due to interval” (Model 3) and β0 represents the invalid dose status for children 
when all predictor variables are held at zero. Provider-level variables include IISParticipation as 
an indicator for provider participation in an IIS and ProviderType as the facility type(s) that the 
child’s provider(s) are employed within. Maternal factors include the MaternalAge, 
MaternalEducation, and IncPov, a measure of income and poverty threshold, as well as a dummy 
variable for whether any of the child’s providers reported a HepBBirthDose which proxies for 
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maternal attitudes and behaviors toward vaccination. Child factors included as controls are 
ChildAge group, ChildRace/Ethnicity, child gender, first-born status, and a Mobility variable to 
indicate if a child had moved from their birth state. 
In addition to the provider, maternal, and child factors described in the Data section, the 
model includes state-by-year fixed effects. These indicators for state and year are meant to 
capture changes in state policies or economic conditions that affect immunizations (e.g. changes 
in funding for public health departments). 
For each regression model, I report the adjusted odds ratios (aORs) and the McKelvey & 
Zavoina’s R2 which most closely approximates the R2 achieved by Ordinary Least Squares’ 
regression (Institute for Digital Research and Education (IDRE), n.d.). 
Results  
Summary statistics. There are 126,657 children ages 19-35 months in the 2012-2016 
NIS datasets, of which 75,346 (59.5%) have adequate provider data for inclusion in this study. 
The sample is reduced further when children with zero recorded doses for the 7 vaccines are 
excluded (N = 980) for a final sample size of 74,366 for the five years of pooled data with yearly 
sample size shown in Table 1. IIS status was available for all children retained in the data set. 
There are no statistically significant differences in the proportion of children with zero vaccines 
over time (data not shown); less than 1% of children each year, with adequate provider data, 
have zero recorded doses (p = .80).  
 In Table 4.1, using provider survey weights, I present a summary of the variables by year 
to assess whether there are any differences in my variable composition over time. There are no 
statistically significant differences over time for child age group (p = .99), gender (p > .99),  
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Table 4.1 Weighted Summary Statistics for Children 19-35 Months of Age in the 2012-2016 National 
Immunization Surveys with Adequate Provider Data and 1+ Reported Vaccines 
 Year   
  2012 2013 2014 2015 2016 Total       p 
Child Age Group        
   19-23    29.7%    30.0%    30.4%    30.2%    30.2%    30.1% .99 
   24-29 33.8 34.0 33.7 33.6 34.0 33.8  
   30-35 36.5 36.0 35.9 36.2 35.8 36.1  
Child Gender        
   Male 51.2 51.2 51.1 51.2 51.3 51.2 > .99 
   Female 48.8 48.8 48.9 48.2 48.7 48.8  
Child Race/Ethnicity        
   Black 13.6 12.7 13.6 12.5 13.1 13.1 .25 
   Hispanic 27.3 27.2 26.4 26.8 26.7 26.9  
   Other/Multiple 11.9 12.2 13.4 12.4 14.0 12.8  
   White 47.2 47.9 46.6 48.3 46.2 47.2  
Child First-born Status        
   No  61.2 60.0 60.0 59.0 59.8 60.0 .38 
   Yes 38.8 40.0 40.0 41.0 40.2 40.0  
Hep B Birth Dose†        
   < 1 Providers reported 24.1 21.8 23.2 23.6 24.1 23.4 .13 
   ≥ 1 Provider(s) reported 75.9 78.2 76.8 76.4 75.9 76.6  
Moved from birth state        
   No  91.3 90.2 89.9 89.8 88.6 90.0 .002 
   Yes   8.7   9.8 10.1   10.2 11.4 10.0  
Maternal Age        
   ≤ 29 years 44.7 44.6 42.4 40.7 37.9 42.1 < .001 
   > 29 years 55.3 55.4 57.6 59.3 62.1 57.9  
Maternal Education        
   < 12 years 18.8 18.3 17.7 15.7 15.1 17.1 < .001 
      12 years (HS degree) 27.1 25.7 25.1 26.1 25.4 25.9  
   > 12 years, no college  22.4 22.2 23.6 23.2 23.0 22.8  
   College Graduate 30.7 33.8 33.6 35.1 36.5 34.2  
Income/Poverty Status        
   Above, > $75k 25.2 27.4 27.1 29.3 31.2 28.0 < .001 
   Above, ≤ $75k 33.3 33.9 33.9 32.1 33.1 33.3  
   Below 36.8 33.4 33.6 32.8 29.2 33.2  
   Unknown   4.7   5.3   5.6   5.8   6.5   5.5  
Provider Type        
   All Public 12.1 12.7 11.8 12.0 12.9 12.3 .008  
   All Hospitals 11.4 12.5 12.5 12.4 13.9 12.6  
   All Private 58.2 56.7 55.6 57.5 56.2 56.8  
   All Military/Other   2.1   2.4   3.1   2.1   2.7   2.5  
   Mixed 16.2 15.7 17.0 16.0 14.3 15.8  
N 16,480 13,450 14,730 14,973 14,733 74,366  
† Hep B birth dose flags are recorded as “No providers marked Hep B birth dose given” or “At least one provider 
marked that a Hep B birth dose was given”. 
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race/ethnicity (p = .25), first-born status (p = .38), and receipt of Hep B birth dose (p = .13). 
However, over time, children are more likely to be living a state different from where they were 
born (p = .002) suggesting increasing mobility in the country. For children with adequate 
provider data, maternal characteristics varies over time. Mothers of these children tend to be 
older (p < .001), more educated (p < .001) with an increase in the number of mothers with 
college degrees, and nominally more affluent (p < .001) with an increase in the number of 
families reporting household incomes greater than $75k. Finally, the proportion of provider 
types, which may be reflective of shifts in family dynamics and behaviors, is notable for a slight 
shift in the number of respondents seeking vaccinations from “all hospital” and “all public” 
compared to “all private” providers or “mixed” (p = .01). 
In Table 4.2, I summarize the children in the dataset by whether their providers sent data 
to an IIS. There are no statistically significant differences in IIS participation by child age group 
(p = .78), gender (p = .14), or whether a child resided in a state different from their birth state (p 
= .10). Differences in IIS participation are demonstrated in all other variables: race/ethnicity, 
first-born status, receipt of a Hep B birth dose, maternal characteristics (age, education, poverty 
status), and provider type. For those with no IIS participation, 8.0% were Black, 20.1% Hispanic 
and 57.4% White compared to those with some/all IIS participation (14.1%, 27.8%, and 46.0% 
respectively, p < .001). Children whose providers reported unknown IIS participation were more 
likely to be first-born (43.4%) compared to those with no participation (40.0%), or some/all 
participation (39.7%, p < .001).  
 Maternal characteristics also demonstrated important differences. The maternal age is 
only available as dichotomous information, however, a statistically significant higher proportion 
of mothers whose children have zero records in an IIS is seen for the older age group when  
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Table 4.2 Weighted Descriptive Statistics by IIS Participation in Children 19-35 Months of Age, with 
Adequate Provider Data, in the 2012-2016 National Immunization Surveys 
 No IIS Participation 
Some/All IIS 
Participation 
Unknown IIS 
Participation 
 
 % Range % Range % Range p 
Child Age Group         
   19-23 29.6 28.1 / 33.9  30.3 29.1 / 30.8 29.8 27.5 / 33.6 .78 
   24-29 34.4 30.8 / 37.0 33.8 32.8 / 35.3 33.0 28.8 / 35.6  
   30-35 36.0 34.5 / 39.4 35.9 35.2 / 36.8 37.1 34.8 / 38.3  
Child Gender        
   Male 53.1 50.3 / 58.1 50.9 50.5 / 51.4 51.1 50.6 / 51.1 .14 
   Female 46.9 41.9 / 49.7 49.1 48.6 / 49.5 48.9 47.9 / 49.4  
Child Race/Ethnicity         
   Black   8.0 6.7 / 9.3 14.1 13.6 / 14.0 13.0 12.1 / 14.7 < .001 
   Hispanic 20.1 14.4 / 24.6 27.8 26.9 / 29.1 28.4 25.4 / 33.5  
   Other/Multiple 14.5 13.2 / 17.5 12.1 10.5 / 13.0 14.7 11.5 / 17.2  
   White 57.4 55.2 / 60.5 46.0 45.0 / 47.8 43.9 37.1 / 47.1  
Child First-born Status        
   No  60.0 56.9 / 62.5 60.7 59.5 / 61.5 56.6 54.4 / 58.3 .001 
   Yes 40.0 37.5 / 43.1 39.3 38.5 / 40.5 43.4 41.7 / 45.6  
Hep B Birth Dose†        
   < 1 Providers reported 27.4 22.6 / 29.9 22.1 20.4 / 22.9 25.6 23.0 / 26.9 < .001 
   ≥ 1 Provider(s) reported 72.6 70.1 / 77.4 77.9 77.1 / 79.6 74.4 73.1 / 77.0  
Moved from birth state        
   No  89.9 87.2 / 91.4 90.2 89.1 / 91.5 88.8 87.0 / 90.5 .10 
   Yes  10.1  8.6 / 12.8   9.8 8.5 / 10.7 11.2 9.5 / 13.0  
Maternal Age        
   ≤ 29 years 31.6 29.0 / 34.5 44.4 39.0 / 48.4 40.2 36.5 / 45.3 < .001 
   > 29 years 68.4 65.5 / 71.0 55.6 51.6 / 61.0 59.8 54.7 / 63.5  
Maternal Education        
   < 12 years  10.2  8.3 / 13.4 18.6 15.9 / 22.4 16.4 13.9 / 19.1 < .001 
      12 years (HS degree) 17.7 10.6 / 22.5 27.8 27.1 / 28.9 23.8 21.5 / 25.5  
   > 12 years, no college  21.3 18.7 / 23.5 23.1 22.5 / 23.7 23.1 21.2 / 25.7  
   College Graduate 50.8 46.1 / 58.2 30.5 27.3 / 33.8 36.7 35.2 / 38.2  
Income/Poverty Status        
   Above, > $75k 44.7 41.8 / 46.9 24.3 20.0 / 28.4 31.3 27.9 / 35.3 < .001 
   Above, ≤ $75k 32.0 31.0 / 33.0 33.5 32.1 / 34.3 32.8 29.7 / 36.7  
   Below 19.3 14.0 / 23.1 36.3 31.6 / 41.2 30.5 27.0 / 33.4  
   Unknown   4.0 3.0 / 6.7   5.9 5.2 / 6.3   5.4 2.8 / 8.1  
Provider Type        
   All Public   5.7 4.7 / 7.2 13.8 13.1 / 15.3 10.6 7.8 / 12.7 < .001 
   All Hospitals   7.6 6.6 / 8.6 12.1 10.7 / 13.6 19.7 18.2 / 22.8  
   All Private 75.5 71.1 / 78.0 54.3 52.8 / 56.1 51.8 47.4 / 55.6  
   All Military/Other   5.9 4.9 / 10.3   1.4 0.9 / 2.1   4.8 3.5 / 6.8  
   Mixed   5.3 4.9 / 5.8 18.4 15.4 / 19.6 13.1 11.1 / 14.7  
   Unknown/Missing‡   0.0 -   0.0 -   0.0 -  
N= 75,346 
† Hep B birth dose flags are recorded as “No providers marked Hep B birth dose given” or “At least one provider 
marked that a Hep B birth dose was given”. 
‡Ranges not available due to the low number of observations in the Unknown/Missing category. Responses were 
omitted in further analyses. 
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compared to those with some/all providers reporting immunizations to an IIS (68.4% vs 55.6, p < 
.001). Mothers of children who are associated with non-IIS-participating providers also tend to 
be more educated and in higher income households. Of those with no IIS participation, 50.8% of 
mothers are college graduates compared to 30.5% of those with some/all IIS participation. While 
the proportion of mothers above the poverty line, but with household incomes less than $75k, did 
not change much by IIS participation, the proportion of mothers above the poverty line with 
income greater than $75k is 44.7% in the no IIS participation group but only 24.3% in IIS 
participation group. This difference is inversely proportional to the women below the poverty 
line (19.3% and 36.3 respectively, p < .001).  
Finally, provider type is associated with IIS participation differences. Private providers 
comprise 75.5% of the no IIS Participation group compared to only 54.3% (p < .001) of the IIS 
Participation group. This difference among IIS Participation was distributed across All Public, 
All Hospitals, and Mixed provider types. These variables are included in the conceptual model as 
controls due to the many differences associated with IIS participation. 
Status of invalid doses. Invalid dose trends vary widely over the five-year data period. 
Data in Table 4.3 shows the count and percentage of invalid doses for age, interval, and 
combined age and interval. Overall, the number of children with invalid doses in the full series 
due to age and interval increases from 2012 (44.2%) to 2016 (50.4%). The two vaccines largely 
responsible for this increase are the Hepatitis B vaccine (+16.1%) and the Polio vaccine which 
saw initial decreases but has been trending upward in the most recent 2016 sample (29.1% in 
2012 to 14.8% in 2014 to 20.6% in 2016) mostly due to invalid age at administration. When 
examining Hep B by interval and age, most of this change in invalid doses is due to age 
(+16.0%) when compared to the change in invalid intervals (+2.2%); invalid polio doses follows 
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a similar trend with initial decreases in invalid age doses from 2012-2014 (-14.3%) to increasing 
rates from 2014-2016 (+4.7%) and an overall decrease from 2012 to 2016 (-0.6%). 
For the other five vaccines, very few changes are seen over the five-year period. Invalid 
DTaPs decline over time (-0.6% from 2012-2016) with improvements in both invalid doses due 
to age (-0.6%) and intervals (-0.5%). The percent of children with invalid PCV, Hib, and VRC 
doses remain largely unchanged (0%, 0%, and -0.1% respectively) over the five-year study 
period, however, there may be the start of an increasing trend in invalid MMRs due to age (from 
1.0% invalid in 2012 to 1.4% in 2016). Lastly, from the data in Table 3, it is apparent that 
majority of invalid doses are due to doses that are administered at an age less than the minimum 
required age criteria published by the ACIP.  
Table 4.3 Frequency and Percentage of Children in the 2012-2016 National Immunization Surveys with 
Invalid Doses Using ACIP Minimum Required Ages and Intervals 
 
†
Data presented as Number of Children (%) 
a Children with zero doses reported are excluded from this analysis. 
b Only 1 MMR and 1Varicella dose is recommended for this age group, however, all doses were evaluated for 
validity. 
 
Logistic regression of IIS participation on invalid doses. Three regression models are 
employed to examine the relationship between IIS participation and invalid doses for the full 
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series: the probability of having any invalid dose, having any invalid dose due to age, and any 
invalid dose due to interval as seen in Table 4. After I determined Hepatitis B as the primary 
driver of invalid doses (see Table 4.3), I made the decision to exclude the Hep B doses from the 
main regression models (Table 4.4) and present them separately in Table 4.5 of the results 
section of this chapter so as not to bias my interpretation of the regression results. 
Models (1) and (2) have the same sample size (N = 73,189) and differs from Model (3)’s 
sample size of N = 72,115 because intervals are calculated from the number of doses, and not 
every child have the same number of vaccines administered. For the three models tested, the 
MeKelvey & Zavoina R2 values were similar and ranged from explaining 9.8% (Model 1) to 
10.2% (Model 2) of the variance of the dependent variables. The regression results using two of 
the independent variables (“any invalid” and “invalid due to age”) were almost identical, so I 
focus mainly on discussing invalid doses due to age or interval. Further, an interaction term 
between IIS participation and year which resulted in similar coefficients and no statistical 
significance (data not shown), so the interaction was excluded from the final model. 
These data show that IIS participation is not a statistically significant predictor of invalid 
doses for the full series for all three models (Table 4.4). When compared to children who had no 
providers reporting vaccines to an IIS, some/all IIS participation is not associated with invalid 
doses.  
State of residence provided some of the most interesting results from the regression 
models, using states’ fixed-effects, suggesting that state immunization programs probably have a 
strong influence on immunization behaviors. In this study, California is used as the referent state 
because of its size, diversity, and research on immunization programs in the state. For the fifty 
states, and D.C., aORs varied widely (Mean aOR = 1.48). Children from Rhode Island are  
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Table 4.4 Adjusted Odds Ratios of Provider IIS Participation on Invalid Dose Status Excluding Hep B Doses 
Logistic Reg. Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
 aOR 95% CI aOR 95% CI aOR 95% CI 
IIS Participation       
   None Ref.  Ref.  Ref.  
   Some/All Providers 1.08 [0.93, 1.25] 1.08 [0.93, 1.26] 1.15 [1.00, 1.34] 
   Unknown 1.06 [0.91, 1.23] 1.06 [0.90, 1.23] 1.11 [0.95, 1.31] 
Year       
   2012 Ref.  Ref.  Ref.  
   2013 0.91 [0.82, 1.02] 0.89 [0.80, 1.00] 1.37*** [1.34, 1.40] 
   2014 0.67*** [0.60, 0.74] 0.70*** [0.63, 0.78] 0.82*** [0.80, 0.84] 
   2015 0.49*** [0.42, 0.58] 0.52*** [0.44, 0.61] 1.18*** [1.15, 1.21] 
   2016 0.69*** [0.60, 0.80] 0.72*** [0.62, 0.83] 0.54*** [0.52, 0.57] 
Provider Type       
   All Public Ref.  Ref.  Ref.  
   All Hospital 1.21* [1.04, 1.41] 1.21* [1.04, 1.42] 0.95 [0.80, 1.22] 
   All Private 1.21* [1.04, 1.40] 1.20* [1.04, 1.40] 1.02 [0.90, 1.14] 
   All Military/Other 0.61*** [0.49, 0.75] 0.57*** [0.46, 0.71] 0.78 [0.61, 1.00] 
   Mixed 1.33*** [1.19, 1.50] 1.33*** [1.18, 1.49] 1.65*** [1.43, 1.91] 
Moved from birth state (No)       
   Yes 1.26*** [1.16, 1.38] 1.25*** [1.15, 1.37] 1.87*** [1.65, 2.12] 
Hep B Birth Dose (None)       
   ≥ 1 Provider(s) reported 1.21*** [1.13, 1.29] 1.22*** [1.13, 1.30] 0.74*** [0.67, 0.81] 
Maternal Age       
   ≤ 29 years 0.98 [0.94, 1.02] 0.98 [0.94, 1.03] 1.13** [1.04, 1.23] 
   > 29 years Ref.  Ref.  Ref.  
Maternal Education       
   < 12 years 0.88** [0.80, 0.96] 0.87** [0.79, 0.95] 1.10 [0.93, 1.31] 
   12 years (HS degree) 0.90*** [0.85, 0.96] 0.89*** [0.84, 0.95] 1.06 [0.94, 1.21] 
   > 12 years, non-college grad 0.89*** [0.85, 0.93] 0.89*** [0.85, 0.93] 0.93 [0.83, 1.03] 
   College grad Ref.  Ref.  Ref.  
Income/Poverty Status       
   Above Poverty, > $75k Ref.  Ref.  Ref.  
   Above Poverty, ≤ $75k 0.95 [0.90, 1.00] 0.95 [0.91, 1.00] 1.19** [1.08, 1.32] 
   Below Poverty 0.94 [0.88, 1.01] 0.94 [0.87, 1.00] 1.38*** [1.21, 1.58] 
   Unknown 1.01 [0.91, 1.12] 1.01 [0.91, 1.11] 1.48*** [1.19, 1.82] 
Child Age Group       
   19-24 months Ref.  Ref.  Ref.  
   25-29 months 1.18*** [1.12, 1.25] 1.18*** [1.11, 1.25] 1.15** [1.06, 1.25] 
   30-35 months 1.25*** [1.19, 1.32] 1.25*** [1.19, 1.32] 1.17** [1.06, 1.29] 
Child Race/Ethnicity       
   White Ref.  Ref.  Ref.  
   Black 0.90** [0.84, 0.97] 0.90** [0.83, 0.97] 1.41*** [1.20, 1.66] 
   Hispanic 0.99 [0.93, 1.06] 0.98 [0.91, 1.05] 1.25*** [1.10, 1.43] 
   Multiple/Other 1.12** [1.04, 1.22] 1.12** [1.03, 1.21] 1.58*** [1.39, 1.79] 
Child Gender (Male)       
   Female 1.00 [0.96, 1.03] 1.00 [0.97, 1.04] 1.00 [0.92, 1.08] 
Child First-born status (No)       
   Yes 1.05* [1.01, 1.09] 1.05* [1.01, 1.09] 0.96 [0.91, 1.02] 
* p < 0.05, ** p < 0.01, *** p < 0.001  N= 72323  N= 72323  N= 72115  
 M&Z R2= 0.098 M&Z R2= 0.102 M&Z R2= 0.100 
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associated with the lowest likelihood of any invalid doses (aOR = 0.35, 95% CI 0.33-0.37) to 
children in North Dakota who are associated with the highest likelihood of any invalid doses 
(aOR = 4.50, 95% CI 4.17-4.84) when compared to California. Children from two states (GA, 
and OR) are as likely as children from California to have any invalid doses. Fifteen (15) states 
are associated with statistically significant lower aORs compared to California (AK, FL, IA, KS, 
LA, MI, MT, NV, NJ, OK, RI, SD, TX, VA, and WV), while the remaining states and D.C. (N = 
33) are associated with higher odds of any invalid doses. Full state-data is available in Appendix 
D of this chapter.  
Time is also associated with differences in invalid doses for the full series but with 
varying results by model. A change in the number of invalid doses between 2013 and 2014, 
shown in Table 3, is also demonstrated in the regression results. Compared to 2012, children in 
the 2014-2016 NIS are associated with lower odds of having invalid doses due to age (for 2016 
the aOR is 0.72, 95% CI 0.62-0.83). When evaluating the effect of year on invalid doses due to 
interval, the trend is not consistent. Children in the 2013 sample are associated with higher odds 
(aOR = 1.37, 95% CI 1.34-1.40) of having an invalid interval dose, but in 2016 are associated 
with statistically significantly lower odds a(OR = 0.54, 95% CI 0.52-0.57) when compared to 
children in 2012.  
Provider types are associated with invalid doses in different ways. Statistically significant 
differences are seen in the regression results primarily in relation to invalid doses due to age. 
Those children with “All Hospital” (aOR = 1.21, 95% 1.04-1.42) or “All Private” (aOR = 1.20, 
95% CI 1.04-1.40) providers are associated with higher odds of invalid doses due to age when 
compared to those children with “All Public” providers. Conversely, those with “All 
Military/Other” providers have lower odds (aOR = 0.57, 95% CI 0.46-0.71) of having invalid 
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doses due to age when compared to those with the public providers. Those with “mixed” 
provider types are associated with statistically significantly higher odds of invalid doses in all 
three models. In the invalid interval model, only “Mixed Providers” are statistically significant 
demonstrating an increase when compared to all public providers (aOR = 1.65, 95% CI 1.43-
1.91). As a check on whether multiple providers were influencing the coefficients, I tested a 
dummy variable that categorized children with one or two identified providers, who all 
responded to the survey, to control for whether all providers responded, and the results were not 
different (data not shown). 
Mobility of children who have moved to a state different from where they were born is 
also associated with statistically higher odds of having invalid doses than children who did not 
move. Although both types of invalid doses are associated with higher likelihood in children who 
have moved, the odds are higher for those invalid doses due to interval (aOR = 1.87, 95% CI 
1.65-2.12) compared to those due to age (aOR = 1.25, 95% CI 1.15-1.37). Receipt of a birth dose 
of Hep B is also associated with invalid doses. For example, children who have at least one 
provider report that the child received a Hep B birth dose have higher odds of an invalid doses 
due to age (aOR = 1.22, 95% CI 1.13-1.30) but have statistically significantly lower odds of 
having invalid doses due to interval (aOR = 0.74, 95% CI 0.67-0.81) when compared to those 
who did not receive the birth dose.  
Other child-level factors associated with invalid doses are child age group, race/ethnicity, 
and first-born status. Children in the 25-29 months and the 30-35 months categories of higher 
odds of invalid doses due to age and interval compared to children in the 19-24 months age 
group. This trend held across all three models. For invalid doses due to age, both 25-29 months 
and 30-35 months groups were associated with increased odds of invalid doses (aOR = 1.18, 
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95% CI 1.11-1.25; and aOR = 1.25, 95% CI 1.19-1.32 respectively) and for invalid intervals 
(aOR = 1.15, 95% CI 1.06-1.25; and aOR = 1.17, 95% CI 1.06-1.29). There was some variability 
in different child race/ethnicities regarding invalid doses. When compared to White children, 
Black children are associated with lower odds of invalid doses due to age (aOR = 0.90, 95% CI 
0.83-0.97) while children of Multiple/Other race ethnicity have higher odds of invalid doses due 
to age (aOR = 1.12, 95% CI 1.03-1.21). Regarding invalid doses due to interval, Black, Hispanic, 
and Multiple/Other racial/ethnic groups demonstrate higher odds of invalid doses (aOR = 1.41, 
95% CI 1.20-1.66; aOR = 1.25, 95% CI 1.10-1.43; and aOR = 1.58, 95% CI 1.39-1.79 
respectively). Finally, children who are first-born in their families are more likely to have invalid 
doses due to age (aOR = 1.05, 95% CI 1.01-1.09) compared to those who have older siblings. 
Maternal characteristics, including age group, income and poverty status, and some levels 
of education, are also significant predictors of invalid doses. The younger maternal age group is 
associated with higher odds of invalid doses due to interval only (aOR = 1.13, 95% CI 1.04-
1.23). Maternal education is only associated with invalid doses due to age. Mothers with less 
than high school education, high school degree, and some college but no degree all have similar 
lower odds of invalid doses due to age when compared with mothers with college degrees (range 
aOR = 0.87-0.89, 95% CI range 0.79-0.95). Finally, mothers who are in the highest income 
category (Above poverty, > $75k) are associated with lower odds of invalid doses due to interval 
than all other categories. As income decreased, or as households fell below the poverty line, the 
association with invalid doses due to interval increased. Children in families above the poverty 
line, but income < $75k had an aOR = 1.19 (95% CI 1.08-1.32) while children below the poverty 
line had an aOR = 1.38 (95% CI 1.21-1.58). Children in families who did not provide their 
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income also had higher likelihood of invalid doses due to interval (aOR = 1.48, 95% CI 1.19-
1.82).  
Association between Hepatitis B vaccinations and invalid doses. In this section, I 
highlight differences between Hep B doses separate from those I present in Table 4.4 with state 
data in Appendix E. When including Hep B invalid doses (any, age, and interval) as the 
dependent variables, IIS participation is associated with statistically significant higher odds of 
having invalid doses when controlling for time, child, maternal, provider, and geographical 
characteristics. Shown in Table 4.5, the aORs for invalid Hep B doses due to age and interval in 
children whose providers participated in an IIS are 1.25 and 1.24 respectively (95% CIs 1.08, 
1.44 and 1.11, 1.38) compared to children whose providers did not participate. Those children 
whose providers’ IIS participation was unknown, also have higher odds of invalid Hep B doses 
(aOR 1.18, 95% CI 1.05, 1.34) compared to children whose providers did not participate in an 
IIS. 
As demonstrated in Table 4.3, over time, children are associated with higher odds of 
invalid Hep B doses due to age with the highest odds occurring in 2015 (aOR 1.44, 95% CI 1.41, 
1.47), though it is unclear if the decrease from 2015 to 2016 (aOR 1.18, 95% CI 1.14, 1.23) will 
continue. This trend is in the opposite direction of what is seen in the full models presented in 
Table 4.4.  
There are few differences in provider type when compared to “All Public” providers. 
Children with “All Private” providers have lower odds of invalid Hep B doses due to interval 
(OR 0.80, 95% CI 0.69, 0.92). Conversely, children with “All Military/Other” providers are 
associated with significantly higher odds of having invalid Hep B doses due to age (OR 1.65, 
95% CI 1.32, 2.15). 
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Table 4.5 Adjusted Odds Ratios of Provider IIS Participation on Invalid Hep B Dose Status 
Logistic Reg. Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
 OR 95% CI OR 95% CI OR 95% CI 
IIS Participation       
   None Ref.  Ref.  Ref.  
   Some/All Providers 1.24** [1.08, 1.43] 1.25** [1.08, 1.44] 1.24*** [1.11, 1.38] 
   Unknown 1.16* [1.02, 1.31] 1.15 [1.00, 1.32] 1.18** [1.05, 1.34] 
Year       
   2012 Ref.  Ref.  Ref.  
   2013 0.87*** [0.85, 0.88] 0.83*** [0.81, 0.84] 0.75*** [0.72, 0.78] 
   2014 0.95*** [0.94, 0.97] 0.97*** [0.95, 0.98] 0.58*** [0.57, 0.59] 
   2015 1.46*** [1.43, 1.49] 1.44*** [1.41, 1.47] 0.99 [0.97. 1.01] 
   2016 1.16*** [1.12, 1.21] 1.18*** [1.14, 1.23] 0.55*** [0.53, 0.57] 
Provider Type       
   All Public Ref.  Ref.  Ref.  
   All Hospital 0.93 [0.81, 1.08] 0.97 [0.84, 1.11] 0.84 [0.70, 1.01] 
   All Private 0.86 [0.74, 1.00] 0.87 [0.76, 1.01] 0.80** [0.69, 0.92] 
   All Military/Other 1.64*** [1.28, 2.11] 1.69*** [1.32, 2.15] 1.24 [0.99, 1.56] 
   Mixed 1.10 [0.99, 1.23] 1.11 [1.00, 1.23] 1.11 [0.97, 1.27] 
Moved from birth state (No)       
   Yes 1.16* [1.01, 1.32] 1.12 [0.96, 1.29] 1.62*** [1.43, 1.83] 
Hep B Birth Dose (None)       
   ≥ 1 Provider(s) reported 5.47*** [4.22, 7.08] 8.76*** [6.58, 11.67] 1.00 [0.88, 1.13] 
Maternal Age       
   ≤ 29 years 0.99 [0.94, 1.04] 0.98 [0.93, 1.02] 1.07 [0.97, 1.17] 
   > 29 years Ref.  Ref.  Ref.  
Maternal Education       
   < 12 years 1.00 [0.89, 1.13] 0.94 [0.83, 1.07] 1.25** [1.09, 1.43] 
   12 years (HS degree) 1.06 [0.98, 1.14] 1.03 [0.95, 1.11] 1.16* [1.03, 1.31] 
   > 12 years, non-college grad 1.10** [1.03, 1.16] 1.08* [1.02, 1.15] 1.08 [0.98, 1.18] 
   College grad Ref.  Ref.  Ref.  
Income/Poverty Status       
   Above Poverty, > $75k Ref.  Ref.  Ref.  
   Above Poverty, ≤ $75k 1.07* [1.01, 1.14] 1.07 [1.00, 1.14] 1.20** [1.07. 1.34] 
   Below Poverty 1.03 [0.95, 1.11] 1.00 [0.93, 1.09] 1.34*** [1.20, 1.49] 
   Unknown 1.16* [1.03, 1.32] 1.16* [1.03, 1.32] 1.52** [1.15, 2.01] 
Child Age Group       
   19-24 months Ref.  Ref.  Ref.  
   25-29 months 0.92** [0.88, 0.97] 0.92** [0.87, 0.96] 1.03 [0.91, 1.15] 
   30-35 months 0.82** [0.77, 0.86] 0.81*** [0.77, 0.85] 0.98 [0.89, 1.08] 
Child Race/Ethnicity       
   White Ref.  Ref.  Ref.  
   Black 1.03 [0.95, 1.13] 1.00 [0.92, 1.09] 1.24** [1.09, 1.42] 
   Hispanic 1.07 [0.99, 1.15] 1.06 [0.99, 1.14] 1.17** [1.04, 1.31] 
   Multiple/Other 1.08 [0.98, 1.18] 1.05 [0.95, 1.16] 1.43*** [1.26, 1.62] 
Child Gender (Male)       
   Female 1.00 [0.97, 1.04] 1.00 [0.97, 1.04] 0.98 [0.93, 1.03] 
Child First-born status (No)       
   Yes 1.09*** [1.04, 1.13] 1.11 [1.06, 1.16] 0.95 [0.89, 1.02] 
* p < 0.05, ** p < 0.01, *** p < 0.001  N= 73,193  N= 73,193    N= 73,001  
 M&Z R2 0.097 M&Z R2=  0.101 M&Z R2= 0.103 
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Maternal characteristics appeared less associated with invalid doses overall except for a 
few notable differences. Children who have at least one provider reporting a birth dose of Hep B 
are associated with significantly higher odds of invalid doses due to age (OR 8.76, 95% CI 6.58, 
11.67) compared to children with no reported birth dose. Maternal education and poverty 
indicators are not strongly associated with invalid doses. Lastly, older child’s age groups are 
associated with lower odds of invalid Hep B doses due to age compared to the youngest age 
group. Children in the 24-29 months (aOR 0.92, 95% CI 0.87, 0.96) and 30-35 months (aOR 
0.81, 95% CI 0.77, 0.85) age groups are associated with lower odds of invalid Hep B doses. 
Child race/ethnicity and first-born status are similarly associated with invalid Hep B doses as the 
full models discussed in Table 4.4.  
Discussion 
 Immunizations are most effective when administered at the appropriate age and intervals 
between doses (Butte et al., 2001; Stokley et al., 2004). An increasingly complex vaccination 
schedule, increased utilization of multiple vaccination providers, and a lack of a unified national 
infrastructure for documenting and tracking immunizations are all obstacles to improving the 
accuracy and completeness of immunization histories, the timing and quality of vaccines, and 
increasing overall rates (Stokley et al., 2004; Stokley et al., 2001; Yusuf et al., 2002). This study 
focuses on inappropriate vaccinations through a retrospective evaluation of the validity of 
administered doses using strict interpretation of the ACIP’s required ages and intervals between 
doses and includes the recommended four-day grace period for retrospective review. The 
literature on invalid doses is scarce and dated and little attention has been paid to link between 
invalid vaccinations and quality and the potential effects invalid vaccines have on overall 
immunity in the population. This study adds to the literature on invalid doses by providing an 
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updated analysis of invalid vaccines for the full series including 4 DTaP, 3 Pol, 1 MMR, 3 Hib, 3 
HepB, 1 Var, and 4 PCV doses over a five-year period. It also examines the relationship between 
IISs and invalid doses using multiple logistic regression modeling and controlling for child, 
maternal, and geographical factors as well as type of immunization provider(s) and time to better 
understand how electronic information systems may relate to the quality of vaccinations.  
Over the study period, 49 out of the 50 states, and the District of Columbia, utilized IISs 
in some capacity. Since IISs have the capability of forecasting needed vaccines in real-time, 
using algorithms incorporating the ACIP schedule, it is reasonable to assume that the improved 
systems for tracking and documentation of vaccines would lead to decreases in the numbers of 
invalid doses. Previously, invalid dose estimates ranged from 8% to 35.5% (Butte et al., 2001; 
Hamlin et al., 1996; Luman et al., 2002; Stokley et al., 2004), and in this study, which includes 
more vaccines and stricter adherence to ACIP guidelines for validity assessments, I estimate that 
about half of all children in the NIS had at least one invalid dose, mostly due to inappropriate 
Hepatitis B and Polio vaccination which is consistent with other literature (Butte et al., 2001). 
From 2012 to 2016, the rates of invalid doses declined slightly for DTaP and were relatively 
unchanged for MMR, Hib, PCV, and Var; and overall rates were consistent with previous 
literature using the 2002 NIS (Stokley et al., 2004). Frequency of invalid doses for Hepatitis B 
declined slightly from 2015 to 2016, but that was after a significant increase in rates from 2014 
to 2015 and remains a large portion of overall invalid doses. Invalid doses for polio increase 
from 2015 to 2016 and is likely responsible for the overall invalid rate increase in the same time 
frame. 
The increases in overall invalid doses in this study may be explained in several ways. 
First, in this study, I analyze more vaccines than what was included in previous studies. In 2000, 
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a new vaccine for PCV was licensed for children (The College of Physicians of Philadelphia, 
n.d.) and would not have been included in the full series in two studies (Butte et al., 2001; 
Luman et al., 2002) and in the other two studies, a select few vaccines were selected for analysis 
and did not include the full series (Hamlin et al., 1996; Stokley et al., 2004). Second, prior 
studies were not consistent in defining or differentiating invalid doses. For example, Luman et al. 
(2002) did not evaluate invalid intervals and Stokley et. al. (2004) did not differentiate invalid 
age from invalid intervals. A third explanation is that, for various reasons, providers are 
administering doses at inappropriate times and at increasing frequency. There were no schedule 
changes in the five-year study period that I could associate with the increases in invalid Hepatitis 
B and Polio doses, so the reasons for these increases are unclear at this time and justify further 
investigation. 
The utilization of Immunization Information Systems (IISs) is one strategy widely 
recommended by public health officials to help improve the quality of doses delivered by 
recommending or forecasting needed vaccines in real-time and reducing vaccination record 
fragmentation which has the potential to improve the accuracy and completeness of records 
(Groom et al., 2015; National Vaccine Advisory Committee, 1999). Ideally, data from IISs 
would be utilized to examine the effect of IISs on vaccination rates but currently still suffer from 
quality concerns and data are frequently incomplete (Khare et al., 2006). Therefore, utilizing a 
well-validated survey, such as the NIS, to examine immunization data is more appropriate in this 
setting. From 2012 to 2016, more than 72% of the children in the sample had providers who 
reported immunization data to an IIS which allowed for this analysis. 
Overall, I find no effect of IIS participation on invalid vaccine status, similar to a 
previous study (Davidson et al., 2003), when I excluded Hepatitis B doses as an outlier vaccine. 
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However, when examined separately, IIS participation was associated with higher likelihood of 
invalid Hepatitis B doses. This is an interesting finding since only two of the three doses in the 
series were assessed for validity due to age, and all three were utilized in the interval validity 
determination. There is no minimum age for the birth dose of Hepatitis B and those who had 
providers that reported these birth doses were associated with higher odds of invalid doses than 
children whose providers did not report one. Previous studies have discussed the complexity 
surrounding the Hepatitis B schedule, and the difficulty providers had in determining the 
patient’s need for a HepB vaccine (Butte et al., 2001), however, those recommendations have not 
changed in recent years and may not explain the significant increase in invalid doses especially 
in light of IISs ability to forecast vaccines that are needed in real-time.  
One factor that contributed to the frequency of invalid doses is the whether a child 
received the birth dose of Hep B, the only vaccine currently recommended at birth. Children with 
at least one provider reporting that a HepB birth dose was administered were far more likely to 
have received invalid doses than children whose providers did not report a birth dose, however, 
that may also be due to the fact that those children were less likely to receive the Hepatitis B 
sequence overall.  
This study was unable to account for several potential factors that could influence IIS 
participation, demonstrated by how little variance the regression models explained. For example, 
provider characteristics are largely absent from the NIS. The type of practice of responding 
providers is available but only in aggregate at the child-level. Therefore, individual providers’ 
behaviors are not able to be explored with this data set. Providers are instrumental in providing 
immunization data to the NIS and low response rates and a lack of publicly available information 
regarding provider practices hinders analysis at the provider level. In the 2016 NIS, only 54.2% 
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of children had adequate provider data so roughly half of children with completed household 
interviews were excluded from analysis because they lacked immunization data from their 
provider(s) (National Center for Immunization and Respiratory Diseases, 2017).  
Second, parental behaviors are not captured in the NIS. I include the receipt of a HepB 
birth dose, socioeconomic variables which are linked with attitudes and acceptance of vaccines, 
and demographics (Luman et al., 2003) to proxy for parental immunization behaviors. Starting in 
2012, the NIS ceased asking parents to recall childhood vaccinations in an attempt to increase 
response rates by shortening the screening interview (National Center for Immunization and 
Respiratory Diseases, 2017). However, this information provided insight to parental awareness 
of child vaccination status.  
Finally, since IISs are implemented and governed at the state-level, there is an important 
relationship between states, year, and IIS participation, which are difficult to uncover with the 
data used in this study. I controlled for states fixed effects and year fixed effects, but other 
unobserved variables may have biased the findings of this study. In a study by Davidson et. al. 
(2003), the authors concluded that the “presence of a registry” was not sufficient to improve 
vaccination rates, but this was based on three years of data and only evaluated DTaP, Polio and 
Hib vaccines. Implementing a control for the length of time since IIS implementation may offer 
additional insight into the IISs’ impact on UTD status11.  
 
1 I attempted to collect the IIS implementation year for each state IIS, and Washington, D.C., using a literature 
search, IIS website search, and contacts at AIRA, however data could not be obtained within the time frame for this 
dissertation. 
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Limitations 
 There are several limitations to this study. First, IIS participation was proxied for using a 
question in the provider record check phase of the NIS. However, in the public use dataset, the 
role of the person responding to the survey is not available. Further, for each child in the NIS, 
data from all providers who responded is aggregated in the public-use file so individual provider 
participation cannot be assessed. Since the information is self-reported, the data are subject to 
errors in understanding of the IIS participation at the practice and/or provider level. 
Second, although rigorous criteria were used in determining validity of each dose in the 
NIS, it was not possible to determine valid “re-vaccinations”. Therefore, some doses that were 
administered before the appropriate interval may have been valid if the interval was calculated 
based on different doses. I attempted to minimize the number of mis-classification errors by 
providing a conservative estimate, adding the four-days grace period suggested by the CDC, and 
using the required ages and intervals for each dose in a series rather than the minimum 
recommended cutoff values.  
Third, I was only able to analyze those with adequate provider data (those with 
immunizations that were reported), and therefore cannot tell if those whose providers did not 
participate would have changed the outcome. Also, The NIS is not able a viable source of 
provider-behavior and is not meant to be analyzed at the provider-level. For the purposes of this 
analysis, it is possible that providers who chose not to participate in the provider record check 
phase of the NIS behave differently from those providers who did participate and may have 
introduced a source of bias into the results. Fourth, the sample size was relatively small for each 
state. I attempted to improve the sample size by pooling five years of data, however, my findings 
demonstrate wide confidence intervals.  
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Lastly, there are known limitations to the NIS as a source of immunization information. 
The NIS provides stable and reliable estimates at a national level but is not reliable at the state 
level. Decreasing response rates by households and providers also add challenges in obtaining 
reliable vaccine information, however, the NIS utilizes a complex stratified survey design and 
provides survey and provider weights that adjust for selection and non-response bias. In several 
cases, imprecise coefficients limited the interpretation of the findings. 
Conclusion  
Protection against vaccine-preventable diseases relies upon timely and accurate 
vaccination of the population. Vaccines that are delivered at sub-optimal timing can result in a 
less robust immune response. Invalid doses are important to the overall quality of vaccinations; 
counting all doses, including invalid ones, gives the appearance of being “vaccinated” but 
without the full protection of antibodies that are induced by vaccine exposure and leads to an 
under-protected community (Luman et al., 2002). Further, the spread of vaccine-preventable 
diseases in communities that believe they are protected can propagate vaccine hesitancy and a 
public perception that “vaccines are ineffective”. Most invalid doses require re-vaccination 
which can also add significant costs and burden on the health care system (e.g. additional 
doctor’s visits, vaccine supply costs). The findings in this study demonstrate a continued need for 
improving the quality of vaccination delivery in the U.S. and targeted efforts to reduce the 
numbers of invalid doses.  
Immunization information systems are population-based electronic repositories with the 
capability of improving tracking, documentation, and forecasting of vaccination needs in real-
time, but their impacts on the timeliness and quality of vaccine delivery are still emerging. 
Although these data suggest that IIS may not contribute to reductions in invalid doses, the NIS 
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may not be the optimal dataset to address the question of IIS effectiveness. Efforts to further 
improve the quality and completeness of IIS data will ultimately allow for more nuanced 
evaluation of the full impact of IISs on vaccination status at state and local levels. Continued 
research into the impact of IIS on immunizations will help public health officials, providers, and 
policymakers determine the amount of investments and strategies for improvement as the 
country continues to face increasing numbers of vaccine-preventable outbreaks. 
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Chapter 5  An Examination of Immunization Information Systems’ Policies and 
State-level Vaccination Rates  
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Introduction 
High levels of vaccination are needed to achieve adequate protection against vaccine 
preventable diseases (VPDs). In 2016, vaccination rates for the full combined series of routinely 
recommended childhood vaccines missed the Healthy People 2020 target of 80% in children 19-
35 months of age (Hill et al., 2017; US Department of Health, Human Services, Office of 
Disease Prevention, & Health Promotion, 2012). Only 70.7% of children 19-35 months of age in 
the U.S. had received the recommended doses for the full combined series including 4 doses of 
Diphtheria Tetanus and acellular Pertussis (DTaP), 3 doses of Polio (Pol), 1 dose of Measles, 
Mumps, and Rubella (MMR), 3 or 4 doses of Haemophilus influenzae b (Hib) depending on the 
manufacturer, 3 doses of Hepatitis B (Hep B), 1 dose of Varicella (Var), and 4 doses of the 
pneumococcal vaccine (PCV), which was 1.5 percentage points lower than 2015 estimates (Hill 
et al., 2017). When examined separately, rates for Polio, MMR, and Hep B met the Healthy 
People 2020 individual vaccine targets of 90%; but lower rates were reported for DTaP, Hib, and 
PCV which was consistent with the decline for the combined series. Declining rates and missed 
vaccination targets represent a continued public health priority and presents an opportunity for 
improving immunization rates and overall protection against vaccine preventable disease.  
 Several factors contribute to these sub-optimal rates of vaccination. Among those factors 
is the lack of an efficient, coordinated way of tracking and documenting vaccinations in the U.S., 
an important challenge considering the vaccination schedule has become more complex in the 
number and timing of routinely recommended vaccines (Stokley et al., 2001). Documentation of 
vaccines in a patient’s medical chart is mandatory but those records often exist only at the 
provider or clinic-level (Centers for Disease Control and Prevention, n.d.; Clark et al., 2006). 
Additionally, children are seeing multiple vaccine providers with increasing frequency creating 
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the opportunity for fragmented and incomplete records, record scattering across different health 
records systems, and increases the chances for missed vaccination opportunities (Stokley et al., 
2001; Yusuf et al., 2002). Incomplete records also increase the likelihood that children will 
receive duplicate vaccines due to an inability to accurately assess individual vaccination status 
which can lead to over-immunization, increased costs due to the demand on vaccine supply, and 
increases in the number of provider visits needed to fully vaccinate a child (Linkins, 2001; 
Stokley et al., 2004). Incomplete records can also lead to inappropriate vaccination, or the 
administration of vaccines at the wrong age or spacing between doses, and oftentimes requires 
re-vaccination so that an optimal immune response and subsequent protection toward VPDs can 
be achieved (Butte et al., 2001; Stokley et al., 2004).  
 At the population-level, incomplete records present challenges when assessing the 
vaccination coverage at local, state, and national levels. Currently, the U.S. uses the National 
Immunization Survey (NIS), a nationally representative cross-sectional survey, to estimate the 
vaccination coverage in children 19-35 months old and in teens 13 to 17 years old (Centers for 
Disease Control and Prevention; Zell et al., 2000). However, the delay between data collection 
and release of survey results, as well as the small sample sizes in each state, makes estimating 
true vaccination rates challenging (Centers for disease control and Prevention; Hill et al., 2015; 
Salmon et al., 2006). Further, although the complex design of the NIS tries to minimize the 
selection and non-response bias (Zell et al., 2000), the data may still be subject to inadequate 
data resulting from record fragmentation, reporting errors, and incomplete records leaving a need 
for more robust data sources. 
Immunization information systems (IISs) are confidential population-based electronic 
repositories that house immunization data and are one strategy recommended for reducing record 
90 
 
fragmentation and improving immunization rates in the U.S. (Stokley et al., 2001). They have 
shown promise in increasing immunization rates by preventing missed opportunities (Freeman & 
DeFriese, 2003), consolidating fragmented records (Kempe et al., 2001), decreasing 
immunization-related costs through reductions in over-vaccination (Feikema et al., 2000), or 
reducing re-vaccinations due to inappropriately delivered doses (Stokley et al., 2004). They also 
offer the capability of real-time data access (Muscoplat & Rajamani, 2017) which would reduce 
the delay between data collection and analysis. 
Over the last three decades, numerous resources have been invested in IISs as a tool to 
increase vaccination coverage in the U.S. through expansion of their functionality and utility to 
standardize and coordinate vaccination documentation and tracking (Centers for Disease Control 
and Prevention, 2018b; Groom et al., 2015). IISs are operationalized primarily at the state-level 
and are therefore subject to wide variability in their design, implementation, operation, and 
utilization (Martin et al., 2015). As a result, a series of functional standards, as described below, 
were created to help immunization programs standardize their IISs and allow for some degree of 
interoperability or functioning across different electronic systems (Immunization Information 
Systems Support Branch within CDC/NCIRD, 2013). IISs should: 
1. Support the delivery of clinical immunization services at the point of immunization. 
2. Support the activities and requirements for publicly-purchased vaccine, including the 
Vaccines For Children (VFC) and state purchase programs. 
3. Maintain data quality (accurate, complete, timely data) on all immunization and 
demographic information in the IIS. 
4. Preserve the integrity, security, availability and privacy of all personally identifiable 
health and demographic data in the IIS. 
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5. Provide immunization information to all authorized stakeholders. 
6. Promote vaccine safety in public and private provider settings. 
While the standards have provided structure for operationalizing IISs, and many IIS 
policies are created to align with these standards, evaluation of IISs are mostly limited to state-
level analyses that may not be broadly applicable (Groom et al., 2015). Additionally, analysis of 
data from an IIS is still in early stages and data may not be reliable enough for accurate 
estimates. There are several studies in the literature regarding specific policies that govern the 
operation of IISs (Freeman & DeFriese, 2003; Hedden et al., 2012; Horlick et al., 2001; Martin 
et al., 2015) but the association of state-level policies immunization outcomes is not well-defined 
in the literature.  
In this chapter, I analyze the relationship between policies as proxies for measuring the 
IIS functional standards and immunization rates at the state-level. To address this research aim, I 
examine two of the functional standards that guide the implementation and operation, supporting 
the delivery of immunizations at the point of service and data quality using several variables: the 
ability of states to forecast vaccine recommendations to electronic health records, the type of 
states’ IIS reporting mandates, patient consent types, and IIS participation by providers. My 
working hypothesis is that states that have policies that meet the requirements of the functional 
standards, and those that encourage participation, will have a higher percentage of children who 
are up-to-date (UTD) for the full combined series of vaccines compared to states that do not meet 
the functional standards. 
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Conceptual Framework 
In this chapter, I analyze the association between IISs and state immunization rates for 
the full combined series of routinely recommended vaccines which was guided by the conceptual 
framework in Figure 5.1.  
 
 
F.S.= Functional Standard 
Figure 5.1 Conceptual Framework for Increasing State Immunization Rates Using Immunization 
Information Systems 
 
The Healthy People 2020 objectives describes several national programmatic 
immunization goals including an objective to vaccinate 80% of children with the full combined 
series by the age of two years (Healthy People 2020 [Internet], Office of Disease Prevention and 
Health Promotion). It is largely up to the individual states to govern their immunization 
programs and assess the progress and success of interventions designed to improve rates within 
the states (Hedden et al., 2012; Horlick et al., 2001). IIS policies influence state immunization 
rates by affecting IIS participation, utilization, or indirectly through operational mechanisms. In 
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this chapter, I focus on Functional Standards 1 and 3 since they are standards specifically related 
to the utilization of IISs and would theoretically have the largest impact on state immunization 
rates as I explain in the following paragraphs. 
I examine the ability of IISs to provide clinical decision support at the point of care 
(described in Functional Standard 1). Interoperability, or the ability of an IIS to communicate 
with electronic health records (EHRs), is an important component of clinical decision support 
tools to assist providers with providing the right immunization at the right time (Dayton, 2014). 
One type of clinical decision support is the ability of an IIS to “forecast” or recommend vaccines 
using complex algorithms informed by the Advisory Committee for Immunization Practices 
(ACIP) immunization guidelines (Muscoplat & Rajamani, 2017). Theoretically, this would help 
ensure the patient is receiving the correct vaccination at the recommended age and appropriate 
interval between doses (Wood et al., 1999). Clinical decision support tools should also improve 
the completeness of the vaccination history since forecasts are available at the point of care when 
EHRs and IISs are interoperable (Muscoplat & Rajamani, 2017). This would reduce the chance 
for inappropriate or over-vaccination (Dayton, 2014) and should prevent missed vaccination 
opportunities while the patient is in the provider’s office.  
Participation in IISs is critical for the operation of an IIS. Providers who administer 
vaccines are the main source of IIS data and directly impacts the level of data accuracy, 
timeliness, and completeness in an IIS (described in Functional Standard 3) (Groom et al., 2015; 
Wood et al., 1999). Record fragmentation and incomplete records, which happens when there are 
multiple vaccine providers (Stokley et al., 2001), delays in reporting vaccines to an IIS 
(American Immunization Registry Association), and incomplete or inaccurate demographic 
information (Robison, 2015) are associated with lower immunization rates, inappropriately timed 
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doses, or extra doses of vaccines (Hamlin et al., 1996; Stokley et al., 2004; Wood et al., 1999). 
Providers’ participation in IISs is driven by policies such as mandates that may require some or 
all providers/facilities to report immunizations to an IIS (Hendrickson et al., 2015; Horlick et al., 
2001) as well as a provider’s personal beliefs and behaviors toward immunizations and IISs 
(Gregorio et al., 1997; Kempe et al., 2017). It is difficult to capture provider behavior toward 
immunizing patients, so I proxy for this by including provider participation rates (Davidson et 
al., 2003) with the assumption that providers who provide fewer immunizations will not 
participate in IISs.  
 In combination with providers providing information to IISs, patient participation is also 
necessary. Patient participation occurs through a variety of mechanisms, and in this study, it will 
be proxied for using the type of IIS consent policy. IISs that use an explicit “opt-in” consent 
policy require patients/parents to give informed consent to have immunization data sent to an 
IIS. While this type of consent policy might place more power in the patient’s hands with regard 
to medical data, it also leads to lower participation rates because it requires additional steps taken 
by the patients and providers to capture and document the consent (Boom et al., 2010). Implicit 
consent, or “opt-out” policies, assume that consent is provided unless patients choose to have 
their data opted out of the IIS (Horlick et al., 2001). This type of policy can lead to higher 
participation rates (Berry et al., 2013) but often parents are typically less aware of this exchange 
of personal data. Some states have strict mandatory consent policies that do not have an opt-out 
provision and in theory would have the highest patient participation rates.  
While the literature surrounding the design and implementation of IISs is robust, there is 
a research gap in how well IISs are meeting the functional standards that guide them. This 
dissertation research explores this gap and adds to the literature on immunization information 
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systems by evaluating the association between IIS policies and state immunization rates as a 
measure of IIS success in meeting two of the functional standards.  
Methods 
Design. This study was a state-level retrospective analysis of IIS policies and the 
relationship with state-level immunization rates using secondary data from the 2016 
Immunization Information Systems Annual Reports, 2015 IIS Legislative Survey, and the 2016 
National Immunization Survey. I utilize descriptive statistics in combination with regression 
analysis to address the research aim guided by the Conceptual Framework in Figure 1. 
Study sample. This study includes states (including Washington, D.C.) as the units of 
analysis (N = 51). New Hampshire was excluded because it did not operate an IIS during the 
study period, 2016, for a final N = 50. City-level IISs, Puerto Rico, and other territories were not 
considered for inclusion since information about how immunization programs and IISs were 
governed or operated was unclear, incomplete, or unavailable at the time of this study.  
Data sources. This study incorporated data from three sources: the 2016 National 
Immunization Survey (NIS), the Survey of State Immunization Information System Legislation 
(IIS Leg) updated in 2015, and the 2016 Immunization Information System Annual Reports 
(IISARs). The data sources are described briefly below with specific variables and descriptions 
for inclusion presented in Table 1. 
The IIS Leg and IISAR serve as the data sources for information on the IIS policies and 
progress toward meeting functional standards and achieving Healthy People 2020 immunization 
objectives (Centers for Disease Control and Prevention, 2018b). The IISAR is an annual report 
required by recipients of federal vaccine funding (Centers for Disease Control and Prevention, 
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2018b). Variables to proxy for the IIS functional standards, including clinical decision support, 
interoperability, and data completeness, were obtained from the IISARs for each state. The IIS 
Leg survey contains information specifically on IIS policies. Respondents are state immunization 
program personnel who are knowledgeable about the implementation and functionality of their 
state’s IIS (Centers for Disease Control and Prevention, 2018b). IIS policies, such as governing 
authority, consent and reporting mandates, were used from this data set to proxy for participation 
in IIS. Information from both surveys are self-reported and respondents supplemented their 
responses with additional data sources such as census estimates (Centers for Disease Control & 
Prevention, 2015b).  
Finally, state immunization rates were estimated from the NIS, the gold standard for 
immunization data in the United States (Khare et al., 2000). The NIS is a nationally 
representative population-based survey of households with children aged19-35 months and their 
immunization providers. Full details about the NIS methodology are available elsewhere in this 
dissertation. Immunization rates were estimated from the aggregated child-level immunization 
data collected from providers who participated in the record-check portion of the survey.  
I merge the IIS Leg and IISAR datasets into a single data file matching on the Federal 
Information Processing Standards (FIPS) state codes. State-level immunization rates are first 
estimated in the NIS, as described in the Dependent variable section, and then coded directly into 
the merged data file. 
Dependent variable. The dependent variable in this study is a state-level estimate for the 
percent of children 19-35 months old who are up-to-date (UTD) for the full combined series of 
vaccines defined as 4 doses of Diphtheria Tetanus and acellular Pertussis (DTaP), 3 doses of 
Polio (Pol), 1 dose of Measles, Mumps, and Rubella (MMR), 3 or 4 doses of Haemophilus 
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influenzae b (Hib) depending on the manufacturer, 3 doses of Hepatitis B (Hep B), 1 dose of 
Varicella (Var), and 4 doses of the pneumococcal vaccine (PCV). I select the full combined 
series, rather than another combination of one or more of the vaccines in the series, for two 
reasons. First, the overall rate of children up-to-date (UTD) for all routinely recommended 
childhood vaccines has consistently missed immunization programmatic targets (Healthy People 
2020 [Internet], Office of Disease Prevention and Health Promotion) and, second, IISs help by 
reducing record fragmentation and missed opportunities (Freeman & DeFriese, 2003; Muscoplat 
& Rajamani, 2017); using an indicator for whether children received their full-series of vaccines 
reduces the need for determining whether there were missed opportunities because children who 
are UTD have received all necessary doses of vaccine.  
The rates are estimated from the 2016 NIS using the recommendations from the 2016 
ACIP child immunization schedule (Centers for Disease Control & Prevention, 2015a). 
Aggregated child-level immunization information was collected from providers who participated 
in the record-check portion of the NIS using provider weights included in the dataset. Children 
were included in the estimate if they resided in 49 states (excluding NH) and Washington, D.C., 
and if they had adequate provider data. Adequate provider data was defined in the NIS as having 
two or more doses reported by at least one provider (National Center for Immunization and 
Respiratory Diseases, 2017). During the data-verification stage, duplicate doses determined by 
date of administration were excluded (National Center for Immunization and Respiratory 
Diseases, 2017). The full combined series flag is a dichotomous variable within the NIS that is 
coded as a Yes/No the child received the full combined series. Based on the state of residence, I 
estimate the percentage of children in each state that have the full combined series flag. State 
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estimates are comparable to previous state rates from NIS-based rates from previous years (Hill 
et al., 2015). 
I code the state-level rates as a continuous variable (0-100%) into the IIS Leg dataset in 
Excel using FIPS codes prior to merging the IIS Leg with the IISAR data.  
Independent variables. For this study, I select variables to serve as proxies for 
measuring how well IISs are achieving IIS Functional Standards (See Table 1). 
Table 5.1 Independent Variables Definitions and Descriptions 
Measure Variable Data 
Source 
Description Measurement 
IIS Participation Mandate IIS Leg Item: Are any entities mandated (by 
legislation, regulations, rules or policy) 
to report immunizations to the IIS? 
No Mandate, Partial 
Mandate, 
Full Mandate 
Patient 
Participation 
Consent IIS Leg Item: What type of consent is required 
from a parent before reporting 
immunization information for their 
child to your IIS? 
Implicit, 
Explicit, 
Mandatory 
Provider 
Participation 
Private Non-
VFC Provider 
Participation 
IISAR Questions 40b & 41b: Number of 
enrolled and reporting Private Non-
VFC providers. ) 
Continuous  
(0-100%)- 
Calculated 
Interoperability Vaccine 
Forecasting 
Capability 
IISAR Question 9: In 2016, did your IIS send 
an immunization forecast to another 
system via HL7? 
Yes/No 
 
Participation. State mandate (Mandate), coded as “no mandate” if a state did not have a 
reporting mandate or reported that no entities are required to report; “partial mandate” includes 
those states that listed one or more entities (e.g. pharmacies, schools, public entities, private 
entities, VFC providers, schools) but not “all”; or “full mandate” if a state requires all 
immunization providers to report vaccines to an IIS. This data is captured in the IIS Leg Survey 
in response to the question, “Are any entities mandated (by legislation, regulations, rules or 
policy) to report immunizations to the IIS?”. I include the mandate as one way to examine 
participation and the relationship between reporting laws on state immunization rates to measure 
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how well IISs maintain accurate, complete and timely data in an IIS as outlined in Functional 
Standard 3 (Horlick et al., 2001) because required reporting should theoretically improve the 
comprehensiveness of vaccination records.  
Consent type is categorized as “Explicit” for those states requiring patients to opt-in, 
“Implicit” for those states requiring patients to “opt-out”, and “Mandatory” for states that require 
participation. Consent policies determine whether patients, or parents/guardians, allow their 
immunization data to be sent to an IIS and directly affects the completeness of records within the 
IIS (Murthy et al., 2017); it can be thought of as less restrictive if patients have to manually 
provide explicit consent, or most restrictive if participation is mandatory. Of the 13 states with 
mandatory consent policies, only one state (MA) allows patients to opt out under specific 
circumstances and is included with the other mandatory consent states. This information is drawn 
from the IIS Leg survey in response to the question, “What type of consent is required from a 
parent before reporting immunization information for their child to your IIS?” 
Provider participation is necessary for the success of an IIS (Freeman & DeFriese, 2003; 
Kim et al., 2007), particularly in the private sector (Linkins & Feikema, 1998) State participation 
rate for private non-Vaccines For Children (VFC) providers is included as a continuous variable 
(0-100%). The VFC program is a federally funded program and provides routinely recommended 
vaccines to uninsured/underinsured children, children on Medicaid, Alaskan Natives, and 
American Indians (Rein, Honeycutt, Rojas-Smith, & Hersey, 2006). Provider participation is 
collected in the IISARs as four different rates: public VFC providers, public non-VFC providers, 
private VFC providers, and private non-VFC providers (Centers for Disease Control & 
Prevention, 2015b).  
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Because many of the partial mandates require public and/or VFC providers to report data 
to an IIS (Centers for Disease Control & Prevention, 2015b; Horlick et al., 2001), I expect the 
public and VFC provider rates to be highly correlated both with each other and with the mandate 
variable. I select “Private non-VFC provider” rates because they are the providers least likely to 
be mandated to report immunizations to an IIS, as they are not participating in programs using 
federal funding for vaccines, and generally have lower participation rates compared to VFC 
providers (data not shown) (Freeman & DeFriese, 2003). Participation rates by these providers 
would provide a conservative estimate of the effect of provider participation on state 
immunization rates. I calculate the private non-VFC provider participation rate by dividing the 
number of actively participating providers by the number of enrolled providers in an IIS. One 
state (SC) did not report private provider rates so I impute a rate using mean substitution 
(Donders, Van Der Heijden, Stijnen, & Moons, 2006) in order to retain SC in the model. I test 
the model with and without SC to ensure that the imputed value would not introduce bias. I 
utilize the private non-VFC provider participation rate as a second proxy for data completeness 
because as provider participation increases, so should the overall number and completeness of 
the records in an IIS.  
Interoperability. I include a binary variable for whether IISs actively send vaccine 
forecasts to providers’ EHRs to proxy for the capability of an IIS to support the delivery of 
vaccinations at the point of care as described in Functional Standard 1. Improving immunization 
rates is partially dependent on accurately identifying the vaccines recommended for a specific 
patient, and then administering those doses at the right age and interval between doses (Dayton, 
2014). At the state level, this can be accomplished by policies that guide the interoperability 
between IISs and provider EHRs (Dayton, 2014). Forecasting capability is collected by IISAR 
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respondents’ answers to the question, “In 2016, did your IIS send an immunization forecast to 
another system via HL7?”, a standard language for messaging between electronic systems (HL7 
International, n.d.). An answer of “Yes” means that the IIS sent at least one vaccine forecast 
directly to a provider’s electronic health record while “No” means it either did not have the 
capability or has the capability but is not currently being utilized by the IIS. An IIS’s forecasting 
ability supports providers by enabling them to deliver vaccines at the point of care during an 
office visit and improves the quality of the vaccines by ensuring compliance with the vaccine 
schedule and helps prevent missed vaccination opportunities (Freeman & DeFriese, 2003).  
Analysis. The analysis plan for this study includes summary statistics and multiple linear 
regression to address the research question. For summary statistics, I present frequencies in 
Table 5.2 for mandate type, consent type, ability to send vaccine forecasts, and display the range 
of rates for private non-VFC provider participation. I also present these data by state in Table 
5.3. 
I utilize two robust multiple linear regression models to examine the association between 
IIS policies for reporting mandate, consent type, interoperability, and the private non-VFC 
provider participation rates, and state-level UTD rates for the full combined series of childhood 
vaccines using two models shown below. In Model 1, I examine the direct effects between a 
reporting mandate, consent type, interoperability, and provider participation, and the state 
immunization rates for the full combined series. It is possible there is an interaction because 
policies and laws governing IISs often intersect with each other in complicated ways (Hedden et 
al., 2012). In Model 2, I examine the interaction between mandate and consent and report the 
predicted probabilities using the Stata margins command for this interaction in Figure 5.2. To 
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determine if predicted rates were different from each other, I examine the 95% confidence 
intervals for overlap. 
In the regression model below, italicized variables are continuous and bolded variables 
represent those categorical variables with more than two categories for each state i: 
Model 1: state_ratei= β0 + β1*Mandatei1 + β2*Consenti2 + β3*VaxForecasti3 + 
β4*PrivNonVFCratei4 + εi 
 
Model 2: state_ratei= β0 + β1*Mandatei1 + β2*Consenti2 + β3*MandateXConsenti3 + 
β4*VaxForecasti4 + β5*PrivNonVFCratei5 + εi 
where β0 is the estimated state up-to-date vaccination rate for the full combined series associated 
with no mandate and holding all other variables constant at zero; “Mandate” is the presence and 
type of mandate each state utilizes for reporting vaccinations to an IIS; “Consent” is the type of 
consent policy for each state for patient participation; “Mandate X Consent” is an interaction 
term between the mandate and consent variables and is included because of potential for one 
policy, such as a “full” or strict mandate requiring everyone to participate, increasing the 
likelihood of another strict policy such as consent type; “VaxForecast” is whether an IIS 
forecasts vaccine needs to provider EHRs; and “PrivNonVFCrate” is the percentages of private 
non-VFC providers who participate out of the number who enrolled in a state IIS. All analyses 
were performed with Stata version 15.1 (StataCorp, 2017). 
Results 
Summary statistics. The average state rate for receipt of the full combined vaccine series 
in children 19-35 months of age is 74.1% with the lowest rate (66.1%) in West Virginia and the 
highest rate (85.8%) in Maine.  
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Summary statistics for the predictor variables are shown in Table 5.2. Nineteen states 
reported no provider mandate to report vaccines to an IIS. Of the 31 states with a mandate, 18 
(58.1%) had a full mandate requiring all immunization providers to report immunizations to an 
IIS and 13 (41.9%) required at least one, but not all, providers to report immunizations. Five 
(10%) of states required Explicit consent for patient’s immunization data to be sent to an IIS 
while many states (N = 32) operated under an Implicit consent policy. Thirteen states (26%) have 
a consent policy mandating that child immunization data be reported to an IIS.  
Table 5.2 Summary of Frequencies and Rates for IIS Policies and Provider Participation 
Characteristic Freq (N = 50) 
Mandate  
None 19 
Partial 13 
Full 18 
Consent  
Explicit   5 
Implicit 32 
Mandatory 13 
Mandate X Consent  
None X Explicit   2 
None X Implicit 15 
None X Mandatory   2 
Partial X Explicit 1 
Partial X Implicit 11 
Partial X Mandatory 1 
Full X Explicit 2 
Full X Implicit 6 
Full X Mandatory 9 
Vaccine Forecasting  
No 20 
Yes 30 
Private Non-VFC Provider Rate Mean = 56.1%, Range (0 -100%) 
 
In Table 5.3, IIS characteristics for mandate, consent, and interoperability, along with 
provider rates, are reported by state. When examined together, absence of a mandate and implicit 
consent occurred most frequently (N = 15) followed by partial mandate and implicit consent (N 
= 11) and full mandate with mandatory consent (N = 9). Two states, MO and NC, have no 
reporting mandate for providers but reported mandatory consent policy for patients’ 
104 
 
participation. Partial mandates with Explicit and Mandatory consent policies are only reported in 
one state each, KS and OR respectively. 
States are divided in their ability to forecast vaccines to provider electronic health 
systems; twenty states (40%) sent vaccine forecasts while thirty states (60%) did not demonstrate 
interoperability by sending vaccine forecasts to providers. Private non-VFC provider 
participation rate, calculated from the number of providers reporting two or more immunizations 
out of the total number enrolled, averages 56.1% across the states with the lowest reported rate 
(0%) in three states: CT, ME, and SD and the highest reported rate (100%) in RI.  
Table 5.3 IIS Characteristics and Provider Participation by State 
 
 
 In Table 5.4, I present the results from the linear regression models to examine the direct 
effects from Model 1 between provider mandate to report immunizations to an IIS, a consent 
policy that would theoretically influence patient participation in an IIS, and private provider rates 
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as a proxy for providers’ behaviors in IIS participation on states’ UTD immunization rates and 
the interaction between mandate and consent types in Model 2   
In Model 1, states with no reporting mandate UTD vaccination rates 4.0 percentage 
points higher than states with full reporting mandates (p = .012, 95% CI 0.94, 7.07) while there 
is no association for states with partial mandates. Consent type and vaccine forecasting did not 
have a statistically significant relationship with state UTD immunization rates. Private non-VFC  
Table 5.4 Multiple Linear Regression Coefficients of IIS Policies and Provider Participation on State Up-to-
Date Immunization Rates 
Outcome: Est. State Rate 
Full Series 
Model 1 
Coeff. (95% CI)   p 
Model 2 
Coeff. (95% CI)      p 
Mandate     
None 4.00 (0.94, 7.07)    .012   3.37 (-3.93, 10.67) .360 
Partial  3.05 (-0.51, 6.60)    .091 -4.92 (-8.10, -1.74) .003 
Full Ref.  Ref.  
Consent     
Explicit   -4.18 (-10.30, 1.95)    .176  -3.81 (-13.11, 5.48)       .410 
Implicit -2.55 (-5.89, 0.80)    .132 -4.61 (-7.52, -1.70)       .003 
Mandatory Ref.  Ref.  
Mandate X Consent     
None X Explicit   -4.09 (-16.77, 8.60)       .520 
None X Implicit     2.58 (-5.11, 10.27)       .500 
Partial X Explicit   12.73 (2.96, 22.49)       .010 
Partial X Implicit     9.41 (5.82, 13.01)    < .001 
Forecast to EHR     
No Ref.  Ref.  
Yes  -0.65 (-3.14, 1.84)    .600      -0.53 (-2.93, 1.88)      .660 
Private Non-VFC Provider 
Participation 
  -0.07 (-0.13, -0.03)    .004  -0.07 (-0.12, -0.02)      .009 
_constant       78.54 (75.38, 81.70) < .001     78.81 (75.42, 82.19)   < .001 
N= 50 R2 = .3096  R2 = .4523  
 
provider participation is negatively associated with states’ UTD immunization rate. For every 
10% increase in participation, states’ UTD rates would be expected to decrease by 0.7 percentage 
points (p = .004, 95% CI -0.12, -0.02). The 56.1% mean private non-VFC provider rate (Table 
5.3) means that in states with the average rate of participation, there would be a decrease of 4.9 
percentage points on the UTD state rate compared to states where no private non-VFC providers 
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participated in an IIS. Private non-VFC providers do not participate in federally funded vaccine 
programs so their participation would be based largely on existing reporting mandates and their 
own behaviors, however, multi-collinearity between the mandate and non-VFC private provider 
rate was not demonstrable with this data. 
In Model 2 (Table 5.4), the interaction between mandate and consent is statistically 
significant for partial mandate, but consent types did not vary in states with no mandate. Using 
marginal effects, the mean predicted state UTD rates for the interaction between IIS mandate and 
consent policies (shown in Figure 5.2) are all statistically significant with an R2 = .4523.   
 
Figure 5.2 Predicted Up-to-Date Rates for the Interaction between Mandate Type and Consent Policies Using 
Margins 
 
State UTD rates varied by consent types dependent on the type of reporting mandate that 
was present. Overall, based upon the confidence intervals, the highest predicted rates would be 
expected in states with no mandate and either implicit (95% CI 73.9, 77.9) or mandatory consent 
(95% CI 71.2, 84.6), partial mandate with either Explicit (95% CI 76.9, 80.2) or Implicit (95% 
CI 72.8, 76.0) consent, and states with a full mandate and Mandatory (95% CI 72.0, 77.0) 
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consent. The lowest predicted rates are expected in states with No mandate and Explicit (95% CI 
64.8, 75.2) consent, Partial mandate with Mandatory (95% CI 68.0, 71.2) consent, or Full 
mandates with Explicit (95% CI 61.7, 80.0) or implicit (95% CI 68.1, 71.6) consent. 
Within states that had no reporting mandate, rates generally increased as consent policies 
became more restrictive. Within states with no mandate, Explicit consent was predicted to have 
lower state UTD rates of 70.0% (95% CI 64.8, 75.2) than Implicit (75.9%) and Mandatory 
(77.9%) consent types which had overlapping confidence intervals (95% CI 73.9,77.9 and 71.2, 
84.6 respectively). The opposite trend is predicted in states with partial mandates. In these states, 
the predicted UTD rates are highest in Explicit (78.5%, 95% CI 76.9, 80.2) consent states and 
lowest in Mandatory states (69.6%, 95% CI 68.0, 71.2). For states with full reporting mandates, 
there is no difference between Explicit and Implicit consent as their confidence intervals overlap 
(95% CI 61.7, 79.7 and 68.1, 71.6 respectively), but mandatory consent policies were associated 
with higher predicted UTD rates at 74.5% (95% CI 72.0, 77.0). Three of the mean predicted rates 
(None/Explicit, None/Mandatory, and Full/Explicit) have wide confidence intervals, likely due 
to the small number of states in those groups (Table 3), so I interpret these results with some 
caution. 
Discussion 
 The U.S. consistently misses immunization targets published as part of the Healthy 
People Initiative. Utilization of IISs has been suggested as a strategy to improve vaccination 
rates by forecasting recommended vaccines in real-time for specific patients at the point of care 
and reducing record fragmentation by consolidating all immunizations in a confidential 
population-based centralized repository (Groom et al., 2015; Hedden et al., 2012; Stokley et al., 
2001). Previously, literature has highlighted the challenges with variations in the design and 
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implementation of IISs at the state-level (Freeman & DeFriese, 2003; Hedden et al., 2012; 
Horlick et al., 2001) which ultimately led to the development of Functional Standards to guide 
the IIS implementation process (Groom et al., 2015). The complex dynamics between federal, 
state, and local policies governing IISs and immunization data further complicate the evaluation 
the success of these systems (Martin et al., 2015). Policies governing the current IISs have been 
described in detail elsewhere by Horlick et al. (2001), but the connection between states’ policies 
and outcomes (immunization rates) are less clear and there is scant evaluative literature on how 
well IISs are meeting the functional standards. 
This study contributes to the literature on IISs in three ways. First, I address a research 
gap in IIS evaluation research through an examination of policies governing the participation in 
IISs and state immunization rates. Individually, I find little association between mandate policies 
or consent types and UTD rates consistent with other literature on the effect of mandate types 
(literature on the effects of consent on immunization rates were not identified) (Kim et al., 2007; 
Mennito & Darden, 2010). However, I do find a statistically significant interaction between 
mandate policy and consent types that has not been previously reported in the literature. Trends 
for the predicted rates vary by consent type depending on mandate category and were uniquely 
different for each mandate type. In states with no reporting mandate, predicted rates increase as 
consent type becomes more restrictive (from explicit to mandatory), however, a decreasing 
predicted rate is associated in states with partial mandates- higher UTD rates in explicit consent 
states and lowest rates in states with mandatory consent. In states with a full mandate, there 
appeared to be no difference between implicit and explicit but mandatory consent was associated 
with higher UTD rates. 
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These findings add a new perspective to the available literature on IIS consent policies 
which has largely focused on how consent types relate to patient participation and costs 
associated with obtaining patient consent. Patient or parental consent is related to whether 
immunization data is included in an IIS (Hedden et al., 2012) and directly impacts the 
completeness of immunization records since non-participation can result in record fragmentation 
for those with multiple providers. Implicit and mandatory consent types are associated with 
higher participation (and inclusion of records) compared to explicit opt-in consent, though higher 
participation does not necessarily mean higher immunization rates as demonstrated in this study. 
In a randomized-controlled trial by Berry et. al, only 4% of parents opted out of an IIS compared 
to the explicit arm where only 21% of parents opted-in when extra steps were required for action 
(Berry et al., 2013). Boom et. al. explain that the effort, time, and cost required by health care 
officials and parents to opt-in are barriers to participation (Boom et al., 2010; Horlick et al., 
2001). It is plausible that parents who voluntarily participate have different immunization 
behaviors than those who do not; the same can be hypothesized about parents who go through 
the effort to opt out of an implicit consent system though that rate is considerably lower.  
Additionally, the studies by Kim et. al. (2007) and Mennito et. al. (2010) on the 
association between IIS mandates and immunization rates are more than ten years old. This 
means IISs have had the opportunity to mature and mandates more time to have effects on 
provider participation. However, the persistent finding of no association between mandate and 
immunization rates seems to suggest that there is more to the story than policy alone. Efforts 
should be made to improve data quality and providers’ awareness about IISs and to have 
additional opportunities to comply with reporting mandates. My findings suggest that further 
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examination into the relationship between providers and parents may provide additional insight 
for improving rates and I discuss provider participation in the following paragraphs. 
Participation in IISs is necessary by providers and patients to achieve complete, timely, 
and accurate immunization records in an IIS (Davidson et al., 2003; Kempe et al., 2001), a 
component of IIS Functional Standard 3. This study adds to the growing literature on provider 
participation in IISs. I found that increases in private non-VFC provider participation 
demonstrated a statistically significant negative association with state immunization rates for the 
full combined series of vaccines. Increasing provider participation rate would theoretically 
improve the quantity of data included in an IIS which should improve the completeness of 
records (Groom et al., 2015) in alignment with IIS Functional Standard 3, however, I found an 
inverse relationship.  
Several factors could contribute to this unexpected finding. Provider behaviors toward 
vaccinations can impact immunization rates and may affect IIS participation it also influences 
parental immunization behaviors as they have been cited as the most important source of 
immunization information (Gellin, Maibach, & Marcuse, 2000; Taylor et al., 1997). While 
reporting mandates are meant to increase provider participation by requiring different entities to 
report vaccinations to an IIS, one study showed that, in spite of a mandate, many providers do 
not participate (Groom et al., 2015) suggesting a behavioral component to participation. Most 
states (67%) do not have enforcement procedures in place to ensure compliance with the 
mandate, though four states (AR, AZ, MI, and WV) do have penalties such as fines for not 
participating  (Horlick et al., 2001). Additionally, some states may incentivize providers into 
enrolling in their IISs in order to increase participation rates in the IIS (U.S. Department of 
Health and Human Services, 2008). In states with penalties, overall provider participation was 79 
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to 86% (national mean = 68% across all provider types), except in WV which had a participation 
rate of 29% (data not shown), suggesting that mandates with penalties may not have universal 
effects.  
As previously mentioned, IIS participation was not associated with UTD rates in this 
study except for lower odds when providers were unclear of their IIS participation, which may 
indicate a lack of knowledge about the availability and capabilities of IISs (Kempe et al., 2017). 
Previous research offers some support to this finding through reports of providers not utilizing 
IISs to their full potential (Clark et al., 2006), but specifics about how providers are utilizing IISs 
in practice remains a persistent gap in the literature and outside the scope of this dissertation 
(Groom et al., 2015). These findings suggest a possible association extending beyond policy and 
includes participant behavior, and the dynamics of provider-participant relationships. 
This study also adds to the literature on IIS interoperability and immunization rates as a 
third contribution. I find that states’ abilities to forecast immunization to provider EHRs through 
IISs is not associated with state UTD rates. Interoperability between IISs and electronic health 
records has been previously documented as an important step in improving the completeness and 
accuracy of patients’ immunization histories (Groom et al., 2015). The IISs’ ability to forecast 
vaccines to provider EHRs is used as a proxy for interoperability, theoretically improving 
immunization delivery at the point of care as laid out in Functional Standard 1. The literature 
suggests that forecasting vaccination needs to EHRs is important at the point of care to assist 
physicians with preventing missed opportunities and ensuring completion of the series on the 
age-appropriate schedule (Hinman et al., 2007). However, I identified only one study that tests 
the ability of IIS vaccine forecasting to improve rates (Bluml et al., 2017).  
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While Bluml et al. (2017) demonstrated improvements in the rate of adult influenza 
vaccines in a proactive study with pharmacists, I found no effect between the ability to forecast 
and UTD rates. Aside from methodological differences including a localized geographic region 
(Washington State), examination of a single vaccine rather than a complex series of routine 
vaccines, and differences in population, one possible explanation for the discordant results may 
be differences in IIS functionality. IISs are implemented in stages and because of variation in 
policies and resources, the systems mature at different rates (Linkins & Feikema, 1998). It is 
possible that Bluml and colleagues benefitted from utilizing a more mature IIS as compared with 
other states. Washington State’s IIS was implemented in 1998 around the same time as large 
investments in IIS infrastructure occurred by the federal and states’ government (Hinman et al., 
2007).  
Limitations  
 My study is affected by several limitations and I interpret my findings with caution as a 
result of these challenges. First, because this is a state-level analysis, my sample size of N= 50 
increases the likelihood of type II errors and limits the statistical power. New Hampshire was 
excluded because it did not operate an IIS in 2016. South Carolina did not collect data on private 
providers in the IISARs, so I used mean substitution to impute the private provider non-VFC rate 
as described earlier. I tested the model with this rate and without SC included to test for an 
introduced bias and the results were similar.  
Second, I am cautious about the findings for the mandate and consent variables on UTD 
state rates. In Model 1, states with “no mandate” were associated with statistically significantly 
higher UTD rates compared with states with full mandates, a finding that is counterintuitive to 
the conceptual framework and findings in other studies. One potential explanation is that there is 
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an omitted variable that has not been identified or for which data is not available at this time. 
Omitted variables are correlated both with the error term and the dependent variable which 
biases the coefficient on the independent variable. I tried to reduce this bias, without success, in 
the following ways: First, I considered whether states had expanded their Medicaid programs 
which would increase access to vaccines through the Vaccines For Children program and thus 
increase state immunization rates. Second, I considered whether the state was utilizing a “home-
grown”, or state-designed IIS, or if a known vendor with standardized infrastructure across 
multiple deployments was utilized which might impact the operation and functional capability of 
a state’s IIS. Third, I examined whether immunization exemption policies or exemption rates 
were influencing state immunization rates and found no statistically significant effect. Fourth, I 
examined whether political ideology, which have known differences in approaching vaccine 
policies (Baumgaertner, Carlisle, & Justwan, 2018), were affecting state immunization rates and 
found no association in my model. Lastly, I examined the effects of using a dichotomous 
mandate variable for any mandate or none and while results were consistent with the literature 
and found no association between mandate and UTD rates, the dichotomous variable treats states 
with partial mandates (who may require as few as one entity type to report to an IIS) the same as 
states that requires all immunization entities to report to the IIS and I want to explore the 
relationships of different types of mandates.  
Provider participation rates are self-reported by state immunization program staff on the 
annual IISAR and were subject to errors in reporting as states may not have an adequate way to 
estimate provider participation. Three states reported a private non-VFC participation rate of 
0.0% (CT, ME, SD) which seems unlikely. I did not impute these values with the mean as these 
states provided a value unlike SC which left the question blank. Further, “participation” was 
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defined in the IISAR as the submission of two or more vaccines and I was unable to determine 
the extent of provider participation. It is possible that providers enrolled and sent minimal 
vaccines to the IIS, perhaps because of a reporting mandate, but do not routinely participate in 
IISs. It is also unclear if provider participation is ever re-evaluated for participation gaps once 
providers have sent immunizations. 
Finally, both the IIS Leg and IISAR data are self-reported by immunization program staff 
and are subject to errors. The CDC offers support in completing these surveys and conducts 
follow-up interviews to verify any inconsistencies in reported data to identify and correct errors.  
Conclusion 
 Immunization information systems are useful tools to consolidate fragmented records and 
improve overall immunization rates, however, the dynamic interactions between policy, 
providers, and patients add a layer of complexity to the evaluation of IISs. In this study, I 
evaluate the association between IIS reporting mandates, consent policies, interoperability and 
provider participation. I find that consent types have different relationships with states’ UTD 
rates dependent upon the state mandate. Further, private non-VFC provider rates are negatively 
associated with UTD rates. Together, these suggest a unique relationship between policy, 
participation, and the provider-patient relationship that is worth further exploration. Finally, 
while interoperability is important for improving the communication between IISs and electronic 
health records, I find no association between sending vaccine forecasts to an EHR and UTD rates 
at the state-level. My findings are consistent with previous literature expands on the knowledge 
that exists about IISs and their potential for improving immunizations in the U.S.  
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Chapter 6 Conclusions 
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In the United States, immunization rates have consistently missed targets set forth by the 
Healthy People Initiative. Contributors to these sub-optimal rates are multi-faceted and include: 
1) inefficient tracking and documentation of immunizations leading to incomplete or fragmented 
records and creates the potential for over-vaccination, 2) missed opportunities and the inability to 
determine vaccine needs at the point of care leading to under-immunized populations, and 3) the 
use of unapproved alternative vaccines schedules resulting from growing hesitancy among 
parents and providers. Coordinated investments into the design and implementation of 
immunization information systems (IISs) have led to widespread adoption of these electronic 
repositories to improve immunization rates. Previous research has demonstrated mixed results in 
the effectiveness of IISs to improve immunization rates.  
The aim of this dissertation was to examine the relationship between immunization 
information systems and vaccinations for the full combined series of seven routinely 
recommended vaccines in U.S. children 19-35 months of age. Specifically, I conducted three 
related studies to examine the association between IIS policies and participation on child up-to-
date status, invalid doses, and state-level UTD immunization rates. I focused on the utilization of 
IISs as well as policies as they relate to the functional standards that guide the operation of state 
IISs in the U.S. In two of the studies, I also controlled for provider type, and child and maternal 
factors that are known to affect immunizations. In studies 1 and 2, I use data from the National 
Immunization Survey and logistic regression modeling to examine the association between 
provider IIS participation and the probability of a child having the full combined series of 
vaccines and whether that participation was related to the probability of having invalid doses. In 
study 3, I use data from the IIS Legislative Survey, the IIS Annual Reports, and the National 
Immunization Survey and linear regression modeling to examine the relationship between state-
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level provider reporting mandates, parental consent types, interoperability of IISs, and private 
provider participation on the state UTD rates. 
Throughout this dissertation, I used study designs that were similar to previous literature, 
when examining UTD status and invalid doses, with a few key differences. First, studies rarely 
include state as a covariate or control variable to account for differences in state policies, 
programs, and economics, whereas I include state as an important predictor of immunization 
status. Second, previous literature includes the use of pooled NIS data to determine the effect of 
IIS participation on UTD status, however, previous studies frequently failed  to control for the 
effect of time on the UTD outcome (Mennito & Darden, 2010; Racine & Joyce, 2007). In this 
study, I include the year as a control for changes in immunizations due to changes in time. 
Differences in my studies’ models may contribute to differences in the child and maternal factors 
that differed from previous literature (e.g. child race/ethnicity) and that were associated with 
UTD status and invalid doses. 
Summary of Findings 
In Chapter 3, I evaluated the link between IIS participation and child UTD status. I found 
no association between IIS participation and child UTD status. Children whose providers were 
uncertain of their IIS participation, however, were associated with lower odds of child UTD. 
These findings are valuable as it demonstrates that even as IISs have had the opportunity to 
mature, the predicted relationship between IIS participation and improved immunization rates is 
still not able to be demonstrated.  
In Chapter 4, the relationship between IIS participation and invalid immunizations was 
examined. First, I provided an updated analysis over a five-year period on the state of invalid 
doses and demonstrated that invalid doses are still problematic. Almost half of all children had at 
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least one invalid dose between 2012 and 2016. This is an important finding because current 
immunization estimates count all doses and doses that are administered too young, or too close 
together, may not stimulate a robust immune response. This leaves a child under-protected and 
may contribute to VPD outbreaks. Secondly, this study demonstrated a statistically significant 
relationship between IIS participation and invalid doses. Children whose providers participated 
in an IIS were associated with higher odds of invalid Hep B doses, although, no association was 
demonstrated with the remaining six vaccines in the full combined series. This finding is counter 
to my hypothesis and indicates that participation may not be reflective of utilization of IIS 
features. 
Lastly, in Chapter 5, I analyzed the effect of an IIS provider mandate, patient consent 
policy type, vaccine forecasting feature, and private non-VFC provider participation rate and the 
relationship to states’ UTD rates. I found no direct effect between mandate and consent on state 
UTD rates except for those states with no reporting mandate. In non-mandated states, UTD rates 
were 4.0 percentage points higher than states with full mandates. I also found a significant 
interaction between mandate and consent type. States with no mandate and mandatory consent 
demonstrated the highest mean predicted UTD rates. Taken together, these findings suggest that 
provider participation is important for success, but a mandate may not be the best way to compel 
participation. For patients/parents, mandatory consent for participation in an IIS offers the 
highest benefit.  
Relationship between IIS participation and immunization rates and quality 
Together, Chapters 3 and 4 examined the effect of IIS participation on child UTD status 
and the probability of having an invalid dose. I hypothesized that IIS participation would be 
associated with increased probabilities of child UTD status and lower probability of invalid 
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doses. Taken together, I fail to reject the null hypotheses for these two questions, however, there 
was value in the findings. 
Similar to previous studies that examined IIS participation (Kim et al., 2007; Mennito & 
Darden, 2010), I found that IIS participation was not associated with the probability of a child 
being UTD for their full combined vaccine series. In Australia, following the implementation of 
an IIS and two years later an incentive program for participation, an increase in immunization 
rates of almost 30% was demonstrated (Groom et al., 2015). In 1995, the CDC launched a 
quality improvement program, AFIX, to help providers increase immunization rates and 
incentivized provider participation in IISs. Studies by Kim et. al. (2007), and Mennito and 
Darden (2010), were conducted nearly ten years after the start of AFIX, and this dissertation 
work more than 20 years after its implementation. Failure to reject the null of no association 
between IIS participation and child UTD status persists despite the predicted theory of 
association. Further, my finding that children whose providers were uncertain of their IIS 
participation status were associated with lower odds of child UTD supports the work done by 
Kim et. al. (2007). These findings indicate that other factors, aside from participation, led to 
increases in immunization rates in Australia and have yet to materialize in the U.S. 
While there was no effect between IIS participation and child UTD status, there was a 
statistically significant and unique relationship between IIS participation and the odds of having 
invalid doses that was not previously reported in the literature. From 2012-2016, invalid doses 
were largely driven by Hep B doses which led to separate analyses for Hep B. For Hep B doses, 
children whose providers participated in an IIS were associated with higher odds of invalid doses 
compared to those whose providers did not use an IIS.  This is the first finding demonstrating a 
statistically significant relationship between IIS participation and immunizations, so I am 
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cautious about the interpretation that IIS participation leads to higher rates of invalid doses due 
to the complex history behind Hep B invalid doses in the literature (Luman et al., 2002; Stokley 
et al., 2004). This finding indicates that there may be differences between participation and 
utilization of IISs. 
States and residential mobility relative to immunizations 
Most discussions on immunization rates occur nationally and state-level discussions. 
However, immunization programs, and IISs, are operationalized at the state-level or local levels 
and would be expected to have policies, programs, economic, and environmental factors that 
affect immunization rates. My research found significant variation across the states with respect 
to estimated immunization rates, invalid doses, and how policies and participation were 
associated with immunizations. I selected California as the reference state for studies 1 and 2 
because it is a large, diverse state with a relatively high UTD immunization rate (79.9%). Taken 
together, 28 states were associated with increased UTD odds but were also associated with 
significantly higher odds of invalid doses compared to California.  
This finding suggests that some states may focus on the delivery of vaccines without 
regard to the timing or appropriateness of doses as all doses are counted in estimates of coverage. 
Interestingly, 13 states with increased UTD odds were associated with lower odds of invalid 
doses suggesting that high rates and appropriateness of doses were considered. These findings 
suggest there could be public health priorities, policies, or programs that exist to help states 
achieve higher quality immunizations. The findings could also indicate a difference in IIS 
maturity or availability of features, or an increased provider awareness of IISs and their 
capabilities.  
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Residential mobility, residing in a state different from where a child was born, was also 
statistically significant for lower odds of child UTD and higher odds of invalid doses, consistent 
with the literature (Stokley et al., 2004; Stokley et al., 2001). These children were less likely to 
have adequate provider data; those without adequate data were excluded from the studies. This 
difference in adequate data likely reflects the problem of record scattering and fragmentation, or 
a difference in provider behaviors toward immunizations (Dayton, 2014; Gaudino et al., 2002; 
Stokley et al., 2001). Together, these findings contribute valuable insight into the role of states 
on immunizations. 
Providers’ IIS participation and behaviors toward immunizations 
Provider participation is mandatory for IISs to be effective, however, my findings, in 
conjunction with the literature, demonstrate that provider participation is complex. Providers can 
be categorized in several ways: public vs. private, VFC provider vs non-VFC provider, 
pediatrician vs. general practitioner vs. other immunization provider, or any combination listed 
(Centers for Disease Control and Prevention, 2018a). Although public providers are associated 
with lower immunization rates (Luman et al., 2002), private providers generally have lower 
participation rates than public providers (Gaudino et al., 2002) and may explain the following 
findings. In Chapters 3 and 4, I found no association between IIS participation and child UTD 
status or invalid doses for the full series, which appears counter to the claim that provider 
participation is necessary for improving immunizations rates. To add further complexity, in 
Chapters 3 and 4, children with “All private” providers were associated with higher odds of child 
UTD status and higher odds of invalid doses. In Chapter 5, I found a negative association 
between private non-VFC provider participation and state UTD rates further supporting that idea.  
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Participation in the VFC program is not associated with improved immunization rates 
(Kim et al., 2007). Often, public providers participate in the VFC program since they frequently 
receive state and federal funds for either Medicaid and/or VFC eligible patients (Dayton, 2014; 
Wood et al., 1999). In this dissertation, I did not include VFC provider rates in Chapter 5 
because of the potential for multi-collinearity with the provider mandate. Mandates often specific 
that VFC recipients must report immunizations. However, my inclusion of a private non-VFC 
provider group is the first to categorize providers using multiple factors. This adds valuable 
insight for health officials trying to determine which providers may benefit from interventions to 
increase awareness and IIS participation might be needed.  
Lastly, provider participation may be influenced by individual provider beliefs (Dayton, 
2014; Gaudino et al., 2002). This is supported by the findings in Chapter 5 that found the greatest 
effect on state UTD rates in states with no reporting mandate. It is possible that when states do 
not require participation, those that choose to participate are more engaged in immunizations 
than those that are required to report but do not have intrinsic desire to do so, supporting the 
claim in the literature that mandates result in lower rates (Madewell et al., 2017).  
Limitations 
There were limitations to this work. First, the primary source for immunization data in 
the U.S. is the National Immunization Survey. Although the NIS is nationally representative and 
utilizes complex stratification, the cross-sectional design prevents causal analyses. The CDC and 
NCIRD employ several strategies to compensate for selection and non-response bias, as well as 
several quality measures to reduce errors in data collection. However, the survey relies on 
parents to accurately identify all immunization providers for the provider record check portion of 
the survey. Additionally, the record check portion of the survey is subject to additional non-
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response bias and reporting errors in the self-reported immunization data. Although survey and 
provider weights were utilized where possible, I noted several differences in the groups that had 
adequate provider data and were included in the study compared with those who did not have 
adequate data. The NIS variables are available as mostly categorical variables and provider data 
is aggregated at the child-level which limits the analytical abilities.  
Policy Implications and Conclusion 
This dissertation research adds to the growing literature on IIS evaluation by examining 
the relationships of IISs on vaccination status. First, this work supports previous work done on 
IIS participation on UTD status as well as adds new findings not previously reported on. Earlier 
work suggests no effect of IIS participation, but over time, I expected that effect to materialize in 
alignment with IIS proponents’ claims and work in other countries. My study supports the 
previous authors’ work of no effect of IIS participation on child UTD status after controlling for 
provider type, state of residence, maternal, and child factors. It also supports the finding that 
there is a persistent knowledge gap about IISs. Children with providers who were uncertain of 
their IIS participation were associated with lower UTD odds. This work contributes new insights 
into the role of IIS participation on immunization quality by finding that IIS participation was 
associated with the odds of a child having invalid doses. These findings were driven largely by 
residential mobility and invalid Hepatitis B doses. 
Second, this dissertation contributes to the literature by expanding the knowledge of how 
IIS policies affect state-level UTD rates. Few studies have examined the impact of policies such 
as mandate and consent type on UTD status and none have examined the impact of vaccine 
forecasting on state UTD rates for the full combined series. While my findings support the 
literature of no effect of mandate type or consent policies, I did identify a statistically significant 
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interaction between mandate and consent that offers additional insight into how policies may 
interact with each other to affect immunization rates. As mandates influence provider 
participation, and consent influences patient participation, this interaction highlights the 
importance of the provider-patient dynamic. 
The third contribution this dissertation makes is by adding information about  
immunization variations across the states. While the previous contribution focuses on the state 
IIS policies, there may be state-level effects that influence immunization rates and invalid doses 
beyond IIS policy alone. Taken together, the findings from the two studies on IIS participation 
and UTD status and invalid doses resulted in interesting findings. Compared to California, a state 
that has a diverse population, and higher immunization rates, only four states were associated 
with lower odds of child UTD and three states showed no effect. However, of the remaining 41 
states and association of higher UTD status, 28 states were associated with higher odds of invalid 
doses. This finding is particularly interesting because it suggests that there may be other state-
level factors that encourage increasing the numbers of vaccines rather than appropriate or quality 
vaccination. Thirteen states had higher child UTD odds but lower odds of invalid doses which 
suggests higher rates and higher quality of immunization.  
Overall, this dissertation work demonstrates the wide variation among states and their 
IISs on immunizations in the U.S. Improvement efforts should continue to focus on improving 
the quality of immunizations by reducing invalid doses and increasing provider awareness and 
participation in IISs. Further, IIS policymakers should take into consideration the interactions 
between different policy statutes. The lack of a reporting mandate was associated with higher 
participation rates than full mandates, when examining the interaction with consent policies, 
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highlighting the influence of provider behavior on immunization rates and the provider-parent 
dynamic. 
Future Directions 
The studies in this dissertation contributed in several meaningful ways to the IIS 
literature and stimulated ideas for future research questions. First, the wide variation of the 
between the relationship of states and immunization status raises questions about the effects of 
IISs on individual vaccine rates and invalid doses. It is possible that IISs are more effective on 
doses that are delivered on a similar schedule (DTaP, Hib, and Polio for example) than trying to 
accommodate the full combined vaccine series. Second, when considering the child UTD status 
and invalid doses together, the results did not always align with the state UTD rates. A deeper 
investigation into different policy interactions by state IISs may also provide insight as to the 
different dynamics that contribute to higher state UTD rates. Lastly, this dissertation work 
sparked my interest in investigating the effects of provider beliefs and behaviors on participation 
in IISs. The highest mean predicted rates were in states with no provider mandate rather than 
states that have a full mandate, counter to my conceptual framework. Exploring the different 
attitudes and examining provider characteristics in more detail with respect to how they relate to 
immunization participation may shed light on why researcher fail to see an effect between IIS 
participation and UTD rates. 
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Appendix A: Supplemental Table 3.1 Summary Statistics States by Adequate Prov. 
Data 
 
  Full Sample 
With Adequate 
Provider Data 
Without Adequate 
Provider Data p 
State    < .001 
Alabama 1.5% 1.5% 1.5%  
Alaska 0.3% 0.3% 0.3%  
Arizona 2.2% 2.3% 2.1%  
Arkansas 1.0% 1.0% 0.9%  
California 12.7% 11.2% 14.5%  
Colorado 1.7% 1.7% 1.6%  
Connecticut 1.0% 1.1% 0.8%  
Delaware 0.3% 0.3% 0.3%  
D.C. 0.2% 0.2% 0.2%  
Florida 5.7% 5.4% 6.0%  
Georgia 3.3% 3.3% 3.2%  
Hawaii 0.5% 0.5% 0.4%  
Idaho 0.6% 0.6% 0.5%  
Illinois 3.9% 3.9% 3.8%  
Indiana 2.1% 2.2% 2.1%  
Iowa 1.0% 1.1% 0.8%  
Kansas  1.0% 1.1% 0.9%  
Kentucky 1.4% 1.5% 1.2%  
Louisiana 1.6% 1.6% 1.6%  
Maine 0.3% 0.4% 0.3%  
Maryland 1.8% 2.0% 1.7%  
Massachusetts 1.8% 1.7% 1.8%  
Michigan 2.8% 3.1% 2.5%  
Minnesota 1.8% 1.8% 1.7%  
Mississippi 0.9% 0.8% 1.1%  
Missouri 1.9% 2.0% 1.7%  
Montana 0.3% 0.3% 0.3%  
Nebraska 0.7% 0.8% 0.6%  
Nevada 0.9% 0.8% 1.0%  
New Hampshire 0.3% 0.3% 0.3%  
New Jersey 2.6% 2.4% 2.9%  
New Mexico 0.7% 0.8% 0.6%  
New York 5.8% 5.6% 6.1%  
North Carolina 3.1% 2.9% 3.3%  
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State Full Sample 
With Adequate 
Provider Data 
Without Adequate 
Provider Data p 
North Dakota 0.3% 0.3% 0.3%  
Ohio 3.5% 3.4% 3.6%  
Oklahoma 1.3% 1.3% 1.4%  
Oregon 1.2% 1.5% 0.8%  
Pennsylvania 3.6% 3.8% 3.3%  
Rhode Island 0.3% 0.3% 0.3%  
South Carolina 1.4% 1.4% 1.5%  
South Dakota 0.3% 0.4% 0.3%  
Tennessee 2.1% 2.4% 1.7%  
Texas 10.2% 9.9% 10.5%  
Utah 1.3% 1.4% 1.1%  
Vermont 0.2% 0.2% 0.1%  
Virginia 2.6% 2.6% 2.6%  
Washington 2.3% 2.5% 2.0%  
West Virginia 0.5% 0.6% 0.5%  
Wisconsin 1.7% 1.8% 1.5%  
Wyoming 0.2% 0.2% 0.2%  
N 27,339 14,988 12,351  
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Appendix B: Supplemental Table 3.2 Summary Statistics States by IIS 
Participation 
 
 IIS Participation  
  None Some/All Unknown p 
State    < .001 
Alabama 0.1% 1.3% 0.1%  
Alaska 0.0% 0.3% 0.0%  
Arizona 0.1% 2.0% 0.2%  
Arkansas 0.0% 0.9% 0.1%  
California 1.9% 5.9% 3.5%  
Colorado 0.1% 1.4% 0.2%  
Connecticut 0.1% 0.7% 0.4%  
Delaware 0.0% 0.2% 0.0%  
D.C. 0.0% 0.2% 0.0%  
Florida 0.1% 4.9% 0.3%  
Georgia 0.0% 3.2% 0.2%  
Hawaii 0.1% 0.3% 0.1%  
Idaho 0.0% 0.6% 0.0%  
Illinois 0.7% 2.6% 0.8%  
Indiana 0.1% 2.0% 0.1%  
Iowa 0.1% 0.9% 0.1%  
Kansas  0.3% 0.7% 0.1%  
Kentucky 0.4% 0.8% 0.2%  
Louisiana 0.0% 1.5% 0.1%  
Maine 0.0% 0.3% 0.0%  
Maryland 0.5% 1.1% 0.4%  
Massachusetts 0.4% 0.9% 0.5%  
Michigan 0.0% 2.9% 0.2%  
Minnesota 0.1% 1.5% 0.3%  
Mississippi 0.1% 0.7% 0.1%  
Missouri 0.7% 0.9% 0.5%  
Montana 0.0% 0.3% 0.0%  
Nebraska 0.1% 0.5% 0.1%  
Nevada 0.0% 0.7% 0.0%  
New Hampshire 0.2% 0.1% 0.1%  
New Jersey 0.2% 2.0% 0.3%  
New Mexico 0.0% 0.7% 0.0%  
New York 0.1% 4.9% 0.6%  
North Carolina 0.2% 2.5% 0.2%  
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 IIS Participation  
State None Some/All Unknown p 
North Dakota 0.0% 0.3% 0.0%  
Ohio 0.3% 2.5% 0.5%  
Oklahoma 0.1% 1.0% 0.2%  
Oregon 0.0% 1.3% 0.1%  
Pennsylvania 0.7% 2.3% 0.8%  
Rhode Island 0.0% 0.3% 0.0%  
South Carolina 0.1% 1.1% 0.3%  
South Dakota 0.0% 0.3% 0.0%  
Tennessee 0.4% 1.7% 0.3%  
Texas 0.8% 7.8% 1.4%  
Utah 0.0% 1.3% 0.1%  
Vermont 0.0% 0.2% 0.0%  
Virginia 0.5% 1.8% 0.3%  
Washington 0.1% 2.1% 0.3%  
West Virginia 0.0% 0.5% 0.1%  
Wisconsin 0.0% 1.7% 0.1%  
Wyoming 0.0% 0.1% 0.0%   
N = 14,751     
 
  
141 
 
Appendix C: Supplemental Table 3.3 Regression Results State aORs 
 
State aOR 95% CI State aOR 95% CI 
Alabama 1.97*** [1.85, 2.11] Montana 1.00 [0.93, 1.08] 
Alaska 1.14*** [1.08, 1.20] Nebraska 1.85*** [1.77, 1.94] 
Arizona 1.00 [0.96, 1.05] Nevada 1.22*** [1.15, 1.28] 
Arkansas 1.28*** [1.20, 1.36] New Hampshire 2.00*** [1.87, 2.14] 
California Ref  New Jersey 1.09*** [1.04, 1.13] 
Colorado 1.45*** [1.39, 1.51] New Mexico 0.87*** [0.81, 0.93] 
Connecticut 1.86*** [1.79, 1.92] New York 1.00 [0.95, 1.06] 
Delaware 1.67*** [1.58, 1.76] North Carolina 1.93*** [1.84, 2.01] 
D.C. 1.20*** [1.13, 1.26] North Dakota 1.17*** [1.09, 1.26] 
Florida 1.08** [1.02, 1.14] Ohio 1.32*** [1.26, 1.39] 
Georgia 1.63*** [1.53, 1.73] Oklahoma 1.03 [0.98, 1.08] 
Hawaii 1.57*** [1.48, 1.67] Oregon 0.65*** [0.62, 0.69] 
Idaho 1.25*** [1.17, 1.33] Pennsylvania 1.72*** [1.64, 1.80] 
Illinois 1.14*** [1.10, 1.18] Rhode Island 1.38*** [1.31, 1.45] 
Indiana 1.08* [1.01, 1.15] South Carolina 1.27*** [1.21, 1.33] 
Iowa 1.47*** [1.38, 1.56] South Dakota 1.43*** [1.34, 1.53] 
Kansas  1.40*** [1.33, 1.47] Tennessee 1.14*** [1.09, 1.20] 
Kentucky 1.65*** [1.56, 1.74] Texas 1.05 [1.00, 1.10] 
Louisiana 0.94 [0.88, 1.01] Utah 1.39*** [1.31, 1.47] 
Maine 1.20*** [1.11, 1.29] Vermont 1.64*** [1.52, 1.78] 
Maryland 1.55*** [1.49, 1.61] Virginia 1.16*** [1.11, 1.21] 
Massachusetts 2.12*** [2.04, 2.20] Washington 1.49*** [1.43, 1.56] 
Michigan 1.29*** [1.21, 1.36] West Virginia 1.10* [1.02, 1.19] 
Minnesota 1.45*** [1.38, 1.54] Wisconsin 1.75*** [1.68, 1.91] 
Mississippi 1.31*** [1.22, 1.41] Wyoming 0.87*** [0.84, 0.94] 
Missouri 1.34*** [1.27, 1.41]    
* p < 0.05, ** p < 0.01, *** p < 0.001  
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Appendix D: Supplemental Table 4.3 Regression Results (Excl. Hep B doses)- 
State aORs 
 
Logistic Reg. 
Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
State aOR 95% CI aOR 95% CI aOR 95% CI 
Alabama 1.79*** [1.71, 1.88] 1.82*** [1.74, 1.90] 0.80*** [0.74, 0.85] 
Alaska 0.38*** [0.36, 0.39] 0.36*** [0.35, 0.38] 1.16*** [1.09, 1.24] 
Arizona 1.14*** [1.08, 1.19] 1.13*** [1.08, 1.19] 0.97 [0.92, 1.02] 
Arkansas 1.91*** [1.80, 2.03] 1.94*** [1.83, 2.06] 0.53*** [0.49, 0.57] 
California Ref  Ref  Ref  
Colorado 1.15*** [1.10, 1.20] 1.12*** [1.07, 1.17] 0.50*** [0.47, 0.53] 
Connecticut 1.39*** [1.33, 1.46] 1.41*** [1.35, 1.48] 1.08** [1.03, 1.13] 
Delaware 2.40*** [2.25, 2.56] 2.44*** [2.29, 2.61] 1.73*** [1.62, 1.85] 
District of Columbia 2.09*** [2.00, 2.17] 2.15*** [2.07, 2.24] 1.89*** [1.77, 2.02] 
Florida 0.73*** [0.70, 0.76] 0.74*** [0.71, 0.77] 1.24*** [1.18, 1.31] 
Georgia 0.95 [0.90, 1.01] 0.94* [0.89, 1.00] 1.32*** [1.23, 1.43] 
Hawaii 2.24*** [2.15, 2.33] 2.28*** [2.18, 2.38] 0.76*** [0.71, 0.81] 
Idaho 1.11** [1.04, 1.18] 1.10** [1.03, 1.17] 1.09 [1.00, 1.18] 
Illinois 1.99*** [1.94, 2.03] 2.03*** [1.99, 2.08] 1.50*** [1.44, 1.56] 
Indiana 1.77*** [1.69, 1.86] 1.76*** [1.67, 1.85] 1.86*** [1.73, 2.00] 
Iowa 0.93* [0.88, 0.99] 0.93** [0.87, 0.98] 0.70*** [0.65, 0.76] 
Kansas 0.73*** [0.70, 0.75] 0.73*** [0.71, 0.76] 0.84*** [0.80, 0.89] 
Kentucky 1.82*** [1.74, 1.91] 1.82*** [1.74, 1.90] 0.95 [0.88, 1.03] 
Louisiana 0.80*** [0.76, 0.85] 0.81*** [0.77, 0.86] 0.88** [0.81, 0.95] 
Maine 2.87*** [2.67, 3.08] 2.85*** [2.65, 3.05] 1.18** [1.07, 1.30] 
Maryland 1.14*** [1.10, 1.18] 1.15*** [1.11, 1.20] 1.15*** [1.09, 1.21] 
Massachusetts 3.19*** [3.10, 3.27] 3.28*** [3.19, 3.37] 1.17*** [1.11, 1.23] 
Michigan 0.75*** [0.70, 0.80] 0.77*** [0.72, 0.82] 0.62*** [0.57, 0.67] 
Minnesota 1.77*** [1.66, 1.89] 1.82*** [1.71, 1.94] 1.30*** [1.21, 1.40] 
Mississippi 3.38*** [3.18, 3.58] 3.49*** [3.29, 3.69] 1.28*** [1.18, 1.40] 
Missouri 1.16*** [1.13, 1.20] 1.20*** [1.16, 1.24] 1.13*** [1.06, 1.20] 
Montana 0.74*** [0.69, 0.79] 0.73*** [0.68, 0.78] 2.53*** [2.32, 2.75] 
Nebraska 3.19*** [3.07, 3.31] 3.28*** [3.15, 3.41] 1.02 [0.96, 1.08] 
Nevada 0.54*** [0.51, 0.56] 0.51*** [0.49, 0.54] 1.12*** [1.07, 1.18] 
New Hampshire 1.61*** [1.54, 1.68] 1.64*** [1.57, 1.72] 0.81*** [0.75, 0.89] 
New Jersey 0.89*** [0.85, 0.93] 0.92*** [0.88, 0.96] 1.25*** [1.20, 1.31] 
New Mexico 1.73*** [1.64, 1.83] 1.77*** [1.68, 1.87] 1.51*** [1.44, 1.58] 
New York 1.51*** [1.43, 1.59] 1.54*** [1.46, 1.62] 0.96 [0.91, 1.01] 
North Carolina 1.06* [1.01, 1.12] 1.08** [1.02, 1.14] 0.46*** [0.43, 0.48] 
North Dakota 4.50*** [4.17, 4.84] 4.62*** [4.28, 4.67] 0.63*** [0.57, 0.69] 
Ohio 1.17*** [1.13, 1.21] 1.20*** [1.16, 1.24] 0.68*** [0.64, 0.72] 
Oklahoma 0.79*** [0.76, 0.83] 0.82*** [0.78, 0.86] 0.71*** [0.67, 0.75] 
Oregon 1.04 [0.98, 1.10] 1.06 [1.00, 1.12] 1.07* [1.00, 1.15] 
Pennsylvania 1.86*** [1.78, 1.93] 1.90*** [1.82, 1.97] 0.79*** [0.74, 0.84] 
Rhode Island 0.35*** [0.33, 0.37] 0.33*** [0.31, 0.35] 1.29*** [1.22, 1.37] 
South Carolina 1.18*** [1.14, 1.22] 1.20*** [1.15, 1.24] 1.03 [0.98, 1.10] 
South Dakota 0.91* [0.85, 0.98] 0.90** [0.84, 0.97] 0.73*** [0.67, 0.79] 
Tennessee 1.19*** [1.15, 1.23] 1.16*** [1.13, 1.21] 1.23*** [1.15, 1.31] 
Texas 0.91*** [0.88, 0.95] 0.90*** [0.87, 0.94] 1.36*** [1.31, 1.42] 
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Utah 1.49*** [1.41, 1.59] 1.53*** [1.45, 1.63] 0.59*** [0.55, 0.64] 
Logistic Reg. 
Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
State aOR 95% CI aOR 95% CI aOR 95% CI 
Vermont 2.07*** [1.94, 2.21] 2.13*** [2.00, 2.27] 1.66*** [1.52, 1.81] 
Virginia 0.94*** [0.92, 0.97] 0.97* [0.94, 1.00] 1.04 [0.98, 1.10] 
Washington 1.11*** [1.06, 1.17] 1.15*** [1.10, 1.20] 0.81*** [0.76, 0.85] 
West Virginia 0.80*** [0.75, 0.85] 0.80*** [0.76, 0.85] 1.04 [0.95, 1.14] 
Wisconsin 1.38*** [1.29, 1.48] 1.42*** [1.32, 1.52] 0.33*** [0.30, 0.36] 
Wyoming 1.78*** [1.68, 1.88] 1.77*** [1.67, 1.87] 1.08 [1.00, 1.17] 
* p < 0.05, ** p < 0.01, *** p 
< 0.001  N = 72,323 N =  72,323 N = 71,115 
 
M&Z R2 = 0.097 
 
M&Z R2 = 0.101 M&Z R2 = 0.103 
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Appendix E: Supplemental Table 4.4 Regression Results (Hep B doses)- State 
aORs 
 
Logistic Reg. Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
State aOR 95% CI aOR 95% CI aOR 95% CI 
Alabama 0.36*** [0.34, 0.38] 0.32*** [0.30, 0.34] 0.51*** [0.47, 0.54] 
Alaska 3.70*** [3.44, 3.97] 3.93*** [3.64, 4.25] 1.66*** [1.57, 1.77] 
Arizona 0.71*** [0.67, 0.75] 0.70*** [0.66, 0.74] 0.87*** [0.83, 0.91] 
Arkansas 0.39*** [0.36, 0.42] 0.33*** [0.30, 0.36] 0.71*** [0.67, 0.76] 
California Ref  Ref  Ref  
Colorado 0.67*** [0.64, 0.70] 0.63*** [0.60, 0.66] 0.54*** [0.51, 0.56] 
Connecticut 0.50*** [0.47, 0.53] 0.49*** [0.46, 0.52] 0.49*** [0.47, 0.51] 
Delaware 0.32*** [0.30, 0.34] 0.33*** [0.31, 0.36] 0.29*** [0.28, 0.31] 
District of Columbia 0.21*** [0.20, 0.22] 0.20*** [0.19, 0.21] 0.35*** [0.33, 0.38] 
Florida 0.42*** [0.40, 0.44] 0.45*** [0.43, 0.47] 0.20*** [0.19, 0.21] 
Georgia 0.43*** [0.40, 0.46] 0.41*** [0.38, 0.43] 0.34*** [0.31, 0.36] 
Hawaii 0.45*** [0.43, 0.48] 0.46*** [0.44, 0.49] 0.70*** [0.65, 0.70] 
Idaho 0.49*** [0.46, 0.52] 0.49*** [0.45, 0.52] 0.73*** [0.69, 0.78] 
Illinois 0.45*** [0.43, 0.47] 0.43*** [0.41, 0.44] 0.63*** [0.61, 0.65] 
Indiana 0.54*** [0.51, 0.58] 0.57*** [0.54, 0.61] 0.40*** [0.38, 0.43] 
Iowa 1.41*** [1.33, 1.50] 1.40*** [1.32, 1.49] 0.57*** [0.54, 0.61] 
Kansas 0.89*** [0.85, 0.93] 0.88*** [0.84, 0.92] 0.48*** [0.46, 0.50] 
Kentucky 0.76*** [0.72, 0.80] 0.74*** [0.71, 0.78] 0.91** [0.86, 0.96] 
Louisiana 0.40*** [0.37, 0.43] 0.39*** [0.37, 0.42] 0.45*** [0.42, 0.48] 
Maine 0.10*** [0.09, 0.11] 0.09*** [0.08, 0.10] 0.35*** [0.32, 0.38] 
Maryland 0.66*** [0.63, 0.69] 0.66*** [0.63, 0.69] 0.52*** [0.50, 0.54] 
Massachusetts 0.23*** [0.22, 0.24] 0.21*** [0.20, 0.22] 0.44*** [0.43, 0.46] 
Michigan 0.56*** [0.51, 0.60] 0.54*** [0.51, 0.59] 0.53*** [0.49, 0.56] 
Minnesota 0.56*** [0.52, 0.60] 0.48*** [0.45, 0.51] 0.63*** [0.60, 0.67] 
Mississippi 0.64*** [0.59, 0.70] 0.66*** [0.61, 0.71] 0.34*** [0.31, 0.37] 
Missouri 0.57*** [0.54, 0.59] 0.52*** [0.50, 0.54] 0.51*** [0.48, 0.53] 
Montana 3.72*** [3.46, 4.00] 3.78*** [3.51, 4.07] 1.96*** [1.84, 2.09] 
Nebraska 0.21*** [0.20, 0.22] 0.20*** [0.19, 0.21] 0.24*** [0.23, 0.25] 
Nevada 0.67*** [0.64, 0.71] 0.69*** [0.65, 0.73] 0.73*** [0.70, 0.76] 
New Hampshire 0.38*** [0.35, 0.41] 0.38*** [0.35, 0.40] 0.49*** [0.46, 0.52] 
New Jersey 0.57*** [0.55, 0.60] 0.54*** [0.51, 0.56] 0.87*** [0.83, 0.90] 
New Mexico 0.48*** [0.45, 0.50] 0.43*** [0.41, 0.45] 0.65*** [0.62, 0.68] 
New York 0.41*** [0.39, 0.43] 0.36*** [0.35, 0.38] 0.67*** [0.64, 0.71] 
North Carolina 0.38*** [0.35, 0.40] 0.35*** [0.33, 0.37] 0.48*** [0.46, 0.51] 
North Dakota 0.37*** [0.34, 0.40] 0.27*** [0.25, 0.30] 0.76*** [0.71, 0.81] 
Ohio 0.57*** [0.55, 0.60] 0.47*** [0.45, 0.49] 1.14*** [1.09, 1.20] 
Oklahoma 0.61*** [0.57, 0.64] 0.57*** [0.54, 0.60] 0.54*** [0.51, 0.57] 
Oregon 0.91** [0.86, 0.97] 0.80*** [0.75, 0.85] 1.14*** [1.08, 1.19] 
Pennsylvania 0.38*** [0.36, 0.40] 0.37*** [0.35, 0.39] 0.47*** [0.45, 0.50] 
Rhode Island 8.74*** [8.23, 9.29] 9.51*** [8.85, 10.21] 1.87*** [1.78, 1.96] 
South Carolina 0.88*** [0.84, 0.92] 0.83*** [0.79, 0.86] 0.99 [0.94, 1.04] 
South Dakota 0.53*** [0.49, 0.57] 0.48*** [0.44, 0.52] 0.59*** [0.56, 0.63] 
Tennessee 0.97 [0.93, 1.01] 0.90*** [0.86, 0.93] 1.32*** [1.25, 1.40] 
Texas 0.51*** [0.49, 0.54] 0.59*** [0.47, 0.51] 0.68*** [0.66, 0.71] 
Utah 0.87*** [0.82, 0.93] 0.89*** [0.84, 0.95] 0.51*** [0.48, 0.55] 
145 
 
Logistic Reg. Models: (1) Any Invalid (2) Invalid Age (3) Invalid Interval 
State aOR 95% CI aOR 95% CI aOR 95% CI 
Vermont 1.65*** [1.54, 1.78] 1.54*** [1.44, 1.66] 1.24*** [1.15, 1.33] 
Virginia 0.40*** [0.38, 0.42] 0.42*** [0.40, 0.44] 0.39*** [0.38, 0.41] 
Washington 0.31*** [0.29, 0.32] 0.28*** [0.26, 0.29] 0.69*** [0.66, 0.72] 
West Virginia 0.39*** [0.37, 0.42] 0.38*** [0.35, 0.41] 0.40*** [0.37, 0.43] 
Wisconsin 1.17*** [1.09, 1.26] 1.18*** [1.09, 1.27] 0.72*** [0.68, 0.77] 
Wyoming 0.49 [0.46, 0.53] 0.47*** [0.44, 0.50] 0.73*** [0.69, 0.78] 
* p < 0.05, ** p < 0.01, *** p < 0.001  N = 73,193 N = 73,193 N = 73,001 
 M&Z R2 = .252 M&Z R2 = .307 M&Z R2 = .103 
 
